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ABSTRACT
The detection of oligomers and aggregates formed by two amyloid proteins, insulin and
amyloid-β (Aβ), is of particular importance due to the role which these species play in Diabetes
and Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques
or alternative techniques must be explored in order to identify and quantify the size of these
oligomeric and aggregate species without disrupting their structure.
Capillary and microchip electrophoresis (CE and ME) are two promising electrophoretic
methods for amyloid oligomer and aggregate detection. The present work demonstrated the
potential for CE and ME to detect native aggregation of insulin and Aβ proteins, in particular the
formation of oligomers and aggregates. Furthermore, the effect of hydrodynamic size on
separation was increased through the use of a highly entangled polymer matrix introduced into
the capillary, thus offering the potential to resolve populations of amyloid species. Using this
novel separation, we investigated variables such as sample salt concentration, sample preparation
method, and fluorescent dye structure. We demonstrated the ability of CE with ultraviolet
detection (UV-CE) to detect native insulin aggregates estimated to range in size from 30 – 100
kDa and native Aβ1-40 aggregates estimated to range in size from 10 – 30 kDa, 10 – 300 kDa and
> 300 kDa. These studies demonstrated the successful detection of physiological concentrations
(pM) of monomeric fluorescein isothiocyanate labeled insulin (FITC-insulin) and carboxyfluorescein labeled Aβ (FAM-Aβ) using CE with laser induced fluorescence detection (LIF-CE).
However, the detection of oligomeric and aggregate species was altered from unlabeled samples,
indicating the need for future work in the study of fluorescent dye attachment.
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INTRODUCTION
The detection of oligomers and aggregates formed by two amyloid proteins, insulin and
amyloid-β (Aβ), is of particular importance due to the role which these species play in Diabetes
and Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques
or alternative techniques must be explored in order to identify and quantify the size of these
oligomeric and aggregate species without disrupting their structure. Capillary and microchip
electrophoresis (CE and ME) are two promising electrophoretic methods for amyloid oligomer
and aggregate detection. The present work demonstrated the potential for CE and ME to detect
native aggregation of insulin and Aβ proteins, in particular the formation of oligomers and
aggregates.
During the earliest portion of this doctoral research (Fall 2009), a literature review was
conducted by the author in order to determine alternative techniques suitable for the detection of
amyloid oligomers and aggregates, in particular Aβ. Furthermore, this literature review was
published in Spring 2012 in the International Journal of Molecular Sciences as a review paper.
Since this publication gave a good outline for the techniques utilized to detect Aβ oligomeric
size, this publication was reproduced in Chapter 1 as a part of the literature review for this
dissertation. The author of this dissertation contributed to writing over 50% of this literature
review. Furthermore, Chapter 3 outlines studies conducted using CE to detect insulin oligomers
and aggregates. This information was published in Fall 2011 in the International Journal of
Molecular Sciences. Again, since this author contributed to writing over 50% of this publication,
this publication was reproduced in Chapter 3 as a part of this dissertation.

1

Chapter 1: Unraveling the Early Events of Aβ Aggregation: Techniques for the
Determination of Aβ Aggregate Size
Pryor, E.; Moss, M. A.; Hestekin, C. N. Int. J. Mol. Sci. Unraveling the Early Events of Aβ
Aggregation: Techniques for the Determination of Aβ Aggregate Size 2012, 13, 3038-3072
Abstract
The aggregation of proteins into insoluble amyloid fibrils coincides with the onset of
numerous diseases. An array of techniques is available to study the different stages of the
amyloid aggregation process.

Recently, emphasis has been placed upon the analysis of

oligomeric amyloid species, which have been hypothesized to play a key role in disease
progression. This paper reviews techniques utilized to study aggregation of the amyloid-β
protein (Aβ) associated with Alzheimer’s disease. In particular, the review focuses on techniques
that provide information about the size or quantity of oligomeric Aβ species formed during the
early stages of aggregation, including native-PAGE, SDS-PAGE, Western blotting, capillary
electrophoresis, mass spectrometry, fluorescence correlation spectroscopy, light scattering, size
exclusion chromatography, centrigugation, enzyme-linked immunosorbent assay, and dot
blotting.
Keywords
amyloid, capillary electrophoresis, centrifugation, dot blotting, enzyme-linked immunosorbent
assay, fluorescence correlation spectroscopy, light scattering, mass spectrometry, nativepolyacrylamide gel electrophoresis, oligomer, size exclusion chromatography, sodium dodecyl
sulfate polyacrylamide gel electrophoresis, photoinduced cross-linking of unmodified proteins,
Western blotting
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1. Introduction
Protein aggregation leads to the formation of insoluble fibrous aggregates, termed
amyloids, which are commonly associated with disease. However, understanding of the
mechanism by which proteins aggregate has remained elusive. Although larger aggregates,
including fibrils, remain important for clinical determination [1,2], small oligomeric aggregates
are of interest due to their potentially toxic nature and hypothesized role in disease progression.
However, the study of oligomers is complex due to the fact that these early aggregates are highly
unstable, present at low concentrations, and difficult to isolate.
Among the diseases to which amyloids contribute are Alzheimer’s disease (AD),
Parkinson’s disease, prion diseases, Type II diabetes mellitus, Huntington’s disease, as well as
many others [3]. The clinical presentation of each amyloid disease is very different, yet the
presence of amyloid fibrils is a common characteristic of each disease. These amyloid fibrils
exhibit a cross β-sheet structure in which the β-strands are oriented perpendicular to and
hydrogen bonding is oriented parallel to the long axis of the fibril [4-9]. In addition, it has been
shown that the amyloidogenic proteins amyloid-β (Aβ), α-synuclein, huntingtin, prion, and islet
amyloid polypeptide (IAPP) form structurally similar soluble oligomeric species, which share an
epitope recognized by oligomer-specific antibodies [10,11]. The commonalities shared by each
amyloid disease protein suggest that studying the aggregation of one amyloid protein could
provide insight into the general aggregation mechanism of other amyloid proteins.
AD is the most common cause of dementia and the most prevalent neurodegenerative
disorder [12,13]. The neurodegenerative effects of AD are hypothesized to arise from Aβ, a
partially folded protein that aggregates during the disease process. Aβ was first identified by
Masters et al. as the aggregated protein [14] deposited within plaque cores found in AD brain. In
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its monomeric form, this protein may be harmless [15]. However, Aβ monomer can selfassemble via a nucleation-dependent pathway into Aβ oligomers, larger Aβ aggregation
intermediates, and eventually the fibrillar aggregates that deposit in the brain (Figure 1) [5,1618]. Steps within the Aβ aggregation pathway are reversible, such that deposited fibrils could
give rise to soluble oligomers and intermediates. Soluble aggregate species that appear between
monomer and insoluble fibrils have been termed within the literature as oligomers [19], micelles
[20], amyloid-derived diffusible ligands (ADDLs) [21,22], βamy balls [23], amylospheroids
(ASPDs) [24], and protofibrils [25,26], and the aggregate sizes associated with these definitions
overlap in range. Smaller species are most commonly referred to as oligomers, including both
low molecular weight and high molecular weight species, while larger intermediates are often
referred to as protofibrils. Controversy exists concerning the exact size of the nucleus formed
within the rate-limiting step of the aggregation pathway; however, most reports speculate that the
nucleus is oligomeric in nature [27-29]. In addition to oligomers formed along the aggregation
pathway, off pathway oligomers and higher order assemblies, which fail to give rise to an
organized fibril structure, have also been identified [29,30].

4

Figure 1: The Aβ aggregation process.

Aβ monomer self-assembles into low

molecular weight oligomeric species that can give rise to either off-pathway
oligomers or nuclei of an undetermined size. Nuclei, which arise within the ratelimiting step of the Aβ aggregation pathway, will increase in size to form high
molecular weight oligomers, soluble aggregation intermediates, and finally the
fibrillar aggregates that deposit in AD brain to yield amyloid plaques.

Figure 1

The Aβ aggregation process
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Aβ proteins comprised of either 40 or 42 amino acids, termed Aβ1-40 and Aβ1-42, are the
major components found in amyloid plaques [31]. Aβ1-42 has implications for the formation of
initial aggregates, while Aβ1-40 is more soluble and is the main circulating form in normal plasma
and cerebrospinal fluid (CSF) [32]. Controversy currently exists over the direct effect Aβ has on
neurodegeneration, but it is theorized that soluble aggregates of Aβ, rather than monomers or
insoluble fibrils, may be responsible for the cellular pathology associated with AD [33-35]. This
hypothesis is supported by experimental observations in vitro which show that soluble
aggregates formed by synthetic Aβ1-40 and Aβ1-42 can induce cellular dysfunction and toxicity in
cultured cells [21,36,37] and in vivo where Aβ dodecamers (Aβ*56) have been isolated from the
brains of transgenic mice and shown to induce memory deficits [38]. In addition, soluble Aβ
aggregates generated in cell culture drastically inhibit hippocampal long-term potentiation in rats
[39]. Furthermore, data from mouse models show a poor correlation between the levels of
insoluble Aβ fibrils and disease severity [40]. It is now more widely accepted that soluble Aβ
oligomers impair cognitive function and, in addition to synapse loss, correlate most accurately
with the stage of neurological impairment [11,41-43]. However, the progression from monomer
to oligomer to insoluble Aβ aggregates is not well understood. Therefore, it is important to
develop an analytical tool that is suitable for analysis of the Aβ aggregation process.
A range of techniques are available to study the different stages of the Aβ aggregation
process. These techniques fall into three main categories: 1) Methods for the quantitative
detection of monomeric and oligomeric Aβ sizes; 2) Methods for the qualitative detection and
characterization of oligomeric Aβ species; 3) Methods for the qualitative detection of Aβ fibrils.
As a result of the imminent need to understand oligomerization events, the focus of this review is
on techniques from the first and second categories, which give information about Aβ oligomeric
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species formed during aggregation. Accumulating evidence suggests that these Aβ oligomeric
species play a role in AD progression and severity. Therefore, it is important to gain a better
understanding of the formation of smaller Aβ species in order to halt the progression of AD. The
ability to identify and quantify the size of these Aβ oligomeric species without disrupting their
structure is of utmost importance in order to effectively study the aggregation process and
develop treatments that target these pivotal oligomerization events. Accordingly, this review
focuses primarily upon techniques that have been employed in the study of in vitro aggregation
of Aβ. Currently, a commonly used technique for the quantification of Aβ oligomer sizes within
in vitro studies is polyacrylamide gel electrophoresis (PAGE). Other techniques that have been
applied for determining the size of Aβ oligomers include Western blotting, capillary
electrophoresis, mass spectrometry, fluorescence correlation spectroscopy, light scattering,
centrifugation, and size exclusion chromatography (SEC). Furthermore, techniques including
enzyme-linked immunosorbent assay (ELISA) and dot blot have been applied to identify Aβ
oligomers, but give no size estimates. In the subsequent sections, we will discuss the application
of each of these techniques to study Aβ oligomers.
2. Electrophoretic Techniques for the Quantification of Aβ Oligomer Sizes
2.1. SDS- and Native-PAGE
SDS-PAGE is the most common electrophoretic technique used for Aβ oligomer size
determination in protein aggregation studies. Furthermore, a review by Bitan et al. cited SDSPAGE as the most common method used to characterize toxic protein oligomers [44]. SDSPAGE relies on the ability of SDS, a negatively charged detergent, to bind to the protein of
interest. This binding typically results in the removal of secondary, tertiary, and quaternary
structures from the protein. The SDS groups attach to the protein in a nearly uniform manner that
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gives the protein a charge approximately proportional to its length, thereby allowing for size
based separations. Following the gel electrophoretic separation of proteins, the gel may be
stained with a dye such as Coomassie Brilliant Blue or silver stain.
Many research groups have utilized SDS-PAGE, as a standalone technique, to study the
evolution of Aβ species over time. A study by Ying et al. used SDS-PAGE to separate oligomers
formed by 100 µM Aβ1-42 incubated at 4°C for 1 day [45]. SDS-PAGE revealed bands for
monomer (4.5 kDa), trimer/tetramer (16.5 kDa), and higher molecular weight intermediates (>83
kDa) that appeared as a smear. The oligomer pattern of freshly dissolved Aβ peptides and Aβ
peptides after a 7 day incubation have been observed by Satoh et al. [46]. Both Aβ1-40 and Aβ1-42
peptides incubated for 7 days as well as the freshly dissolved Aβ1-42 peptide exhibited a range of
species from 5 - 20 kDa (Figure 2). However, the resolution of these species was low due to gel
smearing. Smearing in these gels may be due to the resolution limitations of the gel or could be
due to continuous associations and disassociations of the aggregating species occurring during
the electrophoresis analysis. Whatever the cause, gel smearing interferes with the ability to
identify a particular species and is often overcome by combining SDS-PAGE with another
technique (see Sections 2.2 and 2.3).
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Figure 2: Tricine-SDS-PAGE analysis of the aggregation states of Aβ peptides
freshly dissolved or incubated for 7 days. Aβ1-42 exhibits bands at 5 - 20 kDa in both
freshly prepared samples and samples incubated for 7 days. Aβ1-40 incubated for 7
days also exhibits a smear at higher molecular weights, which is absent in freshly
prepared samples. Reprinted from [46], with permission from Elsevier.

Figure 2

Tricine-SDS-PAGE analysis of the aggregation states of Aβ peptides freshly dissolved or
incubated for 7 days

9

Although the anionic micelles formed by SDS enhance separation, they can also induce
non-native behavior. SDS has been reported to accelerate the generation of Aβ fibrils.
Sureshbabu et al. have shown that Aβ1-42 freshly prepared in phosphate buffered saline exhibits
monomer, trimer (~13.5 kDa), and tetramer (~18 kDa) bands when analyzed via Western
blotting [47]. The addition of 1.5 mM SDS to the sample produced bands at 20 and 50 kDa. They
proposed that the addition of 1.5 mM SDS causes Aβ1-42 to develop a partial helical structure
whose hydrophobicity induces aggregation. One way to counter this phenomenon is to add urea
to the sample to further denature the peptide and prevent aggregation. However, the migration
behavior of Aβ peptides in urea SDS-PAGE is inconsistent. A study by Kawooya et al. showed
that the Aβ peptide exhibits an unusual electrophoretic mobility in urea SDS-PAGE that is
proportional to the sum of the hydrophobicity consensus of the peptide rather than the number of
amino acids in the peptide [31]. Therefore, under these conditions SDS-PAGE may provide
information about the hydrophobicity of the peptide and not the size. The drawbacks of SDSPAGE may be overcome by using native-PAGE to separate various Aβ sizes under conditions
that allow the protein to remain in a native state.
Native or “non-denaturing” gel electrophoresis is similar to SDS gel electrophoresis,
except this technique is run in the absence of SDS. With native-PAGE, protein mobility depends
on both charge and hydrodynamic size. This differs from SDS-PAGE, where protein mobility
depends primarily on molecular mass. Since Aβ aggregation is a process that involves changes in
protein conformation, native-PAGE is often a suitable technique to detect various sizes of Aβ
species. A study by Iurascu et al. used both SDS-PAGE and Tris-tricine PAGE to analyze the
species formed by a solution of Aβ1-40 solubilized in fibril growth buffer at pH 7.5 for 5 days at
37°C [48]. They found that SDS-PAGE was able to detect Aβ1-40 monomeric species, Aβ1-40
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oligomeric species of 20 kDa, and high molecular weight aggregates >98 kDa. In contrast, Tristricine PAGE was able to separate these Aβ oligomers into monomer, dimer, trimer, and high
molecular weight Aβ sizes. Klug et al. have also compared native and SDS-PAGE analyses of
Aβ aggregation [49]. They observed the presence of oligomers and high molecular weight
species using native-PAGE with the majority of Aβ species observed in the high molecular mass
region of the gel. In contrast, SDS-PAGE showed lower molecular weight species (<14 kDa)
with only trace amounts of high molecular weight species (>50 kDa), suggesting that the
removal of higher order protein structures by SDS may destabilize aggregates. The differences
between native-PAGE and SDS-PAGE highlight the importance of examining more than one
method for studies of the various Aβ aggregate sizes formed throughout the aggregation process.
2.2 SDS-PAGE in Combination with Western Blotting
Western blotting is a popular technique used to further process samples after
electrophoretic separation. This technique provides a more sensitive detection of separated
proteins. This detection is achieved by transferring separated proteins to a membrane where they
are detected using antibodies specific to the protein of interest. Antibodies may be either
monoclonal or polyclonal and are typically specific for a particular part of the Aβ sequence or a
particular amyloid conformation. Some common antibodies and their recognition motifs are
listed in Table 1. Selecting the proper antibody is an important consideration in order to achieve
detection of the desired Aβ species or aggregation state.
Numerous research groups have utilized Western blot analyses of SDS-PAGE separations
to characterize SDS-stable Aβ assemblies [21,39,45,50-54]. Ryan et al. analyzed Aβ1-42 oligomer
preps via silver staining and immunoblot with the 6E10 antibody [53]. The band intensity for
monomer, trimer, and tetramer bands was similar for both methods. However, 46 and 56 kDa
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intermediate sized oligomers were more apparent in the immunoblot analysis. Moore et al. have
also found that immunoblot stains of Aβ1-42 oligomers yield better results than silver stains [55].

12

Table 1: Antibodies used for Aβ detection in Western blot analysis and their
respective Aβ recognition motifs.
Table 1 Antibodies used for Aβ detection in Western blot analysis and their respective Aβ
recognition motifs
Antibody

Recognition Motif

Monoclonal/Polyclonal

References

6E10

Aβ1-17

Monoclonal

[50,52-54]

Ab9

Aβ1-16

Monoclonal

[55]

6C6

Aβ1-16

Monoclonal

[50]

4G8

Aβ17-24

Monoclonal

[50]

2G3

Aβ31-40

Monoclonal

[51]

BA-27

Aβ1-40, C-terminal

Monoclonal

[56]

BC-05

Aβ1-42, C-terminal

Monoclonal

[56]

A8

amyloid oligomers

Monoclonal

[45]

A11

amyloid oligomers

Monoclonal

[10,57,58]

NU-4

amyloid oligomers

Monoclonal

[59]

OC

amyloid fibrils

Polycolonal

[60]
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SDS-PAGE with Western blotting has also been used to monitor the formation of Aβ
oligomers in cell culture. A study by Walsh et al. employed SDS-PAGE followed by Western
blotting to probe the formation of Aβ oligomers in APP-expressing Chinese hamster ovary
(CHO) cells [50]. Bands corresponding to ~4, 6, 8, and 12 kDa were obtained using the
monoclonal antibody 6E10. However, it was necessary to concentrate the Aβ protein via
immunoprecipitation with an Aβ-specific antibody prior to performing electrophoretic
separation.
Within in vitro studies of Aβ aggregation, Aβ is typically solubilized in 1,1,1,3,3,3hexafluoro-2-propanol (HFIP) to break up any residual aggregates that may be present in
solution [61]. The HFIP is allowed to evaporate, and the peptide film is either resuspended in an
organic solvent such as dimethyl sulfoxide (DMSO) and diluted into culture media or
resuspended in a buffer solution such as phosphate buffered saline (PBS). Following incubation,
samples are analyzed to detect the presence of oligomeric species. Dahlgren et al. utilized such
an Aβ1-40 oligomer preparation employing DMSO and F12 culture media with incubation at 4°C
for 24 hours [52]. Western blot analysis using the 6E10 antibody showed bands corresponding to
monomer and tetramer. Similar results were obtained by Stine et al. using the same sample
preparation [54]. Walsh et al. utilized an Aβ1-40 oligomer preparation in PBS (pH 7.4) at 37°C
[51]. After 5 days, Western blot analysis using the antibody 2G3 showed bands corresponding to
monomer, dimer, and tetramer. However, intermediate sizes of oligomeric species >20 kDa were
not obtained.
In addition to Aβ1-40, oligomeric Aβ1-42 species formed in vitro have been well
characterized using Western blot analyses. Stine et al. studied the formation of Aβ1-42 oligomers
using two different antibodies, 6E10 and 4G8 [54]. At 0 hours, bands for monomer, trimer, and a
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faint tetramer band were obtained. After 24 hours, these bands were more intense and a smear
corresponding to oligomeric species ranging from 30 to 70 kDa was present. Furthermore, no
differences in the band patterns obtained using the 6E10 and 4G8 antibodies were observed.
Dahlgren et al. obtained comparable 24 hour incubation results using the same oligomer
preparation as Stine et al. [52]. In addition, similar 0 and 24 hour results were obtained by Ryan
et al. using a monomer preparation with dilution into PBS and an oligomer preparation with
dilution into cold PBS+0.05% SDS [53]. Stine et al. also examined the effect of temperature and
ionic strength on the oligomeric band pattern obtained after incubation of 100 μM Aβ1-42 for
24 hours. An increase in temperature from 4 to 37°C resulted in a decreased intensity of
monomer and trimer bands and an increased intensity of the tetramer band. In addition, a smear
for oligomeric species ranging from 30 to 70 kDa appeared at 25°C with increased intensity at
37°C. The effect of ionic strength was probed using the oligomer preparation at 37°C with
incubation for 24 hours in either 10 mM Tris (pH 7.4) or 10 mM Tris supplemented with 150
mM NaCl. Both preparations yielded bands for monomer, trimer, and tetramer. However, the
oligomer preparation in 10 mM Tris gave an intense oligomer smear from 30 to 97 kDa while the
preparation in 10 mM Tris supplemented with 150 mM NaCl showed a less intense oligomer
smear from 40 to 50 kDa. Ying et al. have also utilized the same Aβ1-42 oligomer preparation as
Stine et al. but employed for detection the monoclonal antibody A8, which is specific for
oligomers [45]. A smear for oligomeric species ranging from 16.5 to 25 kDa was observed with
antibody A8 (Figure 3, lanes 2 and 3). A poorer resolution of oligomers and larger species were
obtained using the 6E10 antibody (Figure 3, lane 4). These results show that 6E10 may be
reacting more strongly with higher molecular weight oligomers or that these antibodies bind
preferentially to different sizes of Aβ1-42 oligomers. While Western blotting does facilitate
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detection of intermediate Aβ oligomers, the presence of a gel smear in many of the studies
outlined above indicates that this technique does not allow quantification of individual sizes of
oligomers in this range.
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Figure 3: Aβ1-42 oligomers obtained upon incubation at 4°C for 24 hours. A 5 mM
Aβ1-42 sample was prepared in DMSO and diluted to 100 µM in Ham’s F12 medium
without phenol red. Oligomer mixture was separated by 15% SDS-PAGE,
transferred to nitrocellulose membranes, and probed with monoclonal antibody A8
(Lanes 2 and 3) or 6E10 (Lane 4). Sample in Lane 2 was heat denatured prior to
analysis, while sample in Lane 3 was untreated. Reprinted from [45] with
permission. The publisher for this copyrighted material is Mary Ann Liebert, Inc.
publishers.

Figure 3 SDS-PAGE with Western Blotting Analysis of Aβ1-42 oligomers obtained upon
incubation at 4°C for 24 hours
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2.3 SDS-PAGE in Combination with Other Techniques
SDS-PAGE has been used in combination with oligomer stabilization techniques. One
such technique that has been applied by Bitan et al. is Photoinduced Cross-Linking of
Unmodified Proteins (PICUP) [62]. PICUP was developed in the Kodadek laboratory in 1999 to
study proteins that naturally form stable homo- or heterooligomers [63]. This technique provides
a snapshot of different oligomer species present in solution at different times. Protein crosslinking is achieved via the visible light excitation of a tris(2,2’-bipyridyl)dichlororuthenium(II)
complex which, through a series of steps, leads to the generation of a free protein radical [62,64].
This radical can attack an unmodified neighboring protein and form a covalent bond. Therefore,
PICUP can be used to covalently freeze components of the sample, and these components may
be separated and analyzed via techniques such as SDS-PAGE [62].
Bitan et al. have applied PICUP to compare low molecular weight fractions of Aβ1-40 and
Aβ1-42, where these fractions were isolated by SEC and analyzed via SDS-PAGE [65]. Aβ1-40
exhibited bands for monomer, dimer, trimer, and tetramer with more faint bands for pentamer
and heptamer (Figure 4, lane 2). A distinctly different low molecular weight Aβ1-42 oligomer size
distribution, consisting of three groups of oligomers of varying band intensity, was obtained
(Figure 4, lane 4). This pattern led to the conclusion that the initial phase of Aβ1-42
oligomerization involves the formation of pentamer/hexamer subunits which then associate to
form larger oligomers and intermediates, or protofibrils [65]. Furthermore, they found that for
Aβ1-40, monomer through tetramer were preexisting species in solution, while pentamer through
heptamer were formed via a diffusion-dependent reaction of these preexisting species with free
monomer. Their results verified that PICUP was capable of “freezing” preexisting oligomers but
was also capturing oligomeric species which were not formed under typical aggregation
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conditions, thereby misrepresenting the true Aβ1-40 oligomerization pattern. In addition, this
study examined samples that were not cross-linked via PICUP before separation by SDS-PAGE.
A single monomer band was obtained for Aβ1-40 (Figure 4, lane 1), while Aβ1-42 exhibited only
bands for monomer and trimer (Figure 4, lane 3). These results indicate that oligomers not
stabilized via PICUP were underestimated by SDS-PAGE results.
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Figure 4: SDS-PAGE analysis of non-cross-linked (lanes 1 and 3) and cross-linked
(lanes 2 and 4) Aβ1-40 and Aβ1-42. Densitometric intensity profiles of lanes 2 and 4
are shown on the right and left sides of the gel, respectively. Molecular weight
standards are shown on the left in kDa. Reprinted with permission from [62].

Figure 4 SDS-PAGE analysis of non-cross-linked and cross-linked Aβ1-40 and Aβ1-42
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SDS-PAGE has also been combined with SEC to investigate Aβ aggregation [25,66,67].
A study by Podlisny et al. used SDS-PAGE and SEC to observe the aggregation process of Aβ140

secreted from CHO cells [66]. Soluble, SDS-stable aggregates of 6 - 25 kDa, were detected

during the first 4.5 hours of incubation at 37°C via added radioiodinated synthetic Aβ1-40 at low
nanomolar concentrations. These 6 – 25 kDa Aβ oligomers represented ~18% of the total Aβ
signal via SDS-PAGE and ~31% of the total Aβ signal via SEC. This low conservation of the Aβ
gel signal over time to oligomeric species again indicates that SDS-PAGE underestimates the
amount of aggregation. A study by Walsh et al. compared size estimations via SEC to those
obtained by analyzing these SEC fractions by SDS-PAGE [25]. Aβ1-40 and Aβ1-42 were dissolved
in Tris-HCl (pH 7.4) and incubated for 48 and 6 hours, respectively, at room temperature. SEC
fractions corresponding to Aβ1-40 dimers, protofibrils, and fibrils produced a single band at ~4
kDa on SDS-PAGE. The SEC fraction for Aβ1-42 dimers produced a single SDS-PAGE band at
~4 kDa, while the SEC fraction for Aβ1-42 protofibrils and fibrils produced a ladder of sizes
ranging only from monomer to pentamer. These results suggest that SDS-PAGE may not
accurately detect Aβ aggregate sizes produced throughout aggregation.
2.4. Summary of SDS-Based Methods
As a standalone technique, SDS-PAGE is able to detect Aβ1-42 species ranging from
monomer to tetramer. Native-PAGE has been used to separate Aβ1-40 species ranging from
monomer to pentamer. However, for higher order oligomers, these techniques only give a range
of sizes that appear as a smear on the gel. SDS-PAGE is often coupled with other techniques
such as Western blotting and PICUP to enhance the resolution of Aβ sizes. By coupling SDSPAGE to these techniques, a better resolution of Aβ1-40 species which appear as individual gel
bands corresponding to monomer, dimer, trimer, and tetramer and Aβ1-42 species which appear as
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individual gel bands corresponding to monomer, trimer, tetramer, and hexamer has been
obtained. However, the resolution of intermediate sized Aβ oligomers ranging from 30 - 70 kDa
by PAGE remains a significant challenge. The addition of SDS may also lead to complications
including the acceleration of aggregation and the increased instability of oligomers, thereby
misrepresenting the distribution of Aβ oligomeric species.
2.5. Capillary and Microfluidic Capillary Electrophoresis
Capillary electrophoresis (CE) is another electrophoretic technique employed for size
based separations of Aβ. CE offers a fast and highly efficient separation of molecules with a
broad range of properties thereby making it well suited for the separation of different sizes of
protein aggregates [68]. CE separates molecules based on electrophoretic mobility, which results
from differences in charge, shape, and/or size, and may be used either with or without SDS.
Thus, CE allows a highly efficient separation and resolution of native forms of Aβ species,
thereby overcoming the problem of gel smearing in many SDS and native-PAGE gel separations.
CE detection typically uses either ultraviolet (UV) absorbance or laser induced fluorescence
(LIF) to detect proteins. UV can detect proteins without any additional labeling, but typically has
a lower sensitivity than LIF. LIF usually requires labeling of the molecules, but is highly
sensitive, with previous reports of CE-LIF detection of double-stranded DNA down to the pg/μL
range [69,70]. The ability to detect biomolecules at these low concentrations is necessary for the
analysis of physiologically relevant protein concentrations.
CE with UV detection has been utilized by various researchers to detect Aβ species from
monomers to large aggregates. Verpillot et al. used CE-UV to separate monomeric Aβ ranging in
size from 37 - 42 residues and differing in length by a single residue, however they did not
examine Aβ aggregation [71]. A study by Sabella et al. applied CE-UV with an SDS rinse for the
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detection of Aβ1-40 and Aβ1-42 oligomers formed in PBS (pH 7.4) at room temperature [72]. At 0
hours, peaks for Aβ1-42 oligomers in a size range from monomers to undecamers (~50
kDa)/dodecamers (~54 kDa) and larger aggregates were obtained (Figure 5, t0). A similar peak
pattern was obtained over an incubation time period of 24 hours with an increase in intensity of
the higher molecular mass (>50 kDa) oligomer peak (Figure 5, t = 1440 minutes). However,
resolution of individual species, especially in the larger aggregate peak, was not achieved.
Compared to Aβ1-42, the peaks for Aβ1-40 were better resolved, but a drastically different peak
pattern was observed. At 0 hours, three peaks ranging in size from 3 to 30 kDa were obtained. A
decrease in the intensity of the 10 to 30 kDa peak was observed over an incubation period of 24
hours with the disappearance of all peaks after 48 hours. This result shows that CE-UV is
capable of detecting small Aβ1-40 species and intermediate oligomeric Aβ1-42 species. In addition,
the CE electrophoretic profiles of Aβ1-40 and Aβ1-42 differ significantly, supporting observations
by PAGE that these two proteins differ in their early stages of aggregation.
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Figure 5: Electropherograms for Aβ1-42 species formed in room temperature PBS
(pH 7.4) at different elapsed aggregation times from t0. CE was performed with 50
mbar pressure injection for 8 s with separation at 16 kV. Molecular weights
corresponding to each peak were determined using Microcon centrifugal filter units
with molecular weight cutoffs of 3, 10, 30, and 50 kDa. Peaks with migration times
of 5 – 10 min represent monomers to undecamers/dodecamers (3 – 50 kDa) and
peaks with migration times of 10 – 15 min represent larger aggregates (>50 kDa).
Reprinted from [72] published by John Wiley and Sons, © 2004 WILEY-VCH
Verlag GmbH & Co. KGaA.

Figure 5 CE Electropherograms for Aβ1-42 species formed in room temperature PBS (pH 7.4) at
different elapsed aggregation times from t0
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A study by Picou et al. also observed substantial differences in the CE-UV
electrophoretic profiles of Aβ1-40 and Aβ1-42 [73]. Two different preparations typically employed
to form Aβ monomer or fibril were used. The Aβ1-40 monomer preparation yielded a single
monomer peak with a molecular weight of 4.3 kDa. In contrast to Aβ1-40, the Aβ1-42 monomer
preparation gave peaks for both monomer and fibrillar species. A peak pattern similar to the Aβ142

monomer preparation was also obtained for the Aβ1-40 fibril preparation. The Aβ1-42 fibril

preparation produced multiple aggregate peaks and no monomer peak. Although this study was
able to separate Aβ monomer from mature fibrils, the detection of oligomeric Aβ species was not
achieved.
LIF detection has also been utilized as a more sensitive means of identifying lower
concentrations of Aβ aggregate species separated using CE. A study of the aggregation patterns
of Aβ1-42 using CE-LIF was conducted by Kato et al. [74]. The fluorescent dye thioflavin T
(ThT) was used to detect two different Aβ1-42 aggregate sizes with a 5 minute analysis time [74].
In addition, this study examined the effect of seeding a freshly prepared Aβ1-42 sample with a
fibrillar Aβ1-42 seed. For samples without a seed, a broad peak was observed with CE-LIF as
opposed to seeded samples that contained both a sharp and broad peak, although no specific sizes
were determined.
In addition to CE-LIF, microfluidic capillary electrophoresis (MCE) has been used to
study Aβ. MCE is similar to CE except operates on a much smaller scale. The advantages of
MCE over conventional electrophoresis methods include low sample consumption and a strong
potential for automation and integration [75,76]. MCE has been utilized to study Aβ monomeric
species. A study by Mohamadi et al. utilized MCE-LIF for the separation of five Aβ isoforms

25

(Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42) [77]. However, MCE has yet to be applied for the
study of Aβ oligomers.
CE as a technique for the detection of Aβ species formed throughout aggregation is still
in its early stages. CE-UV has been utilized to detect small Aβ1-40 species ranging from 3 - 30
kDa as well as to separate Aβ1-40 monomer from fibrillar species. Aβ1-42 species ranging from 3 50 kDa and >50 kDa have been detected using CE-UV. In addition, the separation of Aβ1-42
monomer from fibrillar species has been achieved using CE-UV, and the separation of two
different Aβ1-42 fibrils has been accomplished with CE-LIF. The development of MCE has
prompted researchers to apply this technique to the study of Aβ, with initial investigations
demonstrating the separation of five Aβ isoforms differing in length by a single residue. The
ability of CE to detect sizes from monomers to fibrils offers the potential to monitor the amyloid
aggregation process over time, and the use of LIF provides the potential for examining
physiologically relevant concentrations. However, further improvements to this technique must
be made in order to enhance the resolution of intermediate sized Aβ species.
3. Spectroscopic Techniques for the Quantification of Aβ Oligomer Sizes
3.1 Mass Spectrometry
Mass spectrometry (MS) is a widely used technique for the detection of monomeric and
oligomeric Aβ. In MS, the sample undergoes vaporization, and components are ionized by
impacting them with an electron beam. Ions are separated by their mass-to-charge ratio using
electromagnetic fields, and the ion signal is processed into a mass spectrum characteristic of the
analyte. MS uses a variety of ionization sources depending on the sample state. For vapor
samples, the most common source used to generate gas-phase ions is a radioactive ionization
(RI) source [78,79]. However, other ion sources such as corona discharge ionization (CDI)
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[80,81], photoionization (PI) [80,82], and secondary electrospray ionization (SESI) [83-86] have
been used as well. The most commonly used ionization source for liquid samples is electrospray
ionization (ESI) [83-86], and for solid samples matrix assisted laser desorption ionization
(MALDI) [87-90] and laser desorption ionization (LDI) [91-93] are widely used ionization
sources. In addition, there are various types of mass analyzers that process the ion signal into a
mass spectrum. These include time-of-flight, quadrupole, ion trap, Fourier transform ion
cyclotron, magnetic sector, and tandem instruments as recently reviewed by Kanu et al. [94]. The
most common MS techniques used for protein analyses are MALDI-MS and ESI-MS.
3.2 Matrix-Assisted Laser-Desorption Ionization (MALDI)-MS
MALDI-MS may be combined with other separation techniques such as SDS-PAGE to
provide more quantitative size estimates. Iurascu et al. utilized SDS-PAGE in combination with
MALDI-MS to analyze a solution of Aβ1-40 solubilized in fibril growth buffer at pH 7.5 for 5
days at 37°C [48]. MALDI-MS indicated that the soluble fraction contained two different ion
mobilities, indicative of oligomerization. Parallel analysis using SDS-PAGE and Tris-tricine
PAGE revealed the presence of oligomeric Aβ1-40 of ~20 kDa (pentamer). A study by Maji et al.
subjected wild-type and tyrosine substituted Aβ1-40 and Aβ1-42 to PICUP and quantified the
resulting aggregate sizes via MALDI-MS and SDS-PAGE [95]. SDS-PAGE yielded wild-type
Aβ1-40 bands for monomer through hexamer. However, MALDI-MS was only able to attain
masses for the monomer through tetramer bands, while masses for the pentamer and hexamer
bands could not be measured. This inconsistency could be attributed to the presence of very
small quantities of pentamer and hexamer. Alternatively, these species may not be desorbed from
the MALDI matrix as readily as smaller oligomers. In addition, MALDI-MS spectra of tyrosine
substituted Aβ1-42 oligomers were not obtained, suggesting that either these oligomers could not

27

be incorporated into the MALDI matrix due to their exceptional hydrophobicity or their covalent
or weak noncovalent interactions were disrupted by the desorption/ionization process. These
results show that although MALDI-MS may be used to quantify Aβ oligomers, this technique
does have drawbacks including limited matrix interactions as well as the inability to distinguish
molecules with overlapping charge-to-mass ratios, expense, and labor intensive analyses [96,97].
In addition, since MALDI is typically coupled with a pre-separation step such as SDS-PAGE, its
detection capabilities may vary depending on the pre-separation technique used.
3.3 Electrospray Ionization (ESI)-MS
ESI-MS has been used to analyze liquid Aβ samples. Palmblad et al. have utilized ESI-MS
to study the effect of Met-35 oxidation on the formation of Aβ1-40 oligomers [98]. They found
that freshly dissolved Aβ1-40 and Aβ1-40Met35(O) both exhibited monomers and dimers (Figure 6,
panels a and b). In addition, Aβ1-40 and Aβ1-40Met35(O) incubated for 41 minutes exhibited
similar monomer and dimer signals (Figure 6, panels e and f). In contrast, trimers and tetramers
were detected for freshly dissolved Aβ1-40 (Figure 6, panel c) whereas these species were not
detectable for freshly dissolved Aβ1-40Met35(O) (Figure 6, panel d). However, after >95 minutes
of incubation, Aβ1-40 and Aβ1-40Met35(O) exhibited similar trimer and tetramer signals (Figure 6,
panels g and h). These results suggest that Met-35 oxidation slows a conformational change that
may be necessary for early formation of Aβ1-40 trimers. Although ESI-MS can be used as a way
to freeze protein oligomers in time, complications arise when a protein could simultaneously
populate a number of states with the same mass-to-charge ratio [97]. This complication makes it
difficult to quantify different size oligomers that have the same mass-to-charge ratio.
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Figure 6: ESI-Mass spectra of 4.0 µM freshly dissolved Aβ1-40 (panels a and c),
freshly dissolved Aβ1-40Met35(O) (panels b and d), Aβ1-40 and Aβ1-40Met35(O)
incubated for 41 minutes (panels e and f), and Aβ1-40 and Aβ1-40Met35(O) incubated
for >95 minutes (panels g and h). Aβ1-40 samples were dissolved in H2O and Aβ140Met35(O)

samples were dissolved in H2O and 2.7% H2O2. Reprinted with

permission from [98]. Copyright (2002) The American Society for Biochemistry and
Molecular Biology.

Figure 6 ESI-Mass spectra of 4.0 µM freshly dissolved Aβ1-40, freshly dissolved Aβ1-40Met35(O),
Aβ1-40 and Aβ1-40Met35(O) incubated for 41 minutes, and Aβ1-40 and Aβ1-40Met35(O) incubated
for >95 minutes
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3.4 Ion Mobility (IM)-MS
IM-MS is capable of separating ions by both their shape and charge, which has rendered
it a successful technique for the separation of conformers of various shapes arising from a single
protein [94,99-101]. Ions are separated in time according to their cross sections by passing them
through a drift cell containing helium gas under the influence of a weak electric field [102]. The
flight times are combined with the drift times to yield the mass-to-charge IM distributions for all
ions in the sample. The ability of IM-MS to separate species that differ in shape or size but have
the same mass-to-charge ratio has made this technique a powerful tool for analyses of the early
stages of Aβ oligomerization.
Various research groups have utilized IM-MS to gain a better understanding of the early
events of Aβ aggregation. Aβ1-40 conformational states in freshly dissolved and aggregated
solutions have been studied by Iurascu et al. [48]. Two different conformational states were
obtained for freshly dissolved Aβ1-40 and the soluble fraction obtained by Aβ1-40 incubation for 5
days at 37°C and pH 7.5. Bernstein et al. used IM-MS to study the aggregation of Aβ1-42 versus
Aβ1-42 with a Phe19→Pro19 substitution [103]. Monomers and large oligomers were produced
by unfiltered Aβ1-42, while protein passed through a 10,000 amu filter yielded monomer, dimer,
tetramer, hexamer, and an aggregate of two hexamers. In contrast, the Pro19 alloform produced
monomer, dimer, trimer, and tetramer but no large oligomers. In a more recent study by
Bernstein et al., a mechanism for Aβ1-40 and Aβ1-42 oligomerization and eventually fibril
formation was postulated [104]. Using IM-MS, this group was able to determine the shape and
size of Aβ1-40 and Aβ1-42 oligomers. Aβ1-40 oligomerization proceeded via the formation of dimer
and tetramer followed by the very slow formation of fibrils containing a β-sheet structure. In
contrast, Aβ1-42 proceeded via the formation of dimer, tetramer, and a hexameric paranucleus
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followed either by the formation of dodecameric species or the slow conversion into fibrils
containing a β-sheet structure. Representative IM-MS data obtained by Berstein et al. for Aβ1-42
and Aβ1-40 are shown in Figure 7. Similar findings about the early oligomerization behavior of
Aβ1-40 and Aβ1-42 were obtained by Murray et al. using IM-MS [102]. In addition, these
researchers found that in an equimolar mixture of Aβ1-40 and Aβ1-42, Aβ1-40 inhibited the
formation of higher molecular weight oligomers by Aβ1-42. This result suggests that Aβ1-40 could
sequester Aβ1-42 into stable tetramers and prevent the further oligomerization of Aβ1-42 into
dodecameric species.
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Figure 7: IM-MS arrival time distributions for (a) 30 µM Aβ1-42 in 49.5% H2O,
49.5% acetonitrile, and 1% NH4OH and (b) 30 µM Aβ1-40 in ammonium acetate (pH
7.4). D = dimer, Te = tetramer, H = hexamer, Do = dodecamer with a z/n = -5/2.
Figure 7a adapted with permission from [103]. Copyright (2005) American Chemical
Society. Figure 7b adapted by permission from Macmillan Publishers Ltd.: Nature
Chemistry [104], copyright (2009).

Figure 7 IM-MS arrival time distributions for (a) 30 µM Aβ1-42 in 49.5% H2O, 49.5%
acetonitrile, and 1% NH4OH and (b) 30 µM Aβ1-40 in ammonium acetate (pH 7.4). D = dimer, Te
= tetramer, H = hexamer, Do = dodecamer with a z/n = -5/2
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3.5 Fluorescence Correlation Spectroscopy
Fluorescence correlation spectroscopy (FCS) has also been utilized to gain information
about the size of Aβ species formed throughout aggregation [24,105-107]. FCS was originally
developed by Eigen and Rigler in the early 1990s [108]. In FCS, unlabeled protein is combined
with fluorescently labeled protein and, at various times throughout aggregation, the fluorescent
dye is excited by a sharply focused laser beam. The emitted fluorescence of a small number of
molecules in solution is observed. The fluorescence intensity fluctuates due to Brownian motion
of the particles, and an intensity correlation function can be used to determine the average
number and average diffusion time (ie. molecular size) of molecules. Advantages of FCS include
high sensitivity (nM range and below), ability to examine a wide range of molecular sizes (ie.
monomer, oligomer, fibrils) [109], fast analysis times [109], and small sample volumes
(femtoliter) [110]. In addition, no pre-separation step is required for the determination of particle
radius via FCS. However, assumptions must be made about the kinetics of the aggregation
process as well as molecular shape in order to determine molecular weight.
Various researchers have employed FCS to monitor Aβ aggregation. A study by
Matsumura et al. utilized FCS to monitor the aggregation of Aβ1-40 and Aβ1-42 and observed
distinct aggregation pathways, dependent upon incubation conditions, that resulted in the
formation of either oligomeric species or fibrils [24]. Two different site-specific labels at either
the N-terminus or Lys16 were used to monitor aggregation. One pathway involved the formation
of 10 - 15 nm spherical Aβ1-42 assemblies of ~330 kDa, termed amylospheroids (ASPDs),
appearing after 5 hours of gentle agitation of a 50 µM Aβ1-42 solution in F12 buffer at 4°C. These
ASPDs were formed from Aβ species of ~12.7 kDa initially present in solution. In addition, the
aggregation pathways were similar for the N-terminus and Lys16 site-specific labels. An
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alternative pathway involved fibril formation from 100 µM Aβ1-40 solutions in Dulbecco’s PBS
(pH 3.5) with gentle agitation at 4°C. This pathway began with dimer formation at 0 hours,
followed by the formation of intermediate sized species of 15 - 40 nm after 2 - 9 hours.
Eventually, larger molecular weight fibrils (14,000 kDa) were formed after 24 hours using Aβ
labeled site-specifically at Lys16. However, much larger aggregates (120,000 and 3,900,000,000
kDa) were formed after 24 hours using Aβ labeled site-specifically at the N-terminus. It was thus
postulated that the Lys16 fluorescent probe interfered with aggregation into larger fibrils. By
employing oligomer formation conditions, Cizas et al. used FCS to observe much smaller Aβ1-42
oligomers [105]. They dissolved Aβ1-42 in HFIP with subsequent dilution into de-ionized water
and incubation at 20°C with or without agitation (500 rpm) for 24 hours. The average radius
observed for unagitated samples was ~3.4 nm while the radius for agitated samples was ~8 nm.
Garai et al. have applied FCS to monitor the Aβ1-40 aggregation process when monomer is
initially the predominant species present in solution (Figure 8, time = 0.05 hours) [107]. After 1
hour, intermediate aggregates of 20 - 100 nm formed and grew to sizes >1000 nm after 24 hours
(Figure 8, time = 2 – 24 hours). These Aβ1-40 intermediate sizes are larger than those observed by
Mastmura et al. and could be due to different sample preparations or the presence of different Aβ
species at 0 hours. These studies again show that although Aβ1-40 and Aβ1-42 differ by only two
amino acid residues, the aggregates formed are considerably different.
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Figure 8: Size distributions obtained via FCS for Aβ1-40 dissolved in 2.8 mM
NaOH, diluted to 10 µM in HEPES (pH 7.4), and incubated at room temperature.
Sample taken at ~3 minutes shows predominantly monomeric species with the
formation of intermediate aggregates of 20 – 100 nm after 1 hour and further growth
into larger aggregates >1000 nm after 24 hours. Reprinted with permission from
[107]. Copyright (2008), American Institute of Physics.

Figure 8 Size distributions obtained via FCS for Aβ1-40 dissolved in 2.8 mM NaOH, diluted to 10
µM in HEPES (pH 7.4), and incubated at room temperature
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3.6 Summary of Spectroscopic Methods
MS is capable of detecting low oligomer concentrations but is expensive and has
difficulty separating species with identical mass-to-charge ratios such as Aβ aggregates [96,97].
To address this problem, MS is often coupled with an upstream separation technique such as
SDS-PAGE [48,95]. In addition, IM-MS has been utilized for the separation of different sizes
and conformations of Aβ1-40 and Aβ1-42 with promising results for small oligomers. However, the
addition of a step such as IM also increases the time needed for analysis and therefore decreases
the chances of detecting transient species. Consistent results for Aβ1-40 and Aβ1-42 oligomer sizes
formed during the earliest events of aggregation have been obtained using MS techniques.
However, the detection of larger Aβ1-40 and Aβ1-42 oligomeric species ranging from ~32 - ~100
kDa has not been achieved using MS. FCS does not require a pre-separation step to determine
the particle radius of species in a sample. This technique has been successfully applied for the
detection of small and intermediate sized Aβ oligomers as well as large Aβ fibrils. However,
FCS yields average values of particle radius for a population of aggregates and not individual
particle sizes or their distributions.
4. Additional Techniques Utilized for Aβ Aggregate Size Determinations
4.1 Light Scattering Techniques
Light scattering techniques have been used to measure Aβ aggregate sizes. Classical, or
multi-angle, light scattering (MALS) employs a well collimated, single frequency light beam to
illuminate a sample of macromolecules [111]. When incident light interacts with the
macromolecules in solution, an oscillating dipole is induced and the light is re-radiated, or
scattered [112]. Aggregated structures induce coherent scattering, and as a result the intensity of
scattered light is dependent upon molar mass. Furthermore, destructive and constructive
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scattering that result from the independent scattering of individual molecular elements can give
rise to an angular dependence of the scattered light, which is a function of the size of the
molecule. Thus, the intensity of the scattered light is measured as a function of scattering angle,
often referred to as Rayleigh scattering, to yield the molar mass and root mean square (rms)
radius of the macromolecules [112]. MALS is ideal for characterizing larger assemblies
(>10 nm). In contrast, for analyses in which smaller molecules are present in solution, dynamic
light scattering (DLS), also known as quasi-elastic light scattering (QELS), is used. DLS
employs a fast photon counter to measure time dependent fluctuations in scattered light at a
single angle (usually 90°), which are related to the rate of diffusion of the macromolecules
[112,113]. Measurement of diffusion rates allows calculation of the hydrodynamic radius (RH) of
macromolecules using the Stokes-Einstein equation [113]. When used as standalone techniques,
MALS yields the weight-averaged molar mass for all molecules in solution. While DLS can
distinguish populations that differ in size by a factor of five or more, individual peaks exhibit a
high degree of polydispersity. Therefore, it is often necessary to utilize a pre-separation step in
conjunction with light scattering to obtain an accurate estimate of the relative amounts of
individual aggregates present in solution. In addition, the exponential dependence of scattering
on aggregate size prohibits the detection of low quantities of small aggregates in the presence of
larger species.
Various researchers have utilized MALS and/or DLS to characterize Aβ assemblies
formed throughout aggregation [114-117]. Carrotta et al. utilized both MALS and DLS to
monitor the aggregation of a 185 µM Aβ1-40 sample at pH 3.1 and 37°C [117]. DLS was used to
characterize aggregate sizes formed during the early stages of aggregation up to ~38 hours, as
shown in Figure 9. After 5 minutes (Figure 9a), an average RH of 7 nm was obtained. The size
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distribution became more polydisperse over time and ranged from 10 - 52 nm after 37 hours
(Figure 9f). However, only average size distributions could be obtained and no information was
reported about the concentrations of each aggregate species (ie. monomer, dimer, etc.). Larger
aggregates (hundreds of microns) were formed after 2 weeks as detected by MALS.
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Figure 9: Time evolution of RH for a 185 µM Aβ1-40 sample incubated at pH 3.1 and
37°C. Distributions were determined using a constrained regularization method.
Reprinted with permission from [117]. Copyright (2005) The American Society for
Biochemistry and Molecular Biology.

Figure 9 Time evolution of RH for a 185 µM Aβ1-40 sample incubated at pH 3.1 and 37°C
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Similar to these findings, Lomakin et al. observed using DLS the initial formation of a
spherocylindrical micelle with average RH of 7 nm immediately following dissolution of Aβ1-40 at
pH 2 [115]. In addition, they reported two different kinetic patterns for aggregation of Aβ1-40
prepared at a concentration either above or below the critical micelle concentration (CMC) of
100 µM [114] Complimentary DLS and MALS studies by Murphy and Pallitto also
demonstrated an effect of Aβ concentration upon aggregate formation [118]. They demonstrated
that dilution of Aβ1-40 from urea into PBS yielded larger aggregates at lower protein
concentrations, while the increase in RH for aggregates was proportional to the protein
concentration. In addition, MALS data indicated that the linear density of aggregates increased
with protein concentration. Thunecke et al. have utilized MALS and DLS to study the
aggregation of Aβ1-40 and Aβ1-42 in acetonitrile-water mixtures [116]. At the onset of
aggregation, Aβ1-42 was present as a 2 nm oligomer and rapidly formed fibrils with a length <50
nm within 4.5 hours. In contrast, Aβ1-40 initially exhibited large aggregates that grew 70 times
slower than aggregates of Aβ1-42. However, the presence of these large aggregates may preclude
observation of a separate population of oligomers. These findings highlight differences in the
dissolution and aggregation of Aβ1-40 and Aβ1-42.
4.2 Light Scattering in Combination with Other Techniques
Because light scattering techniques provide information about the weight-average molar
mass and radius for all molecules in solution, they are often coupled with a pre-separation
technique such as asymmetric field flow fractionation (AFFF) [119] or SEC [25,120,121] to
better characterize individual Aβ oligomeric species. A study by Nichols et al. utilized MALS
with SEC as well as DLS to characterize Aβ1-40 protofibrils following growth by monomer
elongation or lateral association [120]. They found that protofibrils isolated by SEC exhibited an
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average RH of 51 nm and molecular weight, determined via MALS of 30,000 kDa. Protofibrils
that had grown by monomer deposition had an average RH of 143 nm and molecular weight of
57,000 kDa, while protofibrils that had grown by lateral association had an average RH of 104
nm and molecular weight of 86,000 kDa. Furthermore, SEC-MALS revealed that the mass per
unit length of protofibrils was unchanged during elongation, but was increased following
association. The temporal change in size of Aβ1-40 protofibrils isolated by SEC has also been
monitored via DLS by Walsh et al. [121]. The initial average RH for protofibrils isolated by SEC
was ~27.8 nm, and protofibril size grew to 80.6 nm over a period of 9 days when 17 µM Aβ1-40
in Tris-HCl (pH 7.4) containing 0.04% w/v sodium azide was incubated at room temperature.
AFFF is another technique that has been coupled with light scattering to estimate the
molecular weight of individual Aβ aggregates. AFFF exploits the parabolic flow profile created
by the laminar flow of a sample through a thin, parallel plate flow channel, where the lower
surface is solvent permeable [122]. A perpendicular force applied to the laminar flow stream
drives molecules towards the permeable boundary layer of the channel [123]. Because Brownian
motion of the particles creates a counteracting force, smaller particles localize higher in the
channel leading to separation of different molecular sizes, with smaller molecules eluting first
[122]. Rambaldi et al. utilized AFFF-MALS to monitor the aggregation of Aβ1-42 in PBS (pH
7.4) at room temperature over 24 hours [119]. At 0 hours, two major peaks were obtained
corresponding to molecular weights of ~60 kDa and ~1,000 - 100,000 kDa. In addition, the
retention time of the ~60 kDa species decreased between 0 and 4 hours, corresponding to an
increase in aggregate size of 6.5 - 4.7 nm. The intensity of the two peaks also decreased over 24
hours, possibly due to irreversible adsorption of the sample to the permeable surface. Although
AFFF-MALS has several advantages, including gentle, rapid, and non-destructive separation,
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improvements to the ultrafiltration membrane are critical to enhance analysis capabilities. In
addition, the smallest molecular weight cutoff for membranes is 5 kDa, making detection of Aβ
monomeric species difficult.
4.3 Centrifugation
Centrifugation has also been explored as a method for determining Aβ size. Here,
sedimentation coefficient (s) values can be correlated with molecular weight. Mok and Howlett
provide a nice overview of sedimentation velocity centrifugation in the context of Aβ analysis
[124]. Ward et al. used density gradient centrifugation to fractionate Aβ1-40 samples incubated at
pH 7.4, 35°C for 30 minutes, 18 hours, or 18 days [26]. Using SDS-PAGE with Western blotting
to analyze sedimented samples, they found that Aβ1-40 incubated for 18 hours contained only
small molecular weight oligomers (4 – 17 kDa), while Aβ1-40 incubated for 18 days showed the
presence of a >250 kDa band as well as significant streaking, indicating other unresolved sizes.
Huang et al. used analytical ultracentrifugation to compare Aβ1-40 samples prepared at pH 3, 5,
and 7 [125]. They determined that at pH 5 there were no soluble aggregate species. At pH 7, they
identified small oligomers with an average molar mass of 12.1 kDa, and at pH 3 they identified a
range of aggregate sizes with an average molecular weight of 1 MDa. Nagel-Stefer et al. also
used sedimentation velocity centrifugation for the analysis of Aβ1-42 samples after 5 days of
agitation at room temperature and were able to detect “globular species” ranging in size from
~270 kDa - 3.8 MDa as well as even larger aggregates [126]. Interestingly, they also compared
three different simulation methods for determining molecular weight from sedimentation values
and obtained molar masses that differed by approximately one order of magnitude.
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4.4 Size Exclusion Chromatography
SEC, a chromatographic technique, separates molecules based on molecular
hydrodynamic volume or size. Molecules too large to penetrate the pores of the column packing
material elute in the void volume, while smaller molecules travel through the pores and elute at
later times. Globular proteins are often used as standards to estimate the size of Aβ oligomers.
However, since Aβ is a linear, hydrophobic peptide, comparisons between the elution behavior
of Aβ oligomers and size standards are difficult [127]. In addition, the sample is subjected to a
several-fold dilution, which facilitates the dissociation of small unstable oligomers [128], thereby
precluding the detection and size estimation of these species.
Although SEC is typically utilized in conjunction with another technique, SEC as a
standalone technique has been employed for the study of Aβ aggregates [129-131]. Englund et
al. used SEC to detect low molecular weight Aβ aggregates, Aβ protofibrils, and Aβ fibrils
formed using different Aβ sample preparations [130]. The size of low molecular weight Aβ
aggregates ranged from 4 - 20 kDa (Figure 10, panel a), while Aβ protofibrils were >100 kDa
(Figure 10, panel c). A more narrow size distribution of Aβ1-42 oligomers of 24 ± 3 kDa
(pentamer - hexamer) has been obtained by Ahmed et al. with SEC [129]. This resolution was
achieved by stabilizing Aβ1-42 oligomers at a low temperature (4°C) and low salt concentration
(10 mM NaCl). Zheng et al. have analyzed via SEC freshly prepared 1 mg/mL Aβ1-40 in PBS
(pH 7.4), diluted from DMSO, and achieved resolution of an Aβ1-40 trimer with molecular weight
of 11.6 - 15.7 kDa [131]. The difference in sizes obtained by Ahmed et al. and Zheng et al. most
likely result from differences in sample preparation. While these studies show promising results
for resolution of a single low molecular weight Aβ oligomer, the resolution of individual

43

intermediate Aβ oligomeric sizes formed during aggregation has not been achieved using SEC as
a standalone technique.
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Figure 10: HPLC-SEC chromatograms of Aβ aggregates produced using sample
preparations of 50 µM synthetic Aβ designed to optimize (a) low molecular weight
Aβ1-40 oligomers and (c) Aβ1-42 protofibrils. To ensure that insoluble fibrils were not
present in solution, these species were removed via centrifugation prior to analysis,
and this was confirmed by an absence of SEC signal in (b), a fibrillar Aβ1-42
preparation. Absorbance at 214 nm is given on the y-axis and retention time is given
on the x-axis. Reprinted from [130] published by John Wiley and Sons, © 2007 The
Authors Journal Compilation © 2007 International Society for Neurochemistry.

Figure 10 HPLC-SEC chromatograms of Aβ aggregates produced using sample preparations of
50 µM synthetic Aβ designed to optimize (a) low molecular weight Aβ1-40 oligomers and (c)
Aβ1-42 protofibrils
sample preparations of 50 µM synthetic Aβ designed to optimize (a) low
molecular weight Aβ1
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4.5 Summary of Additional Aβ Aggregate Size Determination Techniques
Light scattering techniques, such as MALS and DLS, have been used to detect both small
and large Aβ aggregates. DLS is more suitable for the detection of smaller aggregates and gives
information about aggregate size, or RH, while MALS has been utilized for the detection of larger
Aβ species, including fibrils, and can provide information about molar mass. MALS and DLS,
however, give a weight-average molar mass or RH for all molecules in solution and must be
coupled to another technique in order to increase the resolution of individual sizes. SEC as a
standalone technique has been utilized to detect low molecular weight Aβ oligomers and
protofibrils, and SEC-MALS has been used to characterize protofibrils formed via different
growth mechanisms. However, due to the dilutions required by SEC, small unstable oligomers
are often dissociated, thereby precluding their analysis. AFFF-MALS does not require a prefractionation step and has been used to separate Aβ oligomers of ~60 kDa from larger species.
This technique yields a gentle, non-destructive separation of molecules. However, further
improvements to the ultrafiltration membranes must be made in order to reduce adsorption of the
sample to the membrane. Centrifugation has also been explored for the separation of small
oligomers (4 – 17 kDa) and larger species (>250 kDa) but requires an uncertain correlation of
sedimentation coefficients with molar mass. Each of these techniques are suitable for the
detection of a wide range of Aβ aggregates present throughout aggregation but present
difficulties with respect to the resolution and quantification of individual Aβ aggregate sizes.
5. Techniques Utilized for Aβ Oligomer Identification
While this review focuses primarily on techniques capable of qualitatively determining
the size of Aβ oligomers, techniques that can identify the presence of oligomers, without
providing information about oligomer size, are also available. Although qualitative in nature, we
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have chosen to briefly discuss two of these techniques, dot blot and ELISA, as a result of their
frequent use and emerging interest.
5.1 Dot Blot
Dot blots employ a protein captured upon a membrane as a spot, or dot. A primary
antibody binds to the protein epitope of interest followed by the binding of a secondary antibody
to facilitate detection. When dot blots are probed with antibodies that specifically recognize
oligomeric Aβ, they can confirm the presence of oligomers but give no information about
aggregate size. Three different Aβ antibodies, oligomer-specific A11 or sequence specific 4G8
and 6E10 (see Table 1 for Aβ binding epitopes), were employed in conjunction with a dot blot
assay for detection of aggregating Aβ by Wong et al. [57]. Aβ1-40 was diluted to 50 µM in PBS
(pH 7.4) and incubated at 37°C. At times ranging from 0 - 3 days, a sample was analyzed via dot
blot, as shown in Figure 11. A11 binding revealed the transient appearance of oliogmers in
uninhibited samples, while detection via 4G8 and 6E10 remained constant until later times when
signals decreased, presumably due to masking of binding sites following aggregation. Changes in
these patterns in the presence of inhibitor demonstrated the ability of the inhibitor to prevent
oligomer formation and slow the evolution of larger aggregates. Necula et al. used a dot blot
assay to monitor the oligomerization of Aβ1-42 dissolved in 100 mM NaOH, diluted to 45 µM in
PBS (pH 7.4), and incubated at room temperature for 10 days [132]. Similar to Wong et al., they
probed the specificity of three different antibodies, oligomer-specific A11 and sequence specific
6E10 and 4G8. At 0 days, 6E10 and 4G8 strongly reacted with Aβ1-42 aliquots, while A11
reacted weakly, indicating that only monomeric species were present. A strong immunoreactivity
for A11 was observed after 4 days and continued to increase in intensity over 10 days, similar to
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results obtained by Wong et al. Again, this was accompanied by a decrease in immunoreactivity
of 6E10 and 4G8.
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Figure 11: Aβ aggregation monitored via dot blot. A 50 µM Aβ1-40 sample was
incubated in PBS (pH 7.4) at 37°C in the presence (+) or absence (-) 3 x Brilliant
Blue G (BBG) inhibitor. Samples were taken on the indicated days and spotted on a
nitrocellulose membrane. Oligomer-specific A11 antibody and Aβ-sequence specific
antibodies 4G8 and 6E10 were used to detect aggregates. Reprinted with permission
from [57]. Copyright (2011) American Chemical Society.

Figure 11 Aβ aggregation monitored via dot blot
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5.2 Enzyme-Linked Immunosorbent Assay
ELISA is a commonly used technique for the identification of Aβ oligomers. ELISA may
be used in a traditional or sandwich assay format. In the traditional format, protein adsorbed at a
surface can be detected using a primary antibody that is specific for Aβ oligomers (see Table 1).
This primary antibody can be directly linked to an enzyme that converts added substrate to a
detectable signal (direct ELISA) or can be coupled with a secondary antibody containing the
enzyme moiety (indirect ELISA).

The latter format serves to enhance the assay signal.

Alternatively, in the sandwich ELISA format, a sequence-specific capture antibody (see Table 1)
adsorbed onto the surface is used to capture Aβ protein, which is subsequently detected using the
same sequence-specific antibody, such that only Aβ species containing multiple monomeric
units, and therefore multiple epitopes, are detected [130,133]. Consequently, this sandwich
ELISA will recognize only aggregated Aβ, but not Aβ monomer. Although ELISA can identify
the presence of Aβ oligomers in a sample, this technique is not capable of determining sizes of
these oligomeric species. Therefore, ELISA is most advantageous for the detection of oligomeric
Aβ within a sample containing many different proteins.
Various researchers have utilized ELISA for the detection of Aβ oligomers [128,130,133135]. A study by Englund et al. employed a sandwich ELISA with monoclonal antibody 158 for
the detection of low molecular weight oligomeric Aβ1-40 produced by dissolving Aβ1-40 in 10 mM
NaOH with dilution to 50 µM in 2 X PBS and Aβ1-42 protofibrils produced by dissolving Aβ1-42
in 10 mM NaOH with dilution to 443 µM in 2 X PBS and incubation overnight at 37°C [130].
Gonzales et al. utilized a similar ELISA assay to detect low molecular weight Aβ1-42 formed by
dissolving Aβ1-42 in HFIP with dilution to 200 nM in PBS (pH 7.2) and incubation at 37°C for 24
hours [133]. The size of these species was confirmed with PAGE to be tetramer and pentamer;
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however, the bands were very faint, indicating the superior sensitivity of the ELISA assay for
these oligomeric species. A detection limit for Aβ1-40 oligomers of 80 nM was obtained in these
studies.
5.3 Summary of Aβ Oligomer Identification Techniques
Dot blots and ELISAs have been employed to detect oligomeric Aβ assemblies. Dot blots
have been used to observe the transient evolution of oligomers during aggregation, but provided
no information about Aβ aggregate size. Low molecular weight Aβ oligomers and Aβ
protofibrils have been detected via ELISA at nanomolar concentrations. However, PAGE was
required to estimate the size of these species. Thus, these techniques can sensitively confirm the
presence of oligomers but yield no size information.
6. Conclusions
This review describes a variety of techniques, summarized in Table 2, that are currently
utilized to determine the size or presence of Aβ aggregates, with a focus upon oligomeric
species. These techniques have been explored for the quantitative detection of different
aggregate sizes with various limitations to their resolution, dependence on pre-analysis
procedures, sensitivity, cost, etc.

Electrophoretic techniques, such as SDS-PAGE, Western

blotting, and CE, are widely used for size-based separations of Aβ aggregates. In particular,
SDS-PAGE and Western blotting are suitable for the detection of monomeric and small
oligomeric Aβ species. The separation of larger oligomers via SDS-PAGE is more difficult due
to the sensitivity of these sizes to denaturing conditions, which can result in aggregate
decomposition during analysis. The recent development of antibodies specific for Aβ oligomers
has led to an increase in the application of Western blotting, dot blotting, and ELISA to study Aβ
aggregation. However, the detection limits of Western and dot blotting prohibit study of
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physiologically relevant Aβ concentrations. While more sensitive, ELISA is better suited for the
identification of specific analytes, such as Aβ oligomers, present within a mixed population but
cannot distinguish individual oligomer sizes. CE with LIF detection offers a highly sensitive
detection of physiologically relevant concentrations, but the application of CE to amyloid
aggregation analyses is still in the early stages. MS is another commonly used technique for Aβ
aggregate size-based separations. MS has been successfully used to detect small oligomeric
species (especially IM-MS) but quantitative analyses of aggregate size may be limited by the
pre-separation step, the ability to differentiate species with highly similar charge-to-mass ratios,
and high equipment costs. FCS, MALS, and DLS may be utilized for determination of Aβ
aggregate size, but yield a weight-averaged molecular weight of species, thereby limiting the
resolution of individual Aβ aggregate species. Centrifugation has been used to examine small
oligomeric species up to large fibrils; however, selection of the method for determination of
molar mass from sedimentation coefficients can play an important role in size estimation. SEC
may be coupled with these approaches or used as a standalone technique; however, SEC is
complicated by dilution of the analyte during separation, inadequate resolution of intermediate
oligomeric species, and limited utility of size standards.
Although each of the methods discussed in this review has the capability to determine Aβ
aggregate size, the pathogenic events that initiate the misfolding of Aβ and formation of
aggregate species remain elusive. Hence, there is a continued need for improvement of these
techniques in order to realize the effective detection of small size differences in Aβ oligomers. In
order to leverage the advantages of each Aβ detection method, a combination of approaches must
be utilized, allowing validation of findings from different techniques and a better understanding
of the early events of the Aβ aggregation process.
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Table 2: Summary of techniques for the quantitative detection and/or identification of Aβ aggregate sizes formed throughout the
aggregation process. process
Table 2 Summary of techniques for the quantitative detection and/or identification of Aβ aggregate sizes formed throughout the aggregation process

Technique

Advantages

SDS-PAGE

• SDS offers strong
size-based
separation

Native PAGE

• Ability to separate
based on charge and
hydrodynamic size
• High sensitivity and
specificity,

Western Blotting
53
Capillary and
Microfluidic Capillary
Electrophoresis

Mass Spectrometry

• Fast, highly
sensitive separation
of proteins based on
charge and
hydrodynamic size
• Low sample volume
• Fast data acquisition
• Can identify
multiple species
with different massto-charge ratios

Disadvantages
• SDS may induce non-native
behavior and destabilize
oligomers
• Gel smearing
• Gel smearing
• Requires specific and
expensive antibodies
• Incomplete transfer of
proteins onto membrane
• Technically demanding
• Low resolution of
intermediate sized Aβ
oligomers
• Irreproducibility
• Inability to distinguish
molecules with overlapping
mass-to-charge ratios
(MALDI, ESI)
• Expensive
• Labor intensive

Aggregate Sizes
Detected
4.5 - 20 kDa,
>83 kDa

8 - 20 kDa,
high molecular
weight
4 - 16 kDa,
16.5 - 25 kDa,
30 - 97 kDa
(with SDSPAGE)
4 - 50 kDa,
>50 kDa,
fibrils

4 - 24 kDa,
~48 kDa,
fibrils,

References
[45,46]

[48,49]

[45,50-54]

[72-74]

[48,95,98,
102-104]

Fluorescence Correlation
Spectroscopy

Light Scattering

Centrifugation
54
Size Exclusion
Chromatography

• High sensitivity,
ability to look at
wide range of sizes
within a sample
• Fast analysis time
• Low sample volume
• Direct measurement
of molar mass and
radius (MALS)
• Simultaneous
detection of multiple
populations within a
sample (DLS)
• Ability to detect a
wide range of sizes
(oligomers – fibrils)
• Fast analysis time

• Well established
technique

• Relies on assumptions
about shape and kinetics of
protein to determine
molecular weight
• Yields average molecular
weight values
• Yields weight-average
molar mass and not size of
individual species or their
distribution
• Exponential dependence of
scattering on aggregate size
• Theoretical size estimate
depends on appropriate
assumptions in the model

• Leads to sample dilution
which can dissociate
unstable oligomers
• Comparisons between
elution behavior of
oligomers and globular
protein standards make
molecular weight
estimations difficult

~10 nm – 1 µm
(small oligomers
– aggregates)

>10 kDa
(MALS)

[24,105,107]

[112,116,117]

1 nm – 1 µm
(DLS)

4 - 17 kDa,
>250 kDa,
~270 kDa - 3.8
MDa

4 - 20 kDa,
24 kDa,
>100 kDa

[26,126]

[129-131]

Enzyme-Linked
Immunosorbent Assay

Dot Blot

• Highly sensitive and
specific
• Ability to measure
specific analytes
within a crude
preparation
• Versatile
• Straight-forward,
rapid technique

• Gives information about
presence of oligomers and
not size
• Requires expensive and
specific antibodies
• Gives information about
presence of oligomers and
not size
• Requires expensive and
specific antibodies

No size
determination

No size
determination

[130,133]

[57,132]
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CHAPTER 2: TECHNIQUES FOR THE DETERMINATION OF INSULIN
AGGREGATE SIZE
1. Insulin protein
Human insulin is a 51-residue protein hormone which stimulates the transport of glucose
from blood into cells [1]. In vivo, insulin exists as a Zn2+ containing hexamer and is stored in the
pancreas [2]. Upon dilution in the bloodstream, insulin dissociates rapidly through dimers to
biologically active monomers [2]. In vitro, insulin exists as a mixture of monomer and
oligomers, including dimers and hexamers [3]. Insulin is prone to form amyloid fibrils under
various conditions in vitro [4,5]. It has been postulated that insulin aggregation in vitro occurs
due to the presence of a destabilized monomer that undergoes non-native self-assembly by
overcoming the free energy barrier [6-8]. This self-assembly proceeds through the formation of
high-order oligomeric species and culminates with the appearance of insoluble fibrillar
aggregates. Insulin fibrillization poses a problem for the treatment of Type II diabetes where
insulin amyloid deposits have been observed at sites of repeated insulin injection [9-11]. These
amyloid deposits are associated with the clinical syndrome, injection-localized amyloidosis
[9,10]. It has been proposed that insulin is destabilized in the presence of hydrophobic interfaces
such as the solid-aqueous interface of insulin pumps [5,12], leading to its aggregation. The
deposition of insulin aggregates can lead to injection site problems for Type II diabetes patients,
such as infection, bleeding, bruising, irritation, and inflammation [13]. In addition, insulin
fibrillization in vitro presents a problem for the quality control of pharmaceutical insulin
production [5]. Therefore, it is important to elucidate the molecular mechanisms underlying
insulin amyloid fibrillization to improve the treatment of diabetes.
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Similar to Aβ, a range of techniques are available to detect the insulin aggregate sizes
formed throughout aggregation. Table 1 summarizes the advantages and disadvantages of these
techniques as well as the insulin aggregate sizes which have been detected. In the subsequent
sections, we will describe these literature studies in more detail.
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Table 1: Summary of techniques for the quantitative detection and/or identification of insulin aggregate sizes formed
throughout the aggregation process.
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Table 3 Summary of techniques for the quantitative detection and/or identification of Aβ and insulin aggregate sizes
formed throughout the aggregation process.
Technique
Advantages
Disadvantages
Insulin Aggregate
Sizes Detected
• SDS may induce non-native
SDS-PAGE
6, 12 kDa [14]
behavior and destabilize
• SDS offers strong size-based
separation
oligomers
• Gel smearing
• Ability to separate based on
Native PAGE
charge and hydrodynamic
• Gel smearing
6 – 30 kDa [15]
size
• Requires specific and
6 – 30 kDa
expensive antibodies
• High sensitivity and
Western Blotting
30 – 185 kDa smear
specificity,
• Incomplete transfer of
(with native-PAGE)
proteins onto membrane
[16]
• Technically demanding
• Fast, highly sensitive
Capillary and
separation of proteins based
• Low resolution of
Microchip
< 30 – 50 kDa
on charge and hydrodynamic
intermediate sized Aβ
Electrophoresis
50
– 100 kDa [17]
size
oligomers
• Low sample volume
• Irreproducibility

Mass Spectrometry

• Fast data acquisition
• Can identify multiple species
with different mass-tocharge ratios

• Inability to distinguish
molecules with overlapping
mass-to-charge ratios
(MALDI, ESI)
• Expensive
• Labor intensive

6 – 68 kDa [18-20]

Fluorescence
Correlation
Spectroscopy

Light Scattering
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Centrifugation

Size Exclusion
Chromatography

• High sensitivity, ability to
look at wide range of sizes
within a sample
• Fast analysis time
• Low sample volume

• Relies on assumptions
about shape and kinetics of
protein to determine
molecular weight
• Yields average molecular
weight values

• Direct measurement of
molar mass and radius
(MALS)
• Simultaneous detection of
multiple populations within
a sample (DLS)

• Yields weight-average
molar mass and not size of
individual species or their
distribution
• Exponential dependence of
scattering on aggregate size

• Ability to detect a wide
range of sizes (oligomers –
fibrils)
• Fast analysis time

• Theoretical size estimate
depends on appropriate
assumptions in the model

• Well established technique

• Leads to sample dilution
which can dissociate
unstable oligomers
• Comparisons between
elution behavior of
oligomers and globular
protein standards make
molecular weight
estimations difficult

No size determination
[21,22]

6, 12 kDa (SECMALS) [23]
2.3 – 6.5 nm
150 – 190 nm
> 700 nm
(DLS) [7,23-26]
6 – 28 kDa[27,28]
28-60 kDa [28]

6, 12, 30, 36 kDa
[23,28-30]

• Good information on surface
features, structure, and shape
Transmission
Electron
Microscopy

Enzyme-Linked
Immunosorbent
Assay

• Highly sensitive and specific
• Ability to measure specific
analytes within a crude
preparation
• Versatile
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Dot Blot

• Straight-forward, rapid
technique

• Results skewed toward
species which adhere to the
support
• Inability to distinguish
between similarly sized
oligomers (ie. dimer and
trimer)
• Laborious sample
preparation
• Expensive
• Gives information about
presence of oligomers and
not size
• Requires expensive and
specific antibodies
• Gives information about
presence of oligomers and
not size
• Requires expensive and
specific antibodies

5 – 15 nm (diameter)
[27,31]
50 nm (diameter) [32]
100s nm -5 µm
(length) [32]

No size determination
[15]

No size determination
[33,34]

2. Electrophoretic techniques for the quantification of insulin oligomer size
2.1 Sodium dodecyl sulfate- and native-polyacrylamide gel electrophoresis (SDS- and nativePAGE)
Compared to Aβ, fewer studies have been conducting which utilize SDS-PAGE to detect
insulin aggregates. Low concentrations of SDS (0.1, 0.3, and 1 µM) have been reported to
accelerate insulin aggregation while higher SDS concentrations (10 to 360 µM) led to a
reduction in insulin aggregation [35]. One way to counter this phenomenon is to add urea to the
sample to further denature the peptide and prevent aggregation. However, it has been shown that
urea increases the rate of insulin fibrillation [5]. The drawbacks of SDS-PAGE may be overcome
by using native-PAGE to separate various insulin sizes under conditions that allow the protein to
remain in a native state.
Native-PAGE followed by Western Blotting has been applied to monitor the sizes of
insulin oligomers formed at pH 2 and 60°C [16]. At 0 hours, insulin monomer (6 kDa) was
present. After incubation for 24 hours, the appearance of ~12 and 18 kDa oligomers was
observed. The formation of insulin species of ~24 kDa with a smear for sizes ranging from 30 to
185 kDa was observed after 48 hours. The differences between native-PAGE and SDS-PAGE
highlight the importance of examining more than one method for studies of the various insulin
aggregate sizes formed throughout the aggregation process.
2.2 Capillary electrophoresis (CE)
The utility of CE for the detection of insulin has been demonstrated by various
researchers. Kunkel et al. have used CE with UV detection to analyze the degradation products
formed by a 0.6 mg/mL human insulin solution in 0.9% NaCl (pH 7.8) which was incubated at
8°C for 2 weeks [36]. Separation of insulin from two degradation products was achieved. A
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study by Gao et al. determined the dimerization constant of bovine insulin at pH 8.4 using CE
with UV detection [37]. However, the determination of changes in insulin size with incubation
time was not accomplished in either of the above mentioned studies. A study by Iwasa et al. used
UV-CE to monitor the aggregation of insulin dissolved in HCl and incubated at 60°C for 1 – 4
days [38]. At 0 hours, a peak for native insulin was present. After 24 and 48 hours of incubation,
this native insulin peak decreased in area and a new peak appeared with a faster migration time
than the native insulin. After 96 hours, all peaks had essentially disappeared, indicating that
insulin was fully aggregated into larger structures. Although this study looked at changes in the
insulin peak pattern over time, no estimates of the sizes of these species were obtained. CE as a
technique for the detection of insulin species formed throughout aggregation is still in its early
stages. However, further improvements to this technique must be made in order to enhance the
resolution of intermediate sized insulin species.
3. Spectroscopic techniques for the quantification of insulin oligomer size
3.1 Electrospray ionization mass spectrometry (ESI)-MS
ESI-MS has been used to analyze liquid insulin samples. Nettleton et al. studied
the time course of insulin oligomer appearance using nano-ESI-MS. Oligomers exhibiting sizes
up to 12 monomeric units were detected when insulin was aggregated at very high, millimolar
concentrations [18]; however, large aggregates could not be studied using this technique. In
addition, identification of insulin oligomers was complicated by the presence of overlapping
charge states among the aggregates present. A study by Devlin et al. analyzed lower
concentrations (0.44 mM) of insulin incubated at pH 2.0 and 60°C [19]. They found that insulin
existed as a mixture of monomeric and dimeric species. These results are consistent with the
observation that low pH helps solubilize proteins, thereby producing monomeric species.
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3.2 Ion mobility mass spectrometry (IM)-MS
Various research groups have utilized IM-MS to gain a better understanding of the early
events of insulin aggregation. Insulin monomer, dimer, and hexamer species formed at pH 7.4
have been detected using IM-MS, but changes in insulin size with aggregation time were not
conducted in this study [20].
3.3 Fluorescence correlation spectroscopy
While FCS has been widely used in the literature as a way to estimate sizes of Aβ
species, less work has been done using FCS to determine insulin sizes. The interaction between
insulin and an inhibitory molecule p-FTAA has been characterized via FCS [22]. Furthermore,
the association constant (Kass) between insulin and its membrane-bound receptor has been
determined via FCS by Zhong et al [21]. These studies illustrate that while FCS is a useful
technique for size estimates, this technique has not been used specifically to determine the sizes
of insulin species formed throughout aggregation.
4. Additional techniques utilized for insulin aggregate size determination
4.1 Light scattering techniques
Light scattering techniques are the more widely used technique to characterize insulin
aggregate sizes. A study by Sluzky et al. utilized DLS to determine the particle diameter of
insulin species generated upon agitation at 37 °C and 80 rpm in PBS (pH 7.4) [7]. A range of
insulin species with diameters from 2.5 to 10 nm were observed initially in solution. Upon
agitation for 1 h in the presence of Teflon spheres, a second peak appeared corresponding to
insulin particles ~150 nm in diameter. After aggregation for 21 h, three species of insulin were
present: native molecules with sizes ranging from 2.5 to 10 nm, stable intermediates with sizes
ranging from 150 to 190 nm, and fully aggregated particles > 800 nm. Similar to the findings by
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Sluzky et al. for the initial insulin sizes in solution, Kadima et al. observed species with a weight
average molecular mass close to that of a hexamer (~5.6 nm) for a 12 mg/mL insulin solution at
pH 7.5 with 100 mM NaCl [24]. Furthermore, they found that a 1.9 mg/mL insulin solution at
pH 10.5 and 10 mM NaCl existed as primarily monomer (~3 nm).
4.2 Light scattering in combination with other techniques
Oliva et al. utilized SEC in conjunction with MALS and DLS to determine the molecular
weight and size of insulin solutions [23]. SEC-MALS detected the presence of monomeric and
dimeric species with r.m.s. radius values of 20 and 40 nm, respectively. In contrast, SEC-DLS
yielded RH values of 2.7, 3.8, and 5.5 nm which correspond to monomer, dimer, and hexamer,
respectively.
4.3 Centrifugation
Ultracentrifugation has been utilized by Whittingham et al. to determine the molecular
mass of insulin species formed under different solution conditions [27]. Insulin dissolved in
sulfuric acid, citric acid, and a pH 2.0 solution existed as a mixture of monomer and dimer. In a
20% acetic acid solution insulin existed as monomer whereas in 0.1 M Tris-HCl at pH 8, insulin
sizes ranging from dimer to tetramer were observed.
4.4 Size exclusion chromatography
A study by Ahmed et al. utilized SEC to monitor the effect of Gdn-HCl on insulin sizes
formed at pH 7.4 [30]. Native insulin eluted at a volume of 6.1 mL, corresponding to hexamer. In
the presence of 0.5 – 3 M Gdn-HCl, insulin existed as a mixture of monomer and dimer while at
Gdn-HCl concentrations > 3.5 M, insulin was primarily monomeric. Similar to Ahmed et al.,
Oliva et al. achieved separation of insulin dimer and monomer formed after incubation for 5 days
at 60°C [23].
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4.5 Transmission electron microscopy
Insulin protofibrils with a diameter of 5 nm and length of 4 – 5 µm have been observed
by Whittingham et al [27]. Furthermore, the protofibrils sizes were found to be highly dependent
on the type of acid used to dissolve insulin. Fibrillar insulin species with a diameter of ~14 – 15
nm formed by twisting at least two protofibrils into a flat ribbon-like fibril have been detected
using TEM by Bouchard et al [31]. Contrary to these findings, Liu et al. observed insulin fibrils
with a width of 50 nm and length of 100s of nm [32]. These fibrils were formed in the presence
of 100 mM NaCl and this most likely explains the differences in diameter obtained.
5. Techniques utilized for amyloid oligomer identification
5.1 Dot blot
Studies utilizing dot blots for the detection of insulin monomer or fibrillar species have
also been conducted, while studies on the detection of insulin oligomeric species are limited. The
binding of aprotinin, an antiprotease which is known to be present in amyloid deposits, to insulin
fibrils has been characterized via dot blots by Cardoso et al [34]. Dots were obtained for 100, 50,
25, and 10 µg of insulin fibrils in the presence of iodinated-aprotinin. Stains used to image
protein gels such as SYPRO Ruby have been used to detect insulin monomer via dot blots [33].
These studies illustrate that dot blots have not been extensively used in the literature for the
detection of insulin oligomers.
6. Summary of electrophoretic and non-electrophoretic based insulin and Aβ size detection
methods
Chapters 1 and 2 describe a variety of techniques that are currently utilized to determine
the size or presence of amyloid aggregates, with a focus upon oligomeric species. These
techniques have been explored for the quantitative detection of different aggregate sizes with
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various limitations to their resolution, dependence on pre-analysis procedures, sensitivity, cost,
etc. Electrophoretic techniques, such as SDS-PAGE, Western blotting, and CE, are widely used
for size-based separations of Aβ aggregates. These techniques have been less widely used to
detect insulin aggregates. In particular, SDS-PAGE and Western blotting are suitable for the
detection of monomeric and small oligomeric insulin Aβ species. The separation of larger
oligomers via SDS-PAGE is more difficult due to the sensitivity of these sizes to denaturing
conditions, which can result in aggregate decomposition during analysis. The recent
development of antibodies specific for Aβ oligomers has led to an increase in the application of
Western blotting, dot blotting, and ELISA to study Aβ aggregation. However, the detection
limits of Western and dot blotting prohibit study of physiologically relevant Aβ concentrations.
While more sensitive, ELISA is better suited for the identification of specific analytes, such as
Aβ oligomers, present within a mixed population but cannot distinguish individual oligomer
sizes. CE with LIF detection offers a highly sensitive detection of physiologically relevant
concentrations, but the application of CE to amyloid aggregation analyses is still in the early
stages. MS is another commonly used technique for Aβ aggregate size-based separations and is a
more widely used technique for the detection of insulin aggregates. MS has been successfully
used to detect small oligomeric species (especially IM-MS) but quantitative analyses of
aggregate size may be limited by the pre-separation step, the ability to differentiate species with
highly similar charge-to-mass ratios, and high equipment costs. FCS, MALS, and DLS may be
utilized for determination of insulin Aβ aggregate size, but yield a weight-averaged molecular
weight of species, thereby limiting the resolution of individual Aβ aggregate species.
Centrifugation has been used to examine small oligomeric species up to large fibrils; but,
selection of the method for determination of molar mass from sedimentation coefficients can
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play an important role in size estimation. SEC may be coupled with these approaches or used as
a standalone technique. SEC is complicated by dilution of the analyte during separation,
inadequate resolution of intermediate oligomeric species, and limited utility of size standards.
TEM is widely used to estimate the size of insulin and Aβ aggregates. TEM is a technique which
is more suited for the detection of protofibrils and fibrils and does not possess the ability to
distinguish between small oligomeric species which differ in size by a single monomer unit.
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CHAPTER 3: MONITORING INSULIN AGGREGATION VIA CAPILLARY
ELECTROPHORESIS
Pryor, E.; Kotarek, J. A.; Moss, M. A.; Hestekin, C. N. Int. J. Mol. Sci. Monitoring Insulin
Oligomer Formation Via Capillary Electrophoresis, 2011, 12, 9369-9388.
Abstract
Early stages of insulin aggregation, which involve the transient formation of oligomeric
aggregates, are an important aspect in the progression of Type II diabetes and in the quality
control of pharmaceutical insulin production. This study is the first to utilize capillary
electrophoresis (CE) with ultraviolet (UV) detection to monitor insulin oligomer formation at pH
8.0 and physiological ionic strength. The lag time to formation of the first detected species in the
aggregation process was evaluated by UV-CE and thioflavin T (ThT) binding for salt
concentrations from 100 mM to 250 mM. UV-CE had a significantly shorter (5–8 h) lag time
than ThT binding (15–19 h). In addition, the lag time to detection of the first aggregated species
via UV-CE was unaffected by salt concentration, while a trend toward an increased lag time with
increased salt concentration was observed with ThT binding. This result indicates that solution
ionic strength impacts early stages of aggregation and β-sheet aggregate formation differently.
To observe whether CE may be applied for the analysis of biological samples containing low
insulin concentrations, the limit of detection using UV and laser induced fluorescence (LIF)
detection modes was determined. The limit of detection using LIF-CE, 48.4 pM, was lower than
the physiological insulin concentration, verifying the utility of this technique for monitoring
biological samples. LIF-CE was subsequently used to analyze the time course for fluorescein
isothiocyanate (FITC)-labeled insulin oligomer formation. This study is the first to report that the
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FITC label prevented incorporation of insulin into oligomers, cautioning against the use of this
fluorescent label as a tag for following early stages of insulin aggregation.
Keywords
capillary electrophoresis; ultraviolet absorbance; laser induced fluorescence; thioflavin T;
insulin; oligomer; amyloid
1. Introduction
Human insulin is a 51-residue protein hormone which stimulates the transport of glucose
from blood into cells [1]. In vivo, insulin exists as a Zn2+ containing hexamer and is stored in the
pancreas [2]. Upon dilution in the bloodstream, insulin dissociates rapidly through dimers to
biologically active monomers [2]. In vitro, insulin exists as a mixture of monomer and
oligomers, including dimers and hexamers [3]. Insulin is prone to form amyloid fibrils under
various conditions both in vitro and in vivo [4,5]. It has been postulated that insulin aggregation
both in vitro and in vivo occurs due to the presence of a destabilized monomer that undergoes
non-native self-assembly by overcoming the free energy barrier [6–8]. This self-assembly
proceeds through the formation of high-order oligomeric species and culminates with the
appearance of insoluble fibrillar aggregates. Insulin fibrillization poses a problem for the
treatment of Type II diabetes where insulin amyloid deposits have been observed at sites of
repeated insulin injection [9–11]. These amyloid deposits are associated with the clinical
syndrome, injection-localized amyloidosis [9,10]. It has been proposed that insulin is
destabilized in the presence of hydrophobic interfaces such as the solid-aqueous interface of
insulin pumps [5,12], leading to its aggregation. The in vivo deposition of insulin aggregates can
lead to injection site problems for Type II diabetes patients, such as infection, bleeding, bruising,
irritation, and inflammation [13]. In addition, insulin fibrillization in vitro presents a problem for
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the quality control of pharmaceutical insulin production [5]. Therefore, it is important to
elucidate the molecular mechanisms underlying insulin amyloid fibrillization to improve the
treatment of diabetes.
The visualization of oligomers, which appear in the early stages of aggregation, is one
key to understanding the molecular mechanisms underlying amyloid formation. Various
techniques have been utilized to detect soluble and low-molecular weight oligomeric species
formed by amyloid proteins such as atomic force microscopy (AFM) [12,14], light scattering
[12,14], hydrogen-deuterium exchange mass spectrometry [15,16], matrix assisted laser
desorption ionization mass spectrometry (MALDI-MS) [17,18], electrospray ionization mass
spectrometry (ESI-MS) [19], ion mobility mass spectrometry (IM-MS) [20–23], and oligomer
specific antibodies [24–26]. A major analytical challenge is developing a technique which is
capable of identification, quantification, and characterization of a wide range of amyloid species.
Electrophoretic techniques can be used to detect soluble and low-molecular weight oligomeric
species and provide a compliment for other traditional techniques. These electrophoretic
techniques include sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) [27–
30], Western immunoblotting [27,29,31–37], and capillary electrophoresis (CE) [38–43]. SDSPAGE is a commonly used technique, but SDS has been reported to accelerate β sheet formation
during amyloid aggregation [44,45], to induce and possibly stabilize aggregation [36], and to
misrepresent the native species and their assembly [46]. Western blotting necessitates the
use of expensive and specific antibodies and can also require a pre-concentration step such as
immunoprecipitation [47,48]. In addition, these gel-based methods can produce smears making
specific oligomer size determination impossible [29,30]. In contrast, CE provides the ability to
inexpensively monitor the aggregation of insulin under native conditions.
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Capillary electrophoresis (CE) offers fast and highly efficient separation of molecules
with a broad range of properties thereby making it well suited for the analyses of biological
samples, which contain different types and sizes of proteins [49]. CE separates proteins based on
electrophoretic mobility, which is related to charge, shape, and/or size. Previous studies have
demonstrated the utility of CE to detect low concentrations of insulin [50–52] and identify
differences in insulin analogs [42]. In this work, we have extended CE to monitor the appearance
of insulin oligomers over time when aggregation is carried out under varying solution conditions.
In addition, we have probed the ability of CE to detect insulin at physiological concentrations.
This study is the first report of the use of UV-CE to monitor insulin oligomer formation at pH
8.0 and physiological ionic strength. Our results demonstrate the utility of CE as a
complimentary technique for studying the early stages of insulin aggregation and define the
hurdles that must be overcome before the aggregation of biological insulin concentrations can be
explored.
2. Results and Discussion
2.1. Detection of Insulin Oligomers Using CE with UV Detection
To explore the use of CE for the detection of insulin oligomers that appear during early
stages of insulin aggregation, lyophilized insulin was solubilized in 5 mM NaOH, diluted into 40
mM Tris (pH 8.0), subjected to 150 mM NaCl, and agitated at 185 rpm to promote amyloid
assembly. The reaction was analyzed using UV-CE at early and late time points to assess the
appearance of oligomers and progression into larger aggregate species. At 0 h, UV-CE
demonstrated the presence of an early, broad peak in addition to a sharper peak migrating at ~70
min (Figure 1A). The size of these species was probed using a filtration analysis similar to that
performed by Sabella et al. who used molecular weight cutoff membranes to size early amyloid-
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β aggregation species detected via UV-CE. For our experiments, we used membranes with
molecular weight cutoffs of 30, 50, and 100 kDa to determine that the species present at 0 h
correspond to molecular weights <30–50 kDa, or oligomers of <5–8 monomer units. A similar
peak pattern was obtained after 4 h with the appearance of another peak migrating at ~90 min
(Figure 1B). At 8 and 12 h, broad peaks migrating at times >90 min appeared (Figure 1C,D). The
size of these species was estimated by filtration analysis to be >50 kDa, or larger than 8
monomer units, thus indicating the detection by UV-CE of the first species in the aggregation
process. By 24 h, aggregate peaks of greater intensity appeared at migration times >150 min,
indicating the formation of larger and more concentrated aggregate species, estimated via
filtration analysis to be <100 kDa, or less than 17 monomer units (Figure 1E). Due to
experimental time constraints, UV-CE runs for the 0, 4, and 8 h time points were terminated at
180 min. Separate experiments with run times of 240 min were conducted for the 0, 4, and 8 h
time points and confirm that no significant species (signal to noise or S/N >3) were present at
migration times >180 min (see supplementary materials).
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Figure 1. Detection of insulin monomer, oligomer, and higher molecular weight
aggregation states using UV-CE. Insulin was aggregated under agitation (185 rpm) at
0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl and at 25 °C. At 0 h
(panel A), 4 h (panel B), 8 h (panel C), 12 h (panel D), and 24 h (panel E), CE was
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s
with separation at 15 kV using 0.5% PHEA separation matrix in a PHEA coated
capillary.

Results

are

representative

of

three

independent

experiments.

Supplementary data confirms the absence of significant peaks at a migration time of
>180 min for 0, 4, and 8 h time points.

Figure 12

Detection of insulin monomer, oligomer, and higher molecular weight aggregation states
using UV-CE
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Other measurement techniques have been employed previously to characterize insulin
oligomers. Quasi elastic light scattering (QELS) [7], high performance liquid chromatography
(HPLC) [53], small angle neutron scattering (SANS) [54], and nanoflow electrospray (nano-ES)
mass spectrometry [55] have been successfully used to detect oligomeric insulin species. A study
by Sluzky et al. utilized QELS to determine the particle diameter of insulin species generated
upon agitation at 37 °C and 80 rpm in PBS (pH 7.4) [7]. Similar to the UV-CE results at 0 hr, a
range of insulin species with diameters from 2.5 to 10 nm were observed initially in solution.
Upon agitation for 1 h in the presence of Teflon spheres, a second peak appeared corresponding
to insulin particles ~150 nm in diameter. After aggregation for 21 h, three species of insulin were
present: native molecules with sizes ranging from 2.5 to 10 nm, stable intermediates with sizes
ranging from 150 to 190 nm, and fully aggregated particles >800 nm. Nayak et al. and
Vestergaard et al. utilized SANS and SAXS to monitor the formation of insulin oligomers and
proposed a model for nucleus formation and growth [54,56]. However, insulin oligomers were
generated

under

extreme

conditions

(45–65

°C,

pH

=

1.6–2.0,

5–10 mg/mL) which may not accurately reflect insulin aggregation in vivo. Nettleton et al.
studied the time course of insulin oligomer appearance using nano-ES. Oligomers exhibiting
sizes up to 12 monomeric units were detected when insulin was aggregated at very high,
millimolar concentrations [55]; however, large aggregates could not be studied using this
technique. In addition, identification of insulin oligomers was complicated by the presence of
overlapping charge states among the aggregates present. The drawbacks of each technique listed
above show that other complementary methods may be needed to verify the results obtained. The
UV-CE method in the current study was able to detect insulin oligomers that appeared transiently
during amyloid formation at a pH of 8.0 and at micromolar insulin concentrations. This
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highlights the potential for CE to be used as a complementary technique to follow the evolution
of insulin oligomer appearance.
2.2. Effect of Salt Concentration on the Time Course for Insulin Oligomer Formation
Solution conditions such as protein concentration [5,57], pH [5], and ionic strength
[5,58,59] have been reported to have a pronounced impact upon the rate at which insulin
aggregates, and understanding these effects can provide insight into the mechanism of insulin
aggregation. Here, CE was employed to study the effect of solution ionic strength on the early
events of insulin aggregation by examining the time to appearance of oligomers formed when
insulin is aggregated at 25 °C and pH 8.0 (40 mM Tris) in the presence of three different
concentrations of NaCl: 100 mM, 150 mM, and 250 mM. Figure 2 illustrates the change in
normalized migration time of the largest species present throughout the early stages of
aggregation. During the first 5 h of aggregation, there was little change in the migration time at
all three salt concentrations. After 5 h, oligomeric species began to form. While the time to
oligomer appearance was unaffected by NaCl concentration (Table 1), the size of oligomers
formed increased with salt concentration. At 10 h, oligomers formed in the presence of 150 and
250 mM NaCl exhibiting significantly longer migration times than those formed in the presence
of 100 mM NaCl (Figure 2). To our knowledge, no other studies have used methods focused on
oligomer detection to examine the effect of ionic strength on insulin aggregation.

92

Table 1. Lag times observed at 100, 150, and 250 mM NaCl by CE versus ThT binding.
Table 4 Lag times observed at 100, 150, and 250 mM NaCl by CE versus ThT binding
NaCl concentration

Lag time for CE

Lag time for ThT Binding

(mM)

(h) 1

(h) 2

100

6.7 ± 1.7

16 ± 1.0 ***

150

5.0 ± 0.0

15 ± 1.4 ***

250

7.6 ± 1.3

19 ± 2.4 ***

1

Results are reported as the mean ± SE, n = 3. 2 Results are reported as the mean ± SE, n = 4.

***

p < 0.001 for comparison between detection via UV-CE and ThT binding.
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Figure 2. Effect of solution ionic strength on the formation of insulin oligomers
detected by UV-CE. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0)
containing 100 mM (), 150 mM (), or 250 mM () NaCl. Aggregation was
induced at 25 °C by continuous agitation (185 rpm) and monitored using UV-CE. CE
was performed with sample injection at 0.5 psi for 8 s with 15 kV separation using
1% PHEA separation matrix in a PHEA coated capillary. Migration times were
normalized to those observed prior to the onset of aggregation using the peak
corresponding to monomer to facilitate comparison between individual runs. Error
bars represent SE, n = 3. For the 10 h time point, the migration times of the 150 mM
and 250 mM NaCl were both determined to be statistically different from the 100
mM NaCl migration time with a p < 0.1.

Figure 13: Effect of solution ionic strength on the formation of insulin oligomers
detected by
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A traditional method of detecting amyloid aggregates containing a cross β-sheet structure
is through the examination of thioflavin T (ThT) binding, which has been used to study insulin
aggregation under a variety of solution conditions. ThT is an intercalating fluorescent dye that
binds to the β-sheet structure within amyloid fibrils, giving rise to a shifted excitation maximum
at 450 nm and a shifted and enhanced emission at 482 nm [5,60]. For our study, ThT was also
used to follow insulin aggregation in order to compare the lag times obtained using ThT
fluorescence with those observed using CE. When insulin was aggregated at pH 8.0 (40 mM
Tris) and 25 °C with agitation (185 rpm) in the presence of 100 mM NaCl, 150 mM NaCl, or 250
mM NaCl, the lag time, or initial increase in ThT fluorescence, was observed at 16 ± 1.0 h, at 15
± 1.4 h, and at 19 ± 2.4 h, respectively (Figure 3, Table 1). These results demonstrate a trend
toward a longer lag time at the highest salt concentration.
Other researchers have examined the effect of ionic strength on insulin structure [58,59]
and aggregation lag time, but under slightly different conditions. At a similar solution pH of 7.0–
8.0, lag times of 6–9 h have been reported in studies that have employed higher insulin
concentrations [61] or higher temperatures with more vigorous agitation [62], which have both
been reported to enhance amyloid protein aggregation [5,57,63–65]. Furthermore, changes in the
lag time to ThT fluorescence have been observed to depend upon the change in solution ionic
strength when insulin is aggregated under continuous agitation. Nielsen et al. observed that an
increase in the NaCl concentration from 50 to 500 mM led to an initial decrease in the lag time
from 1.6 to 1.3 h, whereas at the highest salt concentration of 500 mM, the lag time increased to
1.5 h [5]. Although much shorter lag times were observed is this study, likely due to the higher
incubation temperature (37 °C) and acidic solution pH (1.6), the latter result parallels the effect
of NaCl concentration on ThT detection of insulin aggregates observed in the current study,
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where an increase in the NaCl concentration to 250 mM resulted in an increase in the lag time
(Figure 3).
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Figure 3. Effect of solution ionic strength on the formation of insulin aggregates
detected by ThT binding. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0)
containing 100 mM (), 150 mM (), or 250 mM () NaCl. Aggregation was
induced at 25 °C by continuous agitation (185 rpm) and monitored via ThT
fluorescence by periodic dilution into 10 µM ThT. Error bars represent SE. Results are
representative of two independent experiments.

Figure 14 Effect of solution ionic strength on the formation of insulin aggregates detected
by ThT binding.
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When results from UV-CE (Figure 2) and ThT binding detection (Figure 3) of the initial
aggregation state are compared (Figure 4, Table 1), it is clear that UV-CE is able to detect the
aggregation process significantly earlier than ThT binding. In the presence of 100 and 150 mM
NaCl, oligomers were detected using UV-CE 10 h prior to the observed increase in ThT
fluorescence, and in the presence of 250 mM NaCl, UV-CE was able to resolve oligomers more
than 11 h prior to the detection of aggregates using ThT. These differences most likely result
from the inability of ThT to recognize early oligomeric species due to their lack of β-sheet
structure. In contrast, UV-CE does not rely on the binding of a dye to this specific conformation
but can instead detect oligomers regardless of their conformation. These results show that CE is
capable of detecting early insulin oligomeric species while ThT binding can be used to verify the
appearance of larger aggregates present in higher quantities. Therefore, CE and ThT binding can
be used in a complimentary manner to detect species formed during all stages of aggregation.
Differences in detection capabilities of UV-CE and ThT binding lead to a more
comprehensive understanding of the effect of NaCl on insulin aggregation. Results from UV-CE
suggest that NaCl has little effect on the appearance of early aggregated states, shown by
filtration studies to be oligomeric in nature. In contrast, results from ThT binding conversely
suggest that increasing the NaCl concentration extends the lag time to formation of aggregated
states with β-sheet conformations (Table 1). This comparison underscores the differences in
amyloid protein aggregation that can be observed between oligomer and β-sheet aggregate
behavior and emphasizes the need for a complimentary detection method, like CE, that can
follow early stages in the aggregation process. A higher solution ionic strength could alter the
structure of oligomers, leading to a slower conversion to the β-sheet structure detectable by ThT
binding. Alternatively, concentrations of oligomers may remain low under conditions of higher
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solution ionic strength, thus precluding their detection by ThT binding, which exhibits high
nanomolar to low micromolar limit of detection, for longer periods of time. An increase in the
lag time detected by ThT binding at higher NaCl concentrations has also been observed in
studies of other proteins that form amyloid aggregates [66]. The conclusion drawn by Lin et al.
in these studies was that short and thick fibrils are formed at higher NaCl concentrations, and
these fibrils are characterized by low intensity ThT binding signals. Thus, the ability of CE to
detect insulin species independent of their conformation and at very low concentrations provides
additional insight into the early events of insulin aggregation.
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Figure 4. Comparison of lag times observed by UV-CE () and ThT binding ().
Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl.
Aggregation was induced at 25 °C by continuous agitation (185 rpm) and monitored
via UV-CE or ThT fluorescence as described in Figure 2 and Figure 3, respectively.

Figure 15 Comparison of lag times observed by UV-CE () and ThT binding
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2.3. Determination of Insulin Limit of Detection
The ability to detect proteins at low concentrations will be necessary for the study of
insulin aggregation at biological concentrations (300 pM) [67]. CE typically uses either UV
absorbance or LIF to detect proteins. UV can detect proteins without any additional labeling, but
typically has a lower sensitivity than LIF. LIF usually requires fluorescent labeling of the
molecule to be detected, but is highly sensitive with previous reports of LIF-CE detection of
double-stranded DNA down to the pg/μL range [68,69]. To determine the insulin detection limit
using UV-CE, insulin monomer prepared at concentrations ranging from 0.005 mg/mL to 0.2
mg/mL was analyzed. The S/N ratio of the insulin peak was >3 at concentrations of 0.01 mg/mL
and higher, defining 0.01 mg/mL (1.72 µM) as the limit of detection for insulin using UV-CE
(Figure 5A). The definition of the detection limit as the analyte concentration with a S/N ratio >3
has been used previously in studies utilizing CE detection [70,71]. In addition, a similar limit of
detection for insulin of 0.02 mg/mL (3.44 µM) has been obtained by Kunkel et al. using UV-CE
[52].
A parallel limit of detection study was performed for fluorescein isothiocyanate (FITC)labeled insulin monomer using LIF-CE. First, injection conditions were optimized by studying a
range of sample injection voltages and injection times. As both the injection voltage and
injection time were increased, observed insulin peaks increased in intensity. However, when the
injection voltage and injection time were increased beyond 12 kV and 12 s, respectively,
significant carryover of insulin between runs was observed due to the large amount of insulin
injected into the capillary. Therefore, an injection voltage of 12 kV and an injection time of 12 s
were selected as optimal. To determine the insulin detection limit using LIF-CE, FITC-labeled
insulin monomer prepared at concentrations ranging from 0.03 to 3 ng/mL was analyzed. The
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S/N ratio of the insulin peak was >3 at concentrations of 0.3 ng/mL and higher, thus establishing
0.3 ng/mL (48.4 pM) as the limit of detection for FITC-labeled using LIF-CE (Figure 5B) and
illustrating the superior limit of insulin detection for LIF-CE compared with UV-CE. In fact, the
LIF detection limit of 48.4 pM is lower than the physiological insulin concentration of 300 pM
[67] and to the authors’ knowledge, is the lowest LIF detection limit of insulin for an
electrophoresis based method. Thus, LIF-CE is a promising technique for the detection of
physiologically relevant insulin concentrations. Figure 5B also demonstrates the detection of four
peaks in addition to the peak corresponding to monomeric protein. These additional peaks are
most likely the presence of dimers and hexamers that have been reported to exist in vitro in
freshly dissolved insulin solutions [72,73]. These species may be present at concentrations below
the limit of insulin detection by UV-CE. The lower limit of detection offered by LIF-CE should
facilitate the detection of these species.
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Figure 5. Limit of detection for monomeric insulin. (A) UV-CE detection of insulin
with a 0.5 psi pressure injection for 8 s at 15 kV separation voltage using 0.1%
PHEA separation matrix in a PHEA coated capillary; (B) LIF-CE detection of insulin
with a 12 kV electrokinetic injection for 12 s at 15 kV separation voltage using 0.1%
PHEA separation matrix in a PHEA coated capillary.

Figure 16 Limit of detection for monomeric insulin.
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2.4. Analysis of FITC Tracer Incorporation into Unlabeled Insulin
The ability of LIF-CE to detect insulin at sub-physiological concentrations suggests that
this technique holds promise for the study of insulin aggregation at physiological insulin
concentrations. Such studies will require the presence of a fluorescent label within insulin
oligomers that appear during early stages of aggregation. Therefore, the ability of FITC-labeled
insulin and unlabeled insulin to co-aggregate was explored. FITC-labeled insulin was selected
because it has been previously shown to be an effective insulin label for LIF-CE applications
[74,75]. FITC is covalently bound to the ε-amino groups of internal lysine residues and the αamino group of the N-terminal residue. Unlike fluorescent amyloid-binding dyes, the covalent
incorporation of this FITC label ensures its presence within both monomeric protein and
aggregates that incorporate the labeled protein, including those that precede the appearance of βsheet structure.
A sample consisting of 75% unlabeled insulin and 25% FITC-labeled insulin was
prepared in 40 mM Tris (pH 8.0) containing 150 mM NaCl and agitated at 185 rpm to promote
amyloid assembly. The reaction was analyzed using LIF-CE to assess the appearance of insulin
oligomers. As shown in Figure 6, no change in the normalized migration time was observed over
a 36 h period. Because oligomers of unlabeled insulin were observed using UV-CE beginning
after 5 h following the onset of aggregation (Figure 2), this result suggested that the presence of
the FITC label was preventing the aggregation of FITC-labeled insulin. To explore this
possibility, LIF-CE was used to monitor the aggregation of 100% FITC-labeled insulin
solubilized in Tris (pH 8.0), subjected to 150 mM NaCl, and agitated at 185 rpm (data not
shown). Again, the normalized migration time was unchanged during the first 24 h following the
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initiation of agitation, confirming that the presence of the FITC label prevents aggregation within
this timeframe.
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Figure 6. Coaggregation of FITC-labeled insulin and unlabeled insulin. Insulin
solutions consisting of 25% FITC-labeled insulin and 75% unlabeled insulin with
LIF detection (, n = 6) and UV detection (, n = 3) were prepared at a
concentration of 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl.
Solutions were subjected to agitation (185 rpm), and the formation of aggregates was
monitored. LIF-CE was performed with a sample injection at 12 kV for 12 s with 15
kV separation and UV-CE was performed with a sample injection at 10 kV for 12 s
with 15 kV separation. Both separations were performed using 1% PHEA separation
matrix in PHEA coated capillary. Migration times were normalized as described in
Figure 2. Error bars represent SE, n = 3–6. Some error bars lie within symbols. For
all time points >0 h, UV data was statistically different from the LIF data with a p <
0.015.

Figure 17 Effect of aggregation time on the normalized migration time for the
coaggregation of FITC-labeled insulin and unlabeled insulin..
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To further determine whether the FITC-labeled insulin was inhibiting the formation of
unlabeled insulin aggregates or failing to incorporate into aggregates formed from the unlabeled
protein, UV-CE was performed in parallel with LIF-CE to monitor the aggregation of 75%
unlabeled insulin and 25% FITC-labeled insulin solubilized in 40 mM Tris (pH 8.0) containing
150 mM NaCl and subjected to agitation at 185 rpm. As shown in Figure 6, the normalized
migration time for UV-CE increased significantly over a period of 36 h, beginning by 10 h
following the onset of agitation, while the normalized migration time for LIF-CE remained
unchanged. These results indicate that insulin oligomers and larger aggregates were formed from
the unlabeled protein and that the FITC-labeled insulin did not incorporate into these aggregates.
Since some small compounds have been previously reported as inhibitors of β-sheet formation, it
is possible that the FITC label is acting as an inhibitor to insulin aggregation. Another possibility
is that the FITC attachment site is critical for proper β-sheet folding. A similar extension of the
lag time to aggregation has been observed following the methylation of amino groups within the
amyloid-β protein [76] and the introduction of a mutant that mimics phosphorlyation of serine
residues within Huntington protein [77]. In addition, the quantity of amyloid aggregates formed
is reduced following the citraconylation of lysine residues within lysozyme [78] or stilbine
modification of ε-amino groups within transthyretin [79]. Therefore, dyes with alternative
properties or attachment sites need to be explored. In particular, less bulky fluorescent probes,
such as BODIPY, or attachment of dyes exclusively at the N- or C- terminus would be less likely
to impact aggregate formation.
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3. Materials and Methods
3.1. Materials
Previous studies have shown no differences between the three-dimensional structures of
bovine and synthetic human insulin [80] and the binding affinity of bovine and synthetic insulin
to insulin receptors at three major sites of insulin action are similar [81]. Similar to human
insulin, bovine insulin contains 51 amino acids but differs from human insulin in residues A8
(Thr→Ala), A10 (Iso→Val), and B30 (Thr→Ala) [82]. Therefore, bovine insulin was used for
all studies. Insulin and fluorescein isothiocyanate (FITC)-labeled insulin from bovine pancreas,
poly-N-hydroxyethyl acrylamide (PHEA) and thioflavin T (ThT) were obtained from SigmaAldrich (St. Louis, MO). Polymerization initiation compound 2,2′-azobis(2-amidinopropane)
dihydrochloride (V-50) was purchased from Wako Chemical (Richmond, CA). Amicon
centrifugal filter units were purchased from Millipore (Billerica, MA).
3.2. Insulin Preparation
Lyophilized insulin and FITC-labeled insulin were stored at −20 °C. Unlabeled insulin
was reconstituted to a final concentration of 0.005–0.2 mg/mL in 40 mM Tris (pH 8.0) containing
0–250 mM NaCl. FITC-labeled insulin was reconstituted to a final concentration of 0.03 ng/mL–
0.2 mg/mL in 40 mM Tris (pH 8.0) containing 0–150 mM NaCl. Samples consisting of 75%
unlabeled insulin and 25% FITC-labeled insulin were prepared by mixing the necessary
proportions of insulin and FITC-labeled insulin from individual stock concentrations of 0.3 and
0.2 mg/mL, respectively.
3.3. Electrophoresis Conditions for UV and LIF Studies
All studies were carried out in 0.1% w/v PHEA coated capillaries with a 0.1–1% PHEA
separation matrix and a capillary temperature of 25 °C. Capillary dimensions for UV-CE studies
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were Lt = 31 cm, Ld = 10 cm and for LIF-CE studies were Lt = 36 cm, Ld = 10 cm. The first UVCE study was conducted using a 0.5% PHEA separation matrix. For the study on the effect of
salt concentration on insulin oligomer formation, the capillary was filled with 1% PHEA and
rinsed with 40 mM Tris (pH 8.0) for 5 min prior to each run. This rinse was utilized to dilute the
PHEA on-column and overcome the long run times associated with the 0.5% PHEA separation
matrix. Polymers of HEA were synthesized as described previously [83] with the following
changes: 4% w/w initial monomer concentration and polymerization for 5 h. CE separations
using UV detection were carried out using a P/ACE MDQ Glycoprotein System from Beckman
Coulter, Inc. (Fullerton, CA) (214 nm filter) interfaced with an IBM computer utilizing 32 Karat
software (V. 5.0, Beckman Coulter, Inc.) for data collection. Samples were pressure injected at
0.5 psi for 8 s and separated at 15 kV. Between each run, the capillary was rinsed with deionized
water for 10 min to ensure that the insulin was not retained on the capillary wall. CE separations
using LIF detection were carried out using an Applied Biosystems (Foster City, CA) 3130
Genetic Analyzer (excitation = 494 nm, emission = 522 nm) interfaced with a Dell computer
utilizing Foundation Data Collection V 3.0 software. Samples were electrokinetically injected at
10 or 12 kV for 12 s and separated at 15 kV.
3.4. Limit of Detection Studies
Unlabeled insulin was prepared at concentrations of 0.05–0.2 mg/mL in 40 mM Tris (pH
8.0), and FITC-labeled insulin was prepared at concentrations of 0.03–3 ng/mL. Immediately
following preparation, 100 μL samples of unlabeled insulin and 10 µL samples of FITC-labeled
insulin were analyzed by UV-CE or LIF-CE, respectively, to determine the intensity of the first
peak. Between runs for determining the limit of detection, the capillary was rinsed with
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deionized water for 20–120 min, and elution of 40 mM Tris (pH 8.0) was analyzed to ensure that
insulin was not retained on the capillary wall.
3.5. Oligomer Formation Assay
To observe the time course for insulin oligomer formation, insulin was solubilized in 5
mM NaOH for 30 min and diluted into 40 mM Tris (pH 8.0) to make a 1 mg/mL stock. The
stock was then diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl and
incubated at 25 °C under continuous agitation (185 rpm). At times of 0, 4, 8, 12, and 24 h, a 50 µL
sample was removed and analyzed by UV-CE, with 0.5% PHEA separation matrix, to determine
the migration time and intensity of all peaks. Separate experiments were conducted using the same
sample preparation and CE conditions in order to determine the size range of insulin oligomers
observed. At 0, 4, 8, and 12 h, a 50 µL sample was taken and ultrafiltrated (20 min, 14,000 × g)
through Amicon filters with cut-off values of 30 kDa, 50 kDa and 100 kDa. The filtrate was
removed and analyzed via UV-CE to determine the relative size of oligomers.
To examine the effect of solution ionic strength on insulin oligomer formation, insulin
was prepared at a concentration of 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 100, 150, or
250 mM NaCl. Samples were incubated at 25 °C under continuous agitation (185 rpm). Both
prior to the onset of agitation and at times between 5 and 24 h following the onset of agitation, a
50 µL sample was removed and analyzed by UV-CE to determine the migration time of the first
and last peaks. In parallel experiments, aggregation was monitored using ThT binding as
described previously [84] by diluting an aliquot into ThT (10 µM) and evaluating fluorescence
using a Perkin-Elmer LS-45 luminescence spectrometer (Waltham, MA) (excitation = 450 nm,
emission = 470–500 nm) with baseline (ThT) subtraction. Lag times to aggregate formation were
determined for individual runs as the last time point prior to a marked increase in signal. For UV-
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CE, this increase was an extension of the migration time for the last peak greater than 2-fold that
of the monomer migration time. For ThT binding, this increase was 5% of the fluorescence
observed at equilibrium.
The co-incorporation of unlabeled insulin and FITC-labeled insulin into oligomers was
examined using LIF-CE and UV-CE in parallel. FITC-labeled insulin was prepared alone at a
concentration of 0.2 mg/mL or combined with unlabeled insulin for final concentrations of 0.2
mg/mL unlabeled insulin and 0.067 mg/mL FITC-labeled insulin (75% unlabeled, 25% FITClabeled). Both samples were prepared in 40 mM Tris (pH 8.0) containing 150 mM NaCl and
incubated at 25 °C under continuous agitation (185 rpm). Both prior to the onset of agitation and
at times between 5 and 24 h following the onset of agitation, the migration times of the first and
last peak were determined by both UV-CE and LIF-CE. Here, a 50 µL sample was removed for
analysis by UV-CE and a 20 µL sample was removed and diluted to 0.013 mg/mL for analysis
by LIF-CE.
3.6. Statistical Analysis
The migration time and intensity of peaks were analyzed using Chromagna (VO 9.8)
software (provided by Mark Miller, NIH) and Origin (V. 8.0) software from OriginLab
Corporation (Northampton, MA). Chromagna software was used to convert the fsa file format of
the ABI 3130 Genetic Analyzer to excel files, which are compatible with Origin. A Gaussian fit
was used to calculate the peak area and migration time in Origin. The migration times of peaks
observed in the insulin oligomer time course and salt concentration studies were normalized in
order to draw qualitative conclusions about the sizes of insulin species present at various times
throughout aggregation. Peak migration times were determined by normalizing the migration
time for the last peak observed relative to the migration time of the first peak observed prior to
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the onset of aggregation. In addition, the peak height for the monomeric peaks detected in the
UV and LIF limit of detection studies was determined and the S/N ratio was calculated. Peaks
with a S/N ratio >3 were considered significant. Statistical analysis for comparison of lag times
was performed using Prism 5 software (GraphPad Software Inc., San Diego, CA). The effect of
detection method upon lag time was assessed using a one-way ANOVA with Bonferroni posttest. Unpaired t-tests were performed using GraphPad QuickCalcs (GraphPad Software Inc., San
Diego, CA) to compare CE normalized migration times.
4. Conclusion
Insulin aggregation poses problems both in vivo and in vitro. These problems include
injection site bleeding and bruising which can occur during the treatment of Type II diabetes in
addition to problems with the pharmaceutical quality control of insulin. Elucidating the
molecular mechanism by which insulin aggregation occurs, in particular the early stages of
aggregation during which oligomeric species are formed, will facilitate the prevention of these
problems. However, most techniques utilized for studies of insulin aggregation are not sensitive
enough to detect physiologically relevant concentrations or oligomeric species present transiently
throughout aggregation under physiologically relevant solution conditions. These limitations
highlight the importance of employing a complementary technique to explore the evolution of
insulin oligomer appearance at physiologically relevant concentrations. The current study
illustrates that CE is a promising technique for monitoring the appearance of oligomeric species
during the early events of insulin aggregation and is the first report of the use of UV-CE to
monitor insulin oligomer formation at pH 8.0 and physiological salt concentration. UV-CE was
employed to demonstrate that a change in salt concentration from 100 mM NaCl to 250 mM
NaCl had little effect on the formation of small oligomeric species. A comparison between the
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use of UV-CE and ThT binding for monitoring insulin aggregation revealed that CE was able to
detect the appearance of aggregated species at significantly earlier times than ThT binding,
demonstrating that CE and ThT binding may be used as complementary techniques to identify
insulin species present at all times throughout aggregation. The lowest concentration of
monomeric insulin that can be detected was determined using both UV and LIF detection modes.
Physiologically relevant insulin concentrations in the picomolar range were detectable using LIF
detection while concentrations in the micromolar range were required for UV detection. Using
UV-CE and LIF-CE to simultaneously monitor the aggregation of a mixture of FITC-labeled
insulin and unlabeled insulin, this study was the first to show that FITC-labeled insulin was
unable to incorporate into oligomers formed by the unlabeled protein. These results demonstrate
that while CE is a promising technique for the detection of physiologically relevant insulin
concentrations, caution must be taken when choosing a dye for detection of oligomeric and
aggregate insulin species. This necessitates further investigation to identify optimum fluorescent
labels for the study of insulin oligomer formation at physiological insulin concentrations.
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Electropherograms for insulin oligomer time course with longer run times
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CHAPTER 4: MONITORING AΒ AGGREGATION VIA CAPILLARY
ELECTROPHORESIS
1. Introduction
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder which currently
affects 5.4 million Americans and is the 6th leading cause of death [1]. The amyloid β protein
(Aβ) is a partially folded protein that contributes to the neurodegenerative effects of AD. In its
monomer form, this protein is harmless [2]. This monomer can self-assemble into Aβ oligomers
and eventually fibrillar aggregates which deposit as amyloid plaques in the brain [3].
Controversy currently exists over the direct effect Aβ has on neurodegeneration, but it appears
likely that soluble aggregates of Aβ (protofibrils or oligomers), rather than monomers or
insoluble fibrils, may be responsible for the toxic effects of AD [4-7]. This hypothesis is
supported by experimental observations in vitro which showed that soluble aggregates formed by
synthetic Aβ1-40 and Aβ1-42 induced toxicity in cultured cells [8,9] and in vivo where soluble Aβ
aggregates generated in cell cultures drastically inhibited hippocampal long-term potentiation in
rats [10]. Furthermore, the direct neuron-to-neuron transfer and corresponding toxicity of soluble
oligomers formed by synthetic Aβ1-42 has been demonstrated [11].
The detection of soluble Aβ oligomeric species, specifically Aβ1-40, is challenging due to
the fact that these intermediate sized species are difficult to isolate because they are transient
[12,13], and present at low concentrations [14]. Many different techniques have been examined
for their ability to detect the smaller oligomeric Aβ species. These include SDS-PAGE and/or
Western blotting [8,15-27], mass spectrometry [20,28-33], and size exclusion chromatography
(SEC) [15]. SDS-PAGE with Western blotting is one of the most common electrophoretic
techniques used for studies of Aβ aggregation. It has been shown that the resolution of low
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molecular weight Aβ1-40 oligomers ranging from 8-24 kDa is difficult due to gel smearing [15].
This study also compared SDS-PAGE to SEC and found that Aβ1-40 was aggregating into higher
molecular weight species (>24 kDa) which were not detectable using SDS-PAGE. SEC is further
complicated by the dissociation of reversible aggregates that occurs upon sample dilution [34].
Western blotting also has been shown to be a promising technique for the detection of oligomeric
Aβ species, but it requires the use of expensive antibodies and gel smearing often limits the
ability to distinguish molecular weights. Mass spectrometry has also been used alone and in
combination with SDS-PAGE to evaluate the sizes formed during the early stages of Aβ
aggregation [20,28-31,33]. Studies by Iurascu et al. and Maji et al. have utilized MS in
combination with SDS-PAGE to detect Aβ1-40 species ranging from monomer to hexamer
[28,29]. Since aggregated species have highly similar mass-to-charge ratios, ion-mobility
coupled with MS (IM-MS) has been the most effective method for the separation of small
oligomers of Aβ by both size and charge. An aggregation mechanism for Aβ1-40 has been
proposed which involves the formation of dimers and tetramers followed by the slow formation
of fibrils containing a β-sheet structure [20,31]. IM-MS is expensive and the addition of a step
such as ion-mobility also increases the time needed for analysis and therefore decrease the
chances of detecting transient species. In addition, these techniques are not capable of detecting
the Aβ oligomerization process under physiological concentrations.
Capillary electrophoresis (CE) as a technique for the detection of Aβ species formed
throughout aggregation is still in its early stages. Therefore, studies on the use of CE for the
detection of Aβ aggregates, especially, Aβ1-40, are limited. The detection of proteins via CE can
be conducted using either ultraviolet (UV) absorbance or laser induced fluorescence (LIF)
detection modes. UV can detect proteins without any additional labeling, but typically has a
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lower sensitivity than LIF. LIF usually requires labeling of the molecules, but is highly sensitive,
with previous reports of LIF-CE detection of synthetic Aβ down to 35 nM [35]. The process of
fluorescence occurs when a photon is emitted by an electronically excited molecule as it relaxes
to its ground electronic state [36]. For LIF-CE, the fluorescence excitation source is typically a
He-Cd, Ar-ion, or He-Ne laser [36]. In general, the fluorescent compound used to label proteins
for analysis via LIF-CE can be 1) covalently bound to the protein or 2) specific for a certain
protein conformation. Furthermore, these fluorescent probes are typically bulky, aromatic
compounds.
The ability of UV-CE to detect Aβ aggregates has been demonstrated in the literature. A
study by Sabella et al. utilized UV-CE to detect small Aβ1-40 species ranging from 3 - 30 kDa
and Aβ1-42 species ranging from 3 - 50 kDa and > 50 kDa [37]. However, this study looked at a
small size range (3 – 50 kDa) and did not use a sieving matrix within the capillary to enhance
resolution. The separation of larger fibrillar species from monomer has been achieved for both
Aβ1-40 and Aβ1-42 using UV-CE [38]. The detection of intermediate sizes larger than monomer
which are formed prior to fibrils was not accomplished. These studies demonstrate the ability of
UV-CE to detect sizes from monomers to fibrils but highlight the need for more studies on the
use of UV-CE to monitor the Aβ aggregation process over time.
The ability of LIF-CE to detect Aβ aggregates using dyes which are specific for the βsheet conformation has been demonstrated in the literature [3,38,39]. These dyes bind structures
containing β-sheets and therefore cannot be used for the detection of small oligomers which
precede β-sheet formation. Carboxy-fluorescein (FAM) and fluorescein isothiocyanate (FITC)
are covalently bound fluorescent dyes which have been used for the detection of monomeric
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insulin and Aβ via LIF-CE [35,40]. Less attention has been paid to the use of LIF-CE to detect
oligomeric and aggregated species formed by FAM or FITC-labeled insulin and Aβ.
These previous studies highlight the potential for CE using a buffer solution to analyze
early stages of the Aβ1-40 oligomerization process. In this chapter, we report the first study on the
use of UV-CE with a polymer separation matrix to detect smaller oligomeric native Aβ1-40
species (10 – 30 kDa) and larger oligomeric and aggregate species (100– 300 kDa and > 300
kDa). To our knowledge this is the first study to investigate the use of a polymer matrix to
increase the effect of hydrodynamic radius of the oligomer species on CE separation to study the
early oligomerization process of Aβ1-40. In addition, we have compared the oligomeric species
sizes detected utilizing a traditional Aβ1-40 oligomer sample preparation with initial dilution into
NaOH compared to a sample thought to contain SEC-purified Aβ1-40 monomer as the initial
species present in solution. Dot blots were utilized to verify the presence of Aβ oligomeric
species detected via UV-CE. Furthermore, we have probed the ability of CE to detect
physiological concentrations of Aβ1-40. The potential for LIF-CE to monitor the aggregation of
FAM-labeled Aβ1-42 is explored and the limitations of LIF-CE as a tool to monitor amyloid
aggregation will be given. We believe that these are the first CE studies to use a polymer matrix
to enhance the separation of native Aβ1-40 oligomers and to determine and compare UV versus
LIF detection limits.
2. Materials and Methods
2.1. Aβ preparation
Aβ1-40 and FAM-Aβ1-40 were stored dessicated at -20°C. 4.33 mg/mL Aβ1-40 and 0.47 mg/
mL FAM-Aβ1-40 peptide stocks were prepared in hexafluoroisopropanol (HFIP) in order to break
down larger aggregates. These stock solutions were split into vials containing 0.0625 mg for
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Aβ1-40 and 0.01563 mg for FAM-Aβ1-40 and the HFIP was allowed to evaporate overnight. Vials
were stored at -80°C.
SEC-purified Aβ1-40 monomer samples were prepared in the laboratory of Dr. Melissa
Moss as described previously [41]. Briefly, Aβ1-40 peptide was reconstituted to a final
concentration of 2 mg/mL in 50 mM NaOH. Preexisting aggregates were removed by size
exclusion chromatography (SEC) on a Superdex 75 HR10/30 column (GE Healthcare,
Piscataway, NJ, USA). Purified Aβ1-40 monomer was flash frozen and shipped overnight on dry
ice to the laboratory of Dr. Christa Hestekin. The purified Aβ1-40 monomer was used fresh or
stored at -80°C.
Aβ1-42 and FAM-Aβ1-42 were stored dessicated at -20°C. 4.51 mg/mL Aβ1-42 and 0.49 mg/
mL FAM-Aβ1-42 peptide stocks were prepared in hexafluoroisopropanol (HFIP) in order to
ensure the samples were monomeric. These stock solutions were split into vials containing
0.0271 mg for Aβ1-42 and 0.006775 mg for FAM-Aβ1-42 and the HFIP was allowed to evaporate
overnight. Vials were stored at -80°C. 5 mM stock solutions of FAM-labeled Aβ1-42 and
unlabeled Aβ1-42 were prepared separately in 100% DMSO and diluted to 0.14 mg/mL in 40 mM
Tris (pH 8.0) containing 10 mM NaCl. These samples were then combined to yield a total final
concentration of 0.14 mg/mL containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled
Aβ1-42.
2.2. Poly(ethylene oxide) coating and separation matrix synthesis
The utility of poly(ethylene oxide) as a capillary coating and separation matrix was
investigated due to the commercial availability of this polymer. All UV-CE studies were
conducted using PEO as a coating and separation matrix in the capillary. One sample of longchained EO polymer (MW = 2,000,000 g/mol) and one sample of short-chained EO polymers
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(MW = 100,000 g/mol) were obtained from Sigma-Adrich (St. Louis, MO). The EO polymer with
MW = 2,000,000 g/mol was diluted to 0.5% w/v in de-ionized water and used for the capillary
coating and the EO polymer with MW = 100,000 g/mol was diluted to 0.5% w/v in 100 mM TrisHCl and used as the protein separation matrix.
2.3.

Poly-N-hydroxyethyl

acrylamide

coating

and

separation

matrix

synthesis

and

characterization
All LIF-CE studies were conducted using PHEA as a coating and separation matrix in the
capillary. Two samples of long-chained HEA polymers (MW = 6,230,000 g/mol and 5,100,000
g/mol) were synthesized as described previously [42] with the following changes: 4% w/w initial
monomer concentration and polymerization for 5 hours. One sample of short-chained HEA
polymer (MW = 2,700,000 g/mol) was synthesized as described previously [43] with the
following changes: 3.5 mL isopropanol added to 200 mL of 4% w/w initial monomer solution.
Solution deoxygenated by bubbling nitrogen through mixture at 47°C for 2 h followed by
polymerization for 4 hours. Once the polymerization was complete, the polymer was dialyzed,
lyophilized, and characterized to confirm its molecular weight by multi-angle laser light
scattering (Wyatt Technology, Santa Barbara, CA). The HEA polymer with MW = 6,230,000
g/mol was diluted to 0.1% w/v in de-ionized water and used for the capillary coating and the
HEA polymers with MW = 5,100,000 and 2,700,000 g/mol were diluted to 1% (UV and LIF
insulin studies) and 0.5% (LIF Aβ studies), respectively, in 40 mM Tris (pH 8.0) and used as
protein separation matrices.
2.4. Electrophoresis conditions for UV and LIF studies
Aβ1-40 oligomer formation studies with analysis via UV-CE were carried out in 0.5% w/v
PEO coated capillaries with a 0.5% PEO separation matrix and a capillary temperature of 25°C.
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Aβ limit of detection and oligomer formation studies with analysis via LIF-CE were carried out
in 0.1% w/v PHEA coated capillaries with a 0.1–1% PHEA separation matrix and a capillary
temperature of 25 °C. Capillary dimensions for UV-CE studies were Lt = 31 cm, Ld = 10 cm and
for LIF-CE studies were Lt = 36 cm, Ld = 10 cm. CE separations using UV detection were carried
out using a P/ACE MDQ Glycoprotein System from Beckman Coulter, Inc. (Fullerton, CA) (214
nm filter) interfaced with an IBM computer utilizing 32 Karat software (V. 5.0, Beckman
Coulter, Inc.) for data collection. Samples were pressure injected at 0.5 psi for 8 s and separated
at 7 kV. Between each run, the capillary was rinsed with deionized water for 10 minutes to
ensure that the Aβ1-40 was not retained on the capillary wall. CE separations using LIF detection
were carried out using an Applied Biosystems (Foster City, CA) 3130 Genetic Analyzer
(excitation = 494 nm, emission = 522 nm) interfaced with a Dell computer utilizing Foundation
Data Collection V 3.0 software from Applied Biosystems (Foster City, CA). For limit of
detection studies, Aβ1-40 and Aβ1-42 samples were electrokinetically injected at 12 kV for 12 s
and separated at 15 kV. For oligomer formation studies, Aβ1-42 samples were electrokinetically
injected at 7 kV for 7 s and separated at 7 kV.
2.5. Aβ oligomer formation assay
To observe the time course for Aβ1-40 oligomer formation, Aβ1-40 was dissolved in 5 mM
NaOH and diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final
concentration of 0.22 mg/mL and incubated at 25°C under continuous agitation (800 rpm). Both
prior to the onset of aggregation and at times between 5 and 48 hours following the onset of
aggregation, a 15 µL sample was removed and analyzed by UV-CE to determine the elution time
and intensity of all peaks. Separate experiments were conducted using the same sample
preparation and CE conditions in order to determine the size range of Aβ1-40 oligomers observed.
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At 0 and 28 hours, a 50 µL sample was taken and ultrafiltrated (20 minutes, 14,100 x g) through
Amicon filters with cut-off values of 10, 30, 50, and 300 kDa. The filtrate and retentate were
removed and analyzed via UV-CE to determine the relative size of oligomers.
To observe the effect of model inhibitory compounds on the formation of Aβ1-40
oligomeric species, Aβ1-40 was dissolved in 5 mM NaOH and diluted into 40 mM Tris-HCl (pH
8.0) supplemented with 5 mM NaCl to a final concentration of 0.22 mg/mL. Congo Red and
Orange G were dissolved in DMSO and added to Aβ1-40 to obtain a mixture containing 2%
DMSO, 0.15 mg/mL Orange G or 0.23 mg/mL Congo Red and incubated at 25°C under
continuous agitation (800 rpm). Both prior to the onset of aggregation and at times of 24 and 28
hours following the onset of aggregation, a 15 µL sample was removed and analyzed by UV-CE
to determine the elution time and intensity of all peaks.
To compare the effect of sample preparation on the Aβ1-40 sizes formed, SEC-purified
Aβ1-40 was diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final
concentration of 0.22 mg/mL and incubated at 25°C under continuous agitation (800 rpm).
Identical time points and aliquot volumes as those given in the previous paragraph were taken
and analyzed via UV-CE. Separate experiments were conducted using the same sample
preparation and CE conditions in order to determine the size range of Aβ1-40 oligomers observed.
At 0 and 5 hours, a 50 µL sample was taken and ultrafiltrated (20 minutes, 14,100 x g) through
Amicon filters with cut-off values of 10 and 30 kDa (0 hours) and 30, 50, and 300 kDa (5 hours).
The filtrate and retentate were removed and analyzed via UV-CE to determine the relative size of
oligomers.
The co-incorporation of unlabeled Aβ1-42 and FAM-labeled Aβ1-42 into oligomers was
examined using LIF-CE. 5 mM stock solutions of FAM-labeled Aβ1-42 and unlabeled Aβ1-42 were
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prepared separately in 100% DMSO and diluted to 0.14 mg/mL in 40 mM Tris (pH 8.0)
containing 10 mM NaCl. These samples were then combined to yield a total final concentration
of 0.14 mg/mL containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled Aβ1-42. This
oligomer preparation was then incubated at 25°C and both prior to the onset of oligomer
formation and at times between 3 and 24 hours following the onset of oligomer formation, a 27
µL sample was removed and combined with 3 µL of 1% tween to obtain a final volume
containing 0.1% tween for analysis by LIF-CE. Tween was added in order to stop oligomer
formation.
2.6. Dot blot analyses of Aβ aggregation
To validate Aβ1-40 oligomer detection via CE with a more commonly used technique for
oligomer detection, Aβ1-40 aggregates were analyzed via dot blotting. Aβ1-40 aggregation
reactions were prepared and incubated as described above for CE measurements on Aβ1-40
oligomer formation. Both prior to the onset of aggregation and at times between 5 and 48 hours
following the onset of aggregation, 3 µL aliquots were spotted on nitrocellulose membranes
(VWR) and allowed to dry for at least 1 hour. Membranes were blocked in 5% skim milk in tris
buffered saline containing 0.01% Tween 20 (TBS-T) for 1 hour. After washing 3 times with
TBS-T, membranes were incubated with either Aβ1-16 specific 6E10 antibody (1:2000 dilution),
Aβ oligomer specific A11 antibody (1:2000 dilution), or Aβ fibril specific OC antibody (1:4000
dilution) for 1 hour at 4°C with gentle shaking. Membranes were again washed with TBS-T and
bound 6E10, A11, and OC antibodies were detected by incubation for 1 hour at 4°C with
alkaline phosphatase-conjugated anti-mouse IgG (1:2000 dilution) or alkaline phosphataseconjugated anti-rabbit IgG (1:3000 dilution). All antibodies were diluted in 5% skim milk in
TBS-T. After washing with TBS-T/MgCl2, a substrate solution containing 15 mL TBS-T/MgCl2
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+ 50 µL of 50 mg/mL 5-bromo-4-chloro-3-indolyl phosphate (BCIP) + 50 µL of 50 mg/mL
nitroblue tetrazolium chloride (NBT) was used to develop the membranes.
2.7. Limit of detection studies
A 0.22 mg/mL unlabeled Aβ1-40 stock solution was prepared in 5 mM NaOH and 40 mM
Tris-HCl (pH 8.0) supplemented with 5 mM NaCl and diluted to concentrations of 0.0087 0.043 mg/mL in 40 mM Tris-HCl (pH 8.0). A 0.47 mg/mL stock solution of FAM-Aβ1-40 and
FAM-Aβ1-42 were prepared separately and diluted in 40 mM Tris-HCl (pH 8.0) to concentrations
of 0.0047 - 4140 ng/mL for FAM-Aβ1-40 and 0.0049 - 4870 ng/mL for FAM-Aβ1-42.
Immediately following preparation, 25 and 10 µL samples were analyzed by UV and LIF-CE,
respectively, to determine the intensity of the first peak. Between runs for determining the limit
of detection, the capillary was rinsed with deionized water for 10 minutes, and elution of deionized water was analyzed to ensure that Aβ1-40, FAM-Aβ1-40 and FAM-Aβ1-42 were not retained
on the capillary wall.
2.8. Statistical analysis
The elution time and intensity of peaks were analyzed using Chromagna (VO 9.8)
software (provided by Mark Miller, NIH) and Origin (V. 8.0) software from OriginLab
Corporation (Northampton, MA). Chromagna software was used to convert the fsa file format of
the ABI 3130 Genetic Analyzer to excel files, which are compatible with Origin software. For
UV-CE studies, a Gaussian fit was used to calculate the peak area and migration time in Origin.
The peak height for the peaks detected in the UV and LIF limit of detection studies was
determined and the signal-to-noise ratio was calculated. Peaks with a signal-to-noise ratio > 3
were considered significant. Unpaired t-tests were performed using GraphPad QuickCalcs
(GraphPad Software Inc., San Diego, CA) to compare peak areas. For LIF-CE studies, the
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migration times of peaks observed in the Aβ1-42 oligomer time course studies were normalized in
order to draw qualitative conclusions about the sizes of Aβ1-42 species present at various times
throughout aggregation. Peak migration times were determined by normalizing the migration
time for the last peak observed relative to the migration time of the first peak observed prior to
the onset of aggregation. Unpaired t-tests were performed using GraphPad QuickCalcs
(GraphPad Software Inc., San Diego, CA) to compare CE normalized migration times.
3. Results and Discussion
3.1. Detection of Aβ1-40 oligomers using CE with UV detection
Although insoluble Aβ fibrils are a post mortem signature, recent studies suggest that
soluble Aβ oligomers impair cognitive function and in addition to synapse loss, correlate most
accurately with the stage of neurological impairment [44-46]. Therefore, it is important to have a
technique which is capable of detecting these soluble oligomeric Aβ species. To explore the
utility of CE for the detection of Aβ1-40 oligomers that appear during early stages of Aβ1-40
aggregation, Aβ1-40 was solubilized in 5 mM NaOH, diluted into 40 mM Tris (pH 8.0), subjected
to 5 mM NaCl, and agitated at 800 rpm to promote amyloid assembly. The reaction was analyzed
using UV-CE at early and late time points to assess the appearance of oligomers and progression
into larger aggregate species. At 0 hours, UV-CE demonstrated the presence of an early, sharp
peak at ~9 min (Figure 1B) in addition to a broader peak migrating at 220 minutes (Figure 1A).
The size of these species was estimated using a filtration analysis similar to that performed by
Sabella et al. who used molecular weight cutoff membranes to size early amyloid-β aggregation
species detected via UV-CE [37]. For our experiments, we used membranes with molecular
weight cutoffs of 10, 30, 50, 100, and 300 kDa to analyze the filtrate obtained after 0 and 28
hours of aggregation (Appendix). The peak obtained at ~9 min was estimated to have a
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molecular weight between 10 – 30 kDa, or oligomers of 2 - 6 monomer units. Furthermore, a
broad peak at 220 min was obtained and indicates the presence of larger species. A similar
monomer peak pattern was obtained after 5, 10, and 24 hours (Figure 1B) while the later peak
became more broad and exhibited a progressively shorter migration time (Figure 1A). This later
broad peak was estimated to have a molecular weight of 100 – 300 kDa. At 28 hours, a set of
sharp peaks with migration times between 8 – 8.5 minutes appeared (Figure 1B). The size of
these species was estimated by filtration analysis to be > 300 kDa, or larger than 70 monomer
units. Furthermore, we have confirmed that this sharp peak corresponds to an oligomeric
structure, and not a fibril structure by looking at the affect of model inhibitory compounds
(Figure 2). These compounds include Orange G, which is known to inhibit the formation of Aβ
fibrils and Congo Red, which is known to inhibit the formation of Aβ oligomers [47]. By 36 and
48 hours, the intensity for the sharp peak at ~8.5 minutes increased and appeared to resolve into
a single species.
In order to better understand the growth process, the peak area for the initially present
species (10 – 30 kDa peak at ~9 minutes) was compared to the peak area for the > 300 kDa
oligomer peak at ~8.5 minutes, which appeared after 28 hours of aggregation (Figure 3). As
shown in Figure 3, the peak area for the 10 – 30 kDa peak initially increases over an
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Figure 1. Detection of smaller, intermediate, and larger molecular weight Aβ1-40
aggregation states using UV-CE. Aβ1-40 was aggregated under agitation (800 rpm) at
0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48
hours, CE was performed in conjunction with UV detection with a 0.5 psi pressure
injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix in a PEO
coated capillary. Panel A) shows all peaks while panel B) is zoomed in on the
smaller peaks. Results are representative of three independent experiments.

Figure 18 Detection of smaller, intermediate, and larger molecular weight Aβ1-40 aggregation states using UV-CE

molecular weight Aβ1-40 aggregation states using UV-CE.
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Figure 2. Comparison of Aβ1-40 peak pattern obtained with and without the presence
of inhibitory compounds. Aβ1-40 was aggregated under agitation (800 rpm, 25 °C) at
0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl in the absence of
inhibitor, or in the presence of 0.23 mg/mL Congo Red or 0.15 mg/mL Orange G. At
0 – 28 hours, CE was performed in conjunction with UV detection with a 0.5 psi
pressure injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix
in a PEO coated capillary.

Figure 19 Comparison of Aβ1-40 peak pattern obtained with and without the presence of
inhibitory compounds
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Figure 3. Effect of aggregation time on the peak areas obtained for 10 – 30 kDa (,
n = 3) and > 300 kDa (, n = 3) Aβ1-40 species. Aβ1-40 was aggregated under
agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl
and at 25 °C. At 0 – 48 hours, CE was performed in conjunction with UV detection
with a 0.5 psi pressure injection for 8 s with separation at 7 kV using 0.5% PEO
separation matrix in a PEO coated capillary. A * represents the first time point in
which peak areas are statistically different with p < 0.05.

Figure 20 Effect of aggregation time on the peak areas obtained for 10 – 30 kDa (, n = 3) and >
300 kDa (, n = 3) Aβ1-40 species
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aggregation time of 24 hours. This initial increase in peak area could be due to the breakdown of
the larger species present at 0 hours into 10 – 30 kDa species. After 28 hours, the 10 – 30 kDa
peak area decreases and a new peak (> 300 kDa) with a faster migration time than the 10 – 30
kDa peak appears. Finally, between 28 – 48 hours of aggregation, both the 10 – 30 kDa and
> 300 kDa peak areas further decrease. We hypothesize that sharp peak (> 300 kDa) with a faster
migration time which appears after 28 hours of aggregation represents a species with an
increased negative surface charge due to conformational changes which occur during oligomer
formation. An increase in negative surface charge of Aβ1-42 fibrils has been observed by Wang et
al [48]. This study utilized surface plasmon resonance to monitor the absorption of Aβ1-42 at
various times throughout aggregation to four model self-assembled monolayers: hydrophobic
CH3-terminated SAM, hydrophilic OH-terminated SAM, negatively charged COOH-terminated
SAMs, and positively charged NH2-terminated SAM. They found that as Aβ grew into larger
aggregates, the amount absorbed onto positively charged NH2-SAM increased while the amount
absorbed onto negatively charged COOH-SAM decreased. This increase in electrostatic
interactions with the positively charged NH2-SAM suggests an increase in negative surface
charge of Aβ1-42 aggregates. Furthermore, a structural model for Aβ1-40 fibrils has been suggested
by Petkova et al. in which the negatively charged N-terminus residues are exposed to solution on
the outside of the fibril [49].
A previous study by Sabella et al. utilized UV-CE with an SDS rinse for the detection of
Aβ1-40 oligomers formed in PBS (pH 7.4) at room temperature [37]. A decrease in the intensity of
the 10 to 30 kDa peak was observed over an incubation period of 24 hours with the
disappearance of all peaks after 48 hours. In contrast to our results, no new peaks were observed
over an aggregation period of 48 hours. Furthermore, Western blot analyses of SDS-PAGE
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separations have been utilized to characterize SDS-stable Aβ1-40 assemblies [22,24,27,32]. A
smear for Aβ1-40 species ranging from ~60 - 80 kDa was obtained after incubation at 4°C for 6
weeks of an Aβ1-40 oligomer preparation employing DMSO and F12 culture media at pH 7.4, 150
mM NaCl [24,27]. This smear obtained with Western blotting could represent the broad peaks
with longer migration times seen in our UV-CE studies (Figure 1A). Our studies are the first to
utilize UV-CE to detect the formation of native Aβ1-40 species ranging from 100 – 300 kDa and
> 300 kDa at near physiological pH.
3.2. Effect of sample preparation on Aβ1-40 aggregate sizes formed
The type of solvent used to dissolve lyophilized Aβ1-40 has been shown to have an effect
on the initial conformation and subsequent aggregation kinetics of this peptide [50]. However,
this study employed organic solvents, which have been known to accelerate Aβ aggregation and
misrepresent the true “native” aggregation of the protein [51]. Furthermore, larger aggregates
which are initially present in solution can serve as “seeds” that promote the formation oligomeric
species [52,53]. Therefore, since a range of Aβ1-40 sizes were detected at the onset of aggregation
(Figure 1A) using a sample preparation thought to produce smaller Aβ sizes, we explored the
aggregation of a sample containing SEC-purified Aβ1-40 as the starting material. Furthermore, we
utilized a non-organic solvent, sodium hydroxide, for initial dissolution of Aβ1-40 peptide.
Preexisting Aβ1-40 aggregates were removed by SEC and samples thought to contain purified
Aβ1-40 monomer were diluted into 40 mM Tris (pH 8.0), subjected to 5 mM NaCl, and agitated at
800 rpm to promote amyloid assembly. The reaction was analyzed using UV-CE at various
points throughout the aggregation process to assess the appearance of oligomers and progression
into larger aggregate species. Similar to the filtration analyses conducted with non-purified Aβ140,

we used membranes with molecular weight cutoffs of 10, 30, 50, and 300 kDa to analyze the
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filtrate obtained after 0 and 5 hours of aggregation (Appendix). At 0 hours, a peak migrating at
~9.5 min was observed, which was estimated to range in size from 10 – 30 kDa (Figure 4A).
After 5 hours of aggregation, a new peak with a faster migration time of ~8 min appeared. The
size of these species was estimated by filtration analysis to be > 300 kDa, or larger than 70
monomer units. A similar peak pattern for the 10 – 30 kDa species and faster eluting oligomer
species was obtained after 10 – 48 hours (Figure 4B) while a later peak appeared which became
more broad and exhibited a progressively shorter migration time (Figure 4A). The size of this
peak was estimated by filtration analyses to be 100 - 300 kDa.
In order to better visualize the differences between SEC-purified Aβ1-40 and non-purified
Aβ1-40 samples, the peak pattern obtained at 0 hours for SEC-purified samples and non-purified
samples is compared (Figure 5A and B). Compared to the non-SEC purified Aβ1-40 sample, no
peak was observed at 220 min for the SEC-purified Aβ1-40 sample, indicating the presence of
predominantly 10 – 30 kDa Aβ1-40 at 0 hours (Figure 5). Furthermore, the area for the 10 – 30
kDa peak at ~9 minutes is compared to the peak area for the > 300 kDa oligomer peak at ~8.5
minutes. Figure 6A shows peak areas for the non-purified Aβ1-40 sample while Figure 6B shows
the peak areas for the SEC-purified Aβ1-40 sample. Compared to the non-purified Aβ1-40 sample,
the SEC-purified Aβ1-40 sample showed a decrease in the 10 – 30 kDa peak area and appearance
of > 300 kDa oligomer peak after 5 hours, which is ~23 hours earlier than non-purified Aβ1-40
sample. Figure 7 shows changes in the 10 – 30 kDa peak area for the SEC-purified Aβ1-40
sample compared to the non-purified Aβ1-40 sample. Initially, an increase in the 10 – 30 kDa peak
area is observed for the non-purified Aβ1-40 sample. Furthermore, the 10 – 30 kDa peak for the
non-purified Aβ1-40 sample decreased after 28 hours while the 10 – 30 kDa peak for the SECpurified Aβ1-40 sample decreases after just 5 hours. The decrease in the 10 – 30 kDa
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Figure 4. Detection of smaller, intermediate, and larger SEC-purified Aβ1-40
molecular weight aggregation states using UV-CE. SEC-purified Aβ1-40 was
aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0)
containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was performed in
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
Panel A) shows all peaks while panel B) is zoomed in on the smaller peaks. Results
are representative of three independent experiments.

Figure 21 Detection of smaller, intermediate, and larger SEC-purified Aβ1-40 molecular weight
aggregation states using UV-CE
144

Figure 5. Comparison of peak pattern obtained at the onset of aggregation for SECpurified Aβ1-40 and non-purified Aβ1-40 using UV-CE. SEC-purified Aβ1-40 and nonpurified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM
Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 hours, CE was performed in
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
Panel A) shows all peaks while panel B) is zoomed in on the smaller peaks.

Figure 22 Comparison of peak pattern obtained at the onset of aggregation for SEC-purified Aβ140 and non-purified Aβ1-40 using UV-CE
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– 30 kDa (, n = 3) and > 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30
kDa (, n = 3) and > 300 kDa (, n = 3) SEC-purified Aβ1-40 species.
Figure 6. Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa
(, n = 3) and > 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30 kDa
(, n = 3) and > 300 kDa (, n = 3) SEC-purified Aβ1-40 species. SEC-purified and
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
A * represents the first time point in which peak areas are statistically different with
p < 0.05 for non-purified Aβ1-40 samples and p < 0.02 for SEC-purified Aβ1-40
samples.

Figure

23Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa (, n = 3) and
> 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30 kDa (, n = 3) and > 300 kDa
(, n = 3) SEC-purified Aβ1-40 species
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Figure 7. Effect of aggregation time on the 10 – 30 kDa peak areas obtained for nonpurified (, n = 3) and SEC-purified (, n = 3) Aβ1-40 species. SEC-purified and
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
A * represents the first time point in which peak areas are statistically different with
p < 0.05 for non-purified Aβ1-40 samples and p < 0.0002 for SEC-purified Aβ1-40
samples.

Figure 24 Effect of aggregation time on the 10 – 30 kDa peak areas obtained for non-purified
(, n = 3) and SEC-purified(, n = 3) Aβ1-40 species
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peak area is accompanied by the appearance of a > 300 kDa oligomer peak for both non-purified
and SEC-purified Aβ1-40 samples. Figure 8 compares the area for the > 300 kDa peak for nonpurified and SEC-purified Aβ1-40 samples. This peak appears ~23 hours earlier compared to nonpurified Aβ1-40 samples.
Our findings that a very short lag time to aggregate formation exists when SEC-purified
monomer is the predominant Aβ1-40 species at the onset of aggregation are similar to those
observed by Taylor et al [54]. This study prepared a solution of Aβ1-40 which consisted of
predominantly monomer, as confirmed by HPLC, and monitored aggregate formation by dilution
to 50 µM in PBS and agitation at 800 rpm. Turbidity measurements showed that aggregate
formation occurred after 60 min. They propose a three-step kinetic model for Aβ1-40 in which; 1)
an unactivated monomer is slowly converted to an activated monomer, 2) an oligomeric nucleus
is formed by the cooperative interaction between four activated monomers that serves as the
growing site for the fibril, 3) fibril growth proceeds by the successive addition of unactivated
monomer to elongate the aggregates. As shown in Figure 3.7, SEC-purified Aβ1-40 has a much
larger initial population of 10 – 30 kDa species compared to the non-purified Aβ1-40. In addition,
the population of 10 – 30 kDa species for the non-purified Aβ1-40 increases initially and then
begins to decrease before forming larger oligomeric species > 300 kDa. This suggests that a
criticial concentration of 10 – 30 kDa species is necessary in order to progress to the next
aggregation state. Furthermore, as shown in Figure 3.8, the > 300 kDa species formed by nonpurified Aβ1-40 samples increases after 28 hours and begins to decrease after 36 hours while the
peak area for the > 300 kDa species formed by SEC-purified Aβ1-40 increases after 5 hours but
does not begin to decrease until 48 hours. We hypothesize that a key size is needed, which is
formed at later points during aggregation, for the seeding effect to encourage the larger
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Figure 8. Effect of aggregation time on the > 300 kDa peak area obtained for nonpurified (, n = 3) and SEC-purified (, n = 3) Aβ1-40 species. SEC-purified and
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
A * represents the first time point in which peak areas are statistically different with
p < 0.04 for non-purified Aβ1-40 samples and p < 0.02 for SEC-purified Aβ1-40
samples.

Figure 25 Effect of aggregation time on the > 300 kDa peak area obtained for non-purified (, n
= 3) and SEC-purified (, n = 3) Aβ1-40 species
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aggregation growth. Whatever the cause, the differences between lag times in addition to peak
areas for samples containing larger aggregates at the onset of aggregation and samples
containing predominantly smaller species at the onset of aggregation highlights the importance
of sample preparation on Aβ1-40 aggregation.
3.3 Validation of CE detection with traditional measures of Aβ aggregation states
The recent development of antibodies specific for Aβ oligomers has led to an increase in
the application of dot blotting to study Aβ aggregation [55-57]. Furthermore, antibodies which
are specific for a certain part of the Aβ sequence or a particular conformation can be used to
detect Aβ1-16 and Aβ fibrillar species, respectively. In these studies, we utilized the conformation
specific antibodies A11 and OC, which are known to recognize Aβ prefibrillar oligomers [55,56]
and Aβ fibrils [55], respectively, and the sequence specific antibody 6E10, which is known to
recognize Aβ1-16 [55,56]. Non-purified and SEC-purified Aβ1-40 samples were agitated using the
same sample and aggregation conditions as were used in the UV-CE studies. Figure 9 shows the
dot blot analysis of Aβ1-40 monomer (Panel A, 6E10 antibody), oligomer (Panel B, A11
antibody), and fibril (Panel C, OC antibody). The top row in each panel is for non-purified
Aβ1-40 samples while the bottom row is for SEC-purified Aβ1-40 samples. At all times during
aggregation, both non-purified and SEC-purified Aβ1-40 samples contain 6E10 positive stains
(Figure 9A). This is expected as both Aβ oligomer and fibril samples have been shown to react
with 6E10 in the literature [55]. A11 and OC positive dots are detected in non-purified Aβ1-40
samples after 24 hours and in SEC-purified Aβ1-40 samples after 5 hours (Figure 9B, C). This
indicates that for non-purified Aβ1-40 samples, oligomeric and fibrillar Aβ1-40 species begin to
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form after 24 hours of aggregation while for SEC-purified Aβ1-40 samples oligomeric and
fibrillar Aβ1-40 species begin to form after 5 hours of aggregation.
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Figure 9. Monitoring Aβ1-40 aggregation by dot blotting. Non-purified Aβ1-40 and
SEC-purified Aβ1-40 samples were aggregated under agitation (800 rpm) at 0.22
mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48
hours, samples were taken and spotted onto a nitrocellulose membrane. Membranes
were stained with Aβ1-16 specific antibody 6E10 (Panel A), oligomer specific
antibody A11 (Panel B) and fibril specific antibody OC (Panel C).

Figure 26 Monitoring Aβ1-40 aggregation by dot blotting
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These results are in agreement with previous studies which utilized dot blots to monitor
Aβ1-40 aggregation. A study by Wong et al. utilized dot blotting to monitor the aggregation of a
50 µM Aβ1-40 sample containing 10 mM NaH2PO4 and 150 mM NaCl at pH 7.4 incubated at
37°C [56]. They observed positive stains for the 6E10 antibody at times ranging from 0 – 3 days
with the highest signal intensity at 1 and 2 days followed by a decrease in intensity at 3 days. A
similar trend to the 6E10 antibody was observed for the A11 antibody but with a much lower
signal intensity at day 0. This study did not look at the binding of OC to Aβ1-40. A comparison
between the binding of A11 and OC to Aβ1-42 has been investigated by Kayed et al [55]. This
study incubated Aβ1-42 under two sets of conditions, one known to promote the formation of
fibrillar oligomers and fibrils while the other set of conditions is known to promote the formation
of prefibrillar oligomers. A mechanism for aggregation was suggested (Figure 10) whereby; 1)
misfolded monomer aggregates to form prefibrillar oligomers (recognized by A11), 2)
prefibrillar oligomers align to form protofibrils followed by a conformational change to form
fibrils (recognized by OC). An alternative mechanism of aggregation was also suggested where;
1) misfolded monomer aggregates to form fibrillar oligomers (recognized by OC), 2) fibrillar
oligomers elongate by the addition of monomer onto the ends of fibrillar oligomers, thus
resulting in fibril formation. A comparison of our dot blot results with the results obtained from
UV-CE suggests that both of these mechanisms of aggregation may be occurring under our
incubation conditions. This is supported by examination of the non-purified Aβ1-40 time course.
After 24 hours of aggregation, dot blots reveal positive stains for A11 and OC (Figure 9B and
C) while the UV-CE peak pattern for the 10 – 30 kDa peak at ~9 min (Figure 1B) remains
virtually the same as earlier time points. After 28 hours, UV-CE shows that the area for the 10 –
30 kDa peak
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Figure 10. Representation of distinct types of Aβ1-42 oligomers and their relationship
to Aβ1-42 fibrils. Monomeric Aβ1-42 misfolds and aggregates to form two different
conformations. One conformation formed is a prefibrillar oligomer, recognized by
A11 (left pathway), which aligns to form protofibrils and undergoes another
conformational change “en bloc” to form fibrils. Alternatively, a fibrillar oligomeric
conformation can be formed which is recognized by OC (right pathway). The fibrillar
oligomers may represent the fibril nuclei which are capable of elongating by
recruiting additional monomers. Addition of monomers to the ends of fibrillar
oligomers and fibrils results in fibril growth. Reprinted from [55] with permission
from Charles Glabe, cglabe@uci.edu, corresponding author for this publication.
Copyright 2007 by the authors; licensee BioMed Central, an open access journal.

Figure 27 Representation of distinct types of Aβ1-42 oligomers and their relationship to Aβ1-42
fibrils
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decreases while a new peak with a faster migration time of ~8 – 8.5 min (> 300 kDa) appears.
Therefore, this fast peak could correspond to the conformational change that the prefibrillar
oligomer undergoes.
3.4 Determination of Aβ1-40 limit of detection
The physiological concentration of Aβ in CSF is 100 – 2000 pM [58]. Therefore, the
ability of a technique to detect Aβ at these low concentrations is necessary to analyze patient
samples. In Chapter 2, we determined the limit of detection for insulin protein to be 1.72 µM and
48.4 pM using UV- and LIF-CE, respectively. To determine the Aβ1-40 limit of detection using
UV-CE, Aβ1-40 was prepared at concentrations ranging from 0.0087 mg/mL to 0.043 mg/mL and
analyzed. The S/N ratio of the Aβ1-40 peak was > 3 at concentrations of 0.02 mg/mL and higher,
defining 0.02 mg/mL (5 µM) as the limit of detection for Aβ1-40 using UV-CE. The definition of
the detection limit as the analyte concentration with a S/N ratio > 3 has been used previously in
studies utilizing CE detection [59,60]. The Aβ detection limit obtained is in agreement with the
detection limit obtained in our previous studies on insulin protein of 1.72 µM [61]. A study by
Verpillot et al. obtained a lower detection limit for Aβ using UV-CE of 0.002 mg/mL (0.5 µM)
[62]. This study utilized a 20 s injection time at 0.5 psi where our studies were conducted using a
8 s injection at 0.5 psi. Therefore, the amount of Aβ injected into the capillary was most likely
higher in the Verpillot et al. study, which would lead to a lower detection limit. Furthermore, the
Aβ detection limit achieved by Verpillot et al. is higher than the physiological Aβ concentration
in CSF of 100 – 2000 pM [58].
A parallel limit of detection study was performed for carboxy-fluorescein (FAM)-labeled
Aβ1-40 and Aβ1-42 using LIF-CE. The optimized injection conditions used previously for the
detection of FITC-insulin were utilized in these studies. To determine the Aβ1-40 and Aβ1-42
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detection limits using LIF-CE, FAM-labeled Aβ1-40 and Aβ1-42 were prepared at concentrations
ranging from 0.0047 - 4140 ng/mL for FAM-Aβ1-40 and 0.0049 – 4870 ng/mL for FAM-Aβ1-42.
The S/N ratio of the FAM-Aβ1-40 peak was > 3 at concentrations of 0.09 ng/mL and higher, thus
establishing 0.09 ng/mL (20 pM) as the limit of detection for FAM-Aβ1-40 using LIF-CE.
Furthermore, the S/N ratio of the FAM-Aβ1-42 peak was > 3 at concentrations of 0.0049 ng/mL
and higher, thus establishing 0.0049 ng/mL (1 pM) as the limit of detection for FAM-Aβ1-42
using LIF-CE and illustrating the superior limit of FAM-Aβ1-42 detection for LIF-CE compared
with FAM-Aβ1-40. In fact, the LIF detection limits of 1 and 20 pM are lower than the
physiological Aβ concentration in CSF of 100 – 2000 pM [58] and to the authors’ knowledge, is
the lowest LIF detection limit of Aβ for an electrophoresis based method. A study by Verpillot et
al. obtained a LIF-CE detection limit for FAM-Aβ of 35 nM [35], thus exhibiting the superior
LIF-CE detection limit for Aβ (1 – 20 pM) obtained in our studies. Thus, LIF-CE is a promising
technique for the detection of physiologically relevant Aβ concentrations.
3.5 Analysis of FAM tracer incorporation into unlabeled Aβ
Similar to FITC, FAM is a fluorescein derivative which contains a carboxylic acid
reactive group where FITC contains an isothiocyanate reactive group (Table 1). These reactive
groups react with primary amines present on internal lysine residues and N-terminal residues via
an SN2 reaction. Insulin contains two N-terminal residues and one lysine residue whereas Aβ
contains one N-terminal residue and two lysine residues. Therefore, the number of possible
attachment sites between the two proteins is similar. Since Aβ1-42 is highly prone to aggregation,
the FAM label may be more likely to incorporate into aggregates formed by Aβ1-42.
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Table 1: Structure and spectral properties of FAM and FITC.
Table 5 Structure and spectral properties of FAM and FITC.
Fluorophore

Structure

Excitation/Emission
Wavelength

Fluorescein isothiocyanate

494/518 [63]

5-Carboxy-fluorescein

492/518 [64]

157

The potential for LIF-CE to monitor the ability of FAM-labeled Aβ1-42 to incorporate into
unlabeled Aβ1-42 was investigated using a sample preparation method which has been previously
shown to promote Aβ1-42 oligomer formation [65]. Figure 11 shows the LIF-CE peak pattern
obtained where Panel A is a zoom in of the data shown in Panel B. At 0 hours, LIF-CE
demonstrated the presence of three peaks with migration times < 30 min (Figure 11A) in
addition to larger, more broad peaks with migration times ranging from 50 – 70 min (Figure
11B). After 3 hours, a similar peak pattern was obtained with the appearance of two more peaks
with migration times of ~31 and 36 min, respectively (Figure 11A). In addition, a peak with a
faster migration time of ~6 min appeared. The area for the peak with a faster migration time of
~6 min increased over an aggregation time of 9 hours then decreased after 24 hours (Figure 12A,
yellow squares). The area for the larger peak at 70 min decreased over a time period of 24 hours
(Figure 12A, green triangles). Figure 12B shows changes in the normalized migration time for
the last peaks in Figure 11A (~36 min) and Figure 11 B (~70 min) relative to the first peak at
~15 min, thus representing growth for faster and slower migrating species, respectively. The
normalized migration time for later peaks did not change over time while the normalized
migration time for earlier peaks increased. These results suggest that FAM-labeled Aβ1-42 was
incorporating into smaller unlabeled Aβ1-42 species but was interfering with the formation of
larger Aβ1-42 species. Based on the peak pattern obtained in Chapter 3 for Aβ1-40 after 28 hours of
aggregation with analysis via UV-CE, we estimate that the peak formed after 3 hours of
aggregation at ~6 min corresponds to a larger species. Furthermore, the peaks with migration
times > 40 min were estimated to be due to larger aggregates. Filtration or dot blot analyses were
not conducted since the studies in Chapter 4 were performed prior to the studies in Chapter 3.
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Figure 11. Coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42. Aβ1-42
solutions consisting of 30% FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF
detection (n = 2) were prepared at a concentration of 0.14 mg/mL in 40 mM Tris (pH
8.0) containing 10 mM NaCl. Solutions were allowed to sit at room temperature and
the formation of aggregates was monitored. Panel A is zoomed in on the early peaks
while panel B shows all peaks. LIF-CE was performed with a sample injection at 7
kV for 7 s with 7 kV separation using 0.5% PHEA separation matrix in PHEA coated
capillary.

Figure 28 Coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42
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Figure 12. Change in peak areas and normalized migration times for the
coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42. Aβ1-42 solutions
consisting of 30% FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF detection
were prepared at a concentration of 0.14 mg/mL in 40 mM Tris (pH 8.0) containing
10 mM NaCl. Solutions were allowed to sit at room temperature and the formation of
small and large species was monitored. Panel A shows the change in peak area for
peaks at ~6 min (, n = 2), and 70 min (, n = 2). Panel B shows the changes in
normalized migration time for the peak at 36 min (, n = 2) and 70 min (, n = 2).
LIF-CE was performed with a sample injection at 7 kV for 7 s with 7 kV separation
using 0.5% PHEA separation matrix in PHEA coated capillary. Peak migration times
were determined by normalizing the migration time for the last peak observed
relative to the migration time of the first peak observed for each incubation time
point. A * represents the first time point in which peak normalized migration times
are statistically different with p < 0.004.

Figure 29 Change in peak areas and normalized migration times for the coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ142
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Other researchers have examined the effect of the FAM label on aggregation. Similar
results were obtained by Jungbauer et al. using SDS-PAGE with Western blotting to analyze a
100 µM FAM-labeled Aβ1-42 sample incubated in phenol-red free Hams F12 media, pH 7.4 at
4°C for 24 hours [66]. This study observed bands for monomer, dimer, trimer, and tetramer (~4.5
– 13.5 kDa) with a smear for larger molecular weight species ranging from 35 – 60 kDa for
FAM-Aβ1-42. Compared to oligomers formed by labeled Aβ1-42, the unlabeled Aβ1-42 trimer and
tetramer bands were less intense and the high molecular weight smear ranged from 40 – 100
kDa. These results suggest that the FAM label could be interfering with the formation of high
molecular weight species ranging from 60 – 100 kDa. Alternatively, the FAM label could be
affecting the kinetics for the formation of Aβ1-40 aggregates as a study by Edwin et al. found that
in some cases it took longer than 3 weeks to observe FAM-Aβ1-40 aggregates using fluorescence
photobleaching recovery [67].
Although it appears that FAM-labeled Aβ1-42 was capable of incorporating into smaller
Aβ1-42 species, we found this behavior to be highly dependent upon the lot obtained from the
manufacturer. Aggregation studies were conducted using identical sample and LIF-CE
conditions as those used to obtain the data shown in Figures 11 and 12 but using different FAMlabeled Aβ1-42 and unlabeled Aβ1-42 lots. Furthermore, these lots were obtained from the same
manufacturer (Anaspec). Figures 13A and B show the peak pattern obtained for the old lot while
Figures 13C and D show the peak pattern obtained for the new lot. Panels A and C are a zoom
in of the early peaks in Panels B and D. Peaks at ~31 and 36 min appear after 3 hours of
aggregation with the old lot (Figure 13A) but not with the new lot (Figure 13C). In both lots,
the peak with a faster migration time of ~5 min appears after 3 hours of
42

and unlabeled Aβ1-42
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Figure 13. Effect of peptide lot on the coaggregation of FAM-labeled Aβ1-42 and
unlabeled Aβ1-42. Aβ1-42 solutions consisting of 30% FAM-labeled Aβ1-42 and 70%
unlabeled Aβ1-42 with LIF detection (n = 2) were prepared at a concentration of 0.14
mg/mL in 40 mM Tris (pH 8.0) containing 10 mM NaCl. Solutions were allowed to
sit at room temperature and the formation of aggregates was monitored. Panels A
and B show the peak pattern obtained for the old lot. Panels C and D show the peak
pattern obtained for the new lot. Panels A and C are zoomed in on the early peaks
shown in Panels B and D. LIF-CE was performed with a sample injection at 7 kV for
7 s with 7 kV separation using 0.5% PHEA separation matrix in PHEA coated
capillary.

Figure 30 Effect of peptide lot on the coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42
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aggregation (Figures 13A and C). Figure 14 compares the change in area for the peak with a
faster migration time obtained with the old lot (yellow squares) and the new lot (green circles).
The overlap in error bars between the two sets of data makes it difficult to draw conclusions
about differences in peak area for the two lots. A similar trend of an increase in peak area after 3
hours followed by a decrease in area after 24 hours is exhibited with both lots.
Lot-to-lot variability in synthetic preparations of Aβ peptides has been observed in the
literature [68,69]. A study by Wogulis et al. observed varying amounts of fibrillar Aβ1-40 for
three lots upon solubilization in water and dilution to 30 µM in tissue culture medium [68].
Furthermore, they found that neuronal cell death required the presence of both soluble and
fibrillar forms of Aβ. Similar to Wogulis et al., we have observed significant lot-to-lot variations
that have the potential to impact the aggregation processs. This indicates the complexity of the
Aβ aggregation process and further highlights the need for a screening technique which more
accurately represents the aggregation process.

-labeled Aβ1-42 and unlabeled Aβ1-42 using two different lots.
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Figure 14. Change in early peak area for the coaggregation of FAM-labeled Aβ1-42
and unlabeled Aβ1-42 using two different lots. Aβ1-42 solutions consisting of 30%
FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF detection were prepared at a
concentration of 0.14 mg/mL in 40 mM Tris (pH 8.0) containing 10 mM NaCl.
Solutions were allowed to sit at room temperature and the formation of oligomers
and aggregates was monitored. The change in area for the peak with a faster
migration time of ~6 min is shown for the old lot (, n = 2) and the new lot (, n =
2). LIF-CE was performed with a sample injection at 7 kV for 7 s with 7 kV
separation using 0.5% PHEA separation matrix in PHEA coated capillary. A *
represents the first time point in which peak areas are statistically different with p <
0.0008.

Figure 31 Change in early peak area for the coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42 using two different lots
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4. Conclusions
Although the exact nature of Alzheimer’s Disease is not well understood, there are
significant indications that it involves the aggregation of the Aβ protein, in particular the ~40
residue hydrophobic proteins Aβ1-40 and Aβ1-42 [70]. This highlights the importance of the
development of a technique which is capable of detecting Aβ sizes produced throughout
aggregation, in particular during the earliest stages of aggregation. Although there are certain
advantages to using techniques such as SDS-PAGE, Western blotting, mass spectrometry, and
SEC for Aβ detection, there are disadvantages as well. These limitations highlight the importance
of employing a complementary technique to explore the evolution of Aβ oligomer appearance.
Therefore, in these studies, we explored the potential of UV-CE to monitor the Aβ1-40
aggregation process. In particular, we utilized a PEO separation matrix to enhance the resolution
of Aβ1-40 oligomers and aggregates. Strikingly, we found that the lag time to oligomer formation
for SEC-purified Aβ1-40 samples was ~23 hours shorter compared to non-purified Aβ1-40 samples.
This indicates that the initial sample sizes present have a drastic effect on the lag time to
oligomer formation. The size of smaller, intermediate, and larger species was estimated using
membrane filtration units. It should be noted that a spherical shape is assumed in order to
generate the molecular weight cutoff for these membranes, thus providing a range of sizes.
Therefore, we confirmed that these species were oligomeric in nature by utilizing dot blots and
two compounds known to inhibit fibrils and oligomers, respectively. Furthermore, we utilized
the sequence specific antibody 6E10 and conformation specific antibodies A11 and OC to
confirm the presence of Aβ1-16, Aβ prefibrillar oligomers, and Aβ fibrils, respectively. The
presence of 6E10 positive spots was observed at all times throughout aggregation for both nonpurified Aβ1-40 samples and SEC-purified Aβ1-40 samples. Positive spots for A11 and OC were
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obtained after 24 hours of aggregation for non-purified Aβ1-40 samples and after 5 hours of
aggregation for SEC-purified Aβ1-40 samples. A comparison of the dot blot and UV-CE results
suggests that non-purified Aβ1-40 samples begin to form both prefibrillar oligomers (A11
positive) and fibrillar oligomers or fibrils (OC positive) after 24 hours of aggregation. These
prefibrillar oligomers could then undergo a conformational change after 28 hours, which is
represented by a sharp UV-CE peak with a faster mobility that corresponds to Aβ1-40 species >
300 kDa. Similar results were obtained for SEC-purified Aβ1-40 samples but with much faster lag
times (~5 hours). Furthermore, we have determined the lowest concentration of Aβ that can be
detected using both UV and LIF detection modes. Physiologically relevant Aβ concentrations in
the picomolar range were detectable using LIF detection while concentrations in the micromolar
range were required for UV detection.
Using UV-CE and LIF-CE to simultaneously monitor the aggregation of a mixture of
FAM-labeled Aβ1-42 and unlabeled Aβ1-42, this study was the first to show that FAM-labeled Aβ142

was capable of incorporating into smaller species formed by unlabeled Aβ1-42 but this ability

was highly dependent on the lot employed. This further illustrates the complexity of the Aβ1-42
aggregation process and necessitates further investigation to identify optimum fluorescent labels
for the study of insulin and Aβ oligomer formation at physiological concentrations. In particular,
less bulky fluorescent probes, such as BODIPY, or attachment of dyes exclusively at the N- or Cterminus would be less likely to impact aggregate formation. Furthermore, since dyes often
change the net protein charge, alternative dyes such as CE503 which do not alter the net charge
may be explored. A more detailed discussion of alternative dyes will be given in the future work
section of this thesis (Chapter 6).
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The studies in Chapter 4 were conducted in order to explore the ability of UV-CE to
monitor the aggregation of Aβ1-40 in a native state and highlight certain advantages and
disadvantages of UV-CE compared to other traditional Aβ detection techniques. In theory, CE is
a fast and highly efficient technique for the detection of charged molecules. Due to the small
charge and/or large size of certain Aβ species present throughout aggregation, the UV-CE
analysis time exceeds 4 hours. Furthermore, there are no commercially available size standards
for the detection of native protein states with CE, thereby making the estimation of Aβ size
difficult. In addition, we found that larger Aβ species can exhibit a shorter migration time, which
is contrary to the general theory of CE which predicts an increase in migration time with size.
Our studies are the first to utilize a polymer separation matrix to enhance the resolution of Aβ
species. CE is also a powerful tool to monitor the disappearance of 10 – 30 kDa Aβ species and
appearance of new peaks throughout aggregation, thereby providing a complementary technique
in which to validate the general trends observed for Aβ aggregation.
In addition, the studies in Chapter 4 were conducted in order to determine the ability of
LIF-CE to monitor FAM-labeled Aβ1-42 aggregation. The limitations of LIF-CE for amyloid
aggregate detection are; 1) the requirement of a fluorescent probe which can interfere with
aggregation and thereby misrepresent the “true” native aggregation of the protein and 2) the
dependence of LIF-CE to monitor aggregation on the particular protein lot employed. The focus
of this thesis is on the detection of amyloid aggregates formed under conditions which mimic
native protein aggregation rather than the detection of physiologically relevant concentrations.
Since it was shown that FITC and FAM could misrepresent native aggregation states, alternative
techniques for the detection of native Aβ were proposed such as dot blots. Therefore, dot blots
were employed in conjunction with UV-CE to better analyze the native aggregation of Aβ.
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CHAPTER 5: MICROCHIP ELECTROPHORESIS FOR DETECTION OF Β-SHEET
FORMATION BY AΒ AGGREGATES
1. Introduction
Electrophoresis in flat planar microchips, or microchip electrophoresis (ME), was
implemented by Harrison, Manz and Widmer in 1992 [1,2]. This miniaturization allowed
electrophoretic processes to be performed in seconds as opposed to minutes with capillary
instrumentation. ME possesses other advantages over conventional electrophoretic methods
including low sample consumption and a strong potential for automation and integration [3,4].
As a result, the application of ME for the analysis and separation of proteins has advanced
enormously in recent years [5].
When considering the translation of protein separations from a capillary format to a
microchip format, several parameters must be taken into account. One of the major challenges
for the application of ME to peptide and protein analyses is the adsorption of protein onto the
silanoate groups present in glass microchannel walls [6,7]. This can lead to peak “tailing” and
decrease the analytical efficiency. Therefore, two main strategies have been devised to suppress
electroosmotic flow (EOF) in glass capillaries and microchannels; 1) covalent modification of
the microchannel surface and 2) dynamic coating of the microchannel surface. Previous studies
in our lab have demonstrated the ability of the dynamic coatings poly(ethylene oxide) (PEO) and
poly-N-hydroxyethyl acrylamide (PHEA) to effectively suppress EOF and enhance the
separation of insulin and Aβ proteins in capillaries [8,9]. In addition, the microchannel separation
length is much shorter than the capillary separation length (8 cm versus 33 cm). Since the peak
resolution increases as the square root of the separation length, the analytical selectivity of ME is
lower than CE. A polymer matrix can be utilized as a separation medium in the microchannel to

178

increase the effect of protein hydrodynamic radius on ME separation, thereby leading to
enhanced resolution. However, higher polymer concentrations or molecular weights must be
utilized with ME compared to CE separations.
Although ME has been applied for analyses of monomeric proteins, less attention has
been paid to the use of ME for the detection of Aβ oligomers and aggregates in the literature. A
study by Mohamadi et al. used a microchannel coating consisting of poly(dimethylacrylamideco-allyl glycidyl ether) and with methylcellulose-Tween 20 in the electrophoresis buffer to
achieve the separation of five synthetic Fluoroprobe-488 labeled Aβ peptides (Aβ1-37, Aβ1-38,
Aβ1-39, Aβ1-40, and Aβ1-42) [6]. The detection of Aβ species larger than monomer was not
achieved. One particularly interesting aspect of Aβ aggregation is the formation of a β-sheet
containing fibrillar structure. Traditionally, the detection of β-sheet aggregates is conducted by
monitoring the emission of Thioflavin T (ThT) using a fluorometer. ThT is an intercalating
fluorescent dye that binds to the β-sheet structure within amyloid fibrils, giving rise to a shifted
excitation maximum at 450 nm and a shifted and enhanced emission at 482 nm [10,11]. A study
by Lee et al. utilized a microfluidic platform and ThT to detect Aβ1-42 aggregates [12]. Aβ1-42
monomers were immobilized on the microchannel surface via N-hydroxysuccinimide ester
activation of the internal surfaces. A fresh solution of Aβ1-42 was continuously fed into the
microchannels and Aβ1-42 aggregation was monitored using ThT fluorescence microscopy, but
electrophoresis was not used to separate Aβ aggregates in this study. In addition to ThT, other βsheet binding dyes such as BTA-1 exist for the detection of Aβ aggregates. BTA-1 is an
uncharged benzothiazole ThT analogue which has been shown to bind Aβ aggregates with a
higher affinity (11.5 nM – 20 nM [13,14] versus 240 – 890 nM [14-16] for ThT) and is 3000
times more fluorescent than ThT [14]. Studies have indicated the ability of BTA-1 to stain both
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plaques and neurofibrillary tangles in post-mortem AD brains, with a preference for plaque
staining [16,17]. Furthermore, the ability of BTA-1 to cross the blood-brain barrier makes it an
attractive candidate for in vivo detection of Aβ fibrils [13]. Unlike ThT, there is no shift in the
excitation and emission maxima of BTA-1 upon binding to β-sheet containing aggregates.
Therefore, the aggregates must be separated prior to analysis with a fluorometer, thus
highlighting the need for a technique which is capable of both separating and detecting β-sheet
containing aggregates.
ME offers the potential to monitor the binding of BTA-1 to Aβ aggregates. Previous
studies in our lab have demonstrated that covalently bound dyes can interfere with the formation
of insulin and Aβ aggregates and thereby misrepresent the “true” native aggregation of the
protein [8]. The use of dyes which bind to the β-sheet structure offer a way to monitor the native
aggregation of Aβ. However, the analysis time for the detection of native unlabeled Aβ
aggregates via UV-CE is very long (~4 hours). ME provides a way to overcome these problems
by; 1) offering the capability to detect the excitation and emission wavelengths of β-sheet
binding dyes and 2) achieving the separation of Aβ aggregates in a much shorter time (minutes
versus hours). Therefore, in these studies, we have explored the utility of ME to detect both
monomeric FAM-labeled Aβ1-42 and the binding of BTA-1 to β-sheet containing Aβ1-40
aggregates. The ME results obtained with BTA-1 are compared to results obtained using a
fluorometer to detect ThT fluorescence.
2. Materials and Methods
2.1. Aβ preparation
Aβ1-40 and FAM-Aβ1-42 were stored dessicated at -20°C. 4.33 mg/mL Aβ1-40 and 0.49 mg/
mL FAM-Aβ1-42 peptide stocks stock were prepared in hexafluoroisopropanol (HFIP) in order to
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ensure the samples were monomeric. These stock solutions were split into vials containing
0.0625 mg Aβ1-40 and 0.006775 mg FAM-Aβ1-42 and the HFIP was allowed to evaporate
overnight. Vials were stored at -80°C. For studies on the detection of FAM-Aβ1-42 via LIF-ME,
FAM-Aβ1-42 was dissolved in 5 mM NaOH and diluted into 40 mM Tris-HCl (pH 8.0) to a final
concentration of 0.15 mg/mL.
2.2.

Poly-N-hydroxyethyl

acrylamide

coating

and

separation

matrix

synthesis

and

characterization
One sample of long-chained HEA polymer (MW = 12,500,000 g/mol) was synthesized as
described previously [18] with the following changes: 4% w/w initial monomer concentration
and polymerization for 5 hours. One sample of short-chained HEA polymer (MW = 1,380,000
g/mol) was synthesized as described previously [19] with the following changes: 3.5 mL
isopropanol added to 200 mL of 4% w/w initial monomer solution. Solution deoxygenated by
bubbling nitrogen through mixture at 47°C for 2 h followed by polymerization for 4 hours. Once
the polymerization was complete, the polymer was dialyzed, lyophilized, and characterized to
confirm its molecular weight by multi-angle laser light scattering (Wyatt Technology, Santa
Barbara, CA). The HEA polymer with MW = 12,500,000 g/mol was diluted to 0.1% w/v in deionized water and used for the capillary coating and the HEA polymer with MW = 1,380,000
g/mol was diluted to 1% in 40 mM Tris (pH 8.0) for FAM-Aβ1-42 studies and 1.5% in 40 mM
Tris (pH 8.0) for Aβ1-40 oligomer studies with BTA-1 and used as protein separation matrices.
2.3. Aβ1-40 aggregation assay with BTA-1 and ThT
To observe the time course for Aβ1-40 aggregate formation, Aβ1-40 was dissolved in 5 mM
NaOH and diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final
concentration of 0.22 mg/mL (50 µM) and incubated at 25°C under continuous agitation (800
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rpm). A 1 mg/mL BTA-1 stock solution was prepared in 100% DMSO and diluted to 0.0064
mg/mL (4160 µM) in 40 mM Tris-HCl (pH 8.0). Both prior to the onset of aggregation and at
times between 8 and 28 hours following the onset of aggregation, an aliquot of Aβ1-40 was
removed and combined with BTA-1 for final Aβ1-40 and BTA-1 concentrations of 0.021 mg/mL
(4.8 µM) and 0.0058 mg/mL (24.2 µM), respectively. A final BTA-1 concentration in solution
(24.2 µM) was chosen, which was 5 times the final Aβ1-40 concentration (4.84 µM). This sample
was analyzed by LIF-ME to determine the elution time and intensity of all peaks.
In parallel experiments, aggregation was monitored using ThT binding as described
previously [20,21] with the following changes: dilution of Aβ1-40 into ThT for final Aβ1-40 and
ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL (24.2 µM), respectively.
Fluorescence was monitored at the onset of aggregation and at times between 5 and 28 hours
following the onset of aggregation using a Shimadzu RF-Mini-150 fluorometer (Columbia, MD)
(excitation = 460 nm, emission = 480–500 nm).
2.4. Microfluidic chips and polymer matrix loading into microfluidic chips
Glass borosilicate microfluidic chips (Micralyne, Edmonton, Alberta, Canada) with the
following properties were used in the experiments: double T injector with an offset of 100 µm,
channel width of 50 µm, channel depth of 20 µm, and separation length of 79 mm. Prior to being
used for ME runs, the uncoated glass microchips were conditioned and dynamically coated by
rinsing them via vacuum with the following: water for 15 min, HCl (aq., 1M) for 15 min, polyN-hydroxyethylacrylamide (coating reagent, aq., 0.1%,) for 15 min, followed by a water rinse.
The chip was filled with the separation matrix polymer (1 – 1.5% PHEA) via vacuum prior to
each experiment.
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2.5. Microchip Electrophoresis
FAM-Aβ1-42 samples were injected at 194-500 V/cm for 20 s and electrophoresed at 214380 V/cm with 24 V/cm pullback at ambient temperature (17-20 °C). Aβ1-40 samples with BTA-1
were injected at 200-600 V/cm for 10-20 s and electrophoresed at 380 V/cm with 12-24 V/cm
pullback at ambient temperature (17-20 °C). The microchip electrophoresis system was custombuilt in the laboratory of Dr. Christa Hestekin. The system consisted of a high voltage power
supply (LabSmith Inc., Livermore, CA) with the ability to independently control 4 electrodes, a
488 nm argon ion laser (JDS Uniphase, San Jose, CA) and a 355 nm semi-conductor laser
(Coherent Inc., Santa Clara, CA), and a high-quantum-efficiency, 1024 x 128 pixel chargecoupled device (CCD) cooled to -50 °C (Andor, South Windsor, CT).
3. Results and Discussion
3.1. Detection of FAM-Aβ1-40 using LIF-ME
The utility of LIF-ME for the detection of FAM-labeled Aβ1-42 was explored. In order to
compare the peak pattern obtained using LIF-ME with that obtained previously with LIF-CE, the
LIF-CE sample injection voltage and time (194 V/cm for 7 s) as well as separation voltage (214
V/cm) were used. Figure 1A shows the LIF-ME peak pattern obtained under these conditions. In
order to enhance the signal intensity, the LIF-ME injection voltage and time were increased
to500 V/cm for 20 s (Figure 1B). The FAM-labeled Aβ1-42 peak pattern obtained utilizing LIFME (Figure 1B) is similar to that obtained using LIF-CE (Figure 1C). In addition, the run time
for LIF-ME is ~3.5 times faster than LIF-CE. In order to further decrease the LIF-ME
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Figure 32 Detection of FAM-labeled Aβ1-42 using LIF-ME and LIF-CE.
Figure 1 Detection of FAM-labeled Aβ1-42 using LIF-ME and LIF-CE. FAM-labeled
Aβ1-42 was prepared at 0.15 mg/mL in 40 mM Tris-HCl (pH 8.0) and analyzed via A)
LIF-ME with 194 V/cm injection for 7 s with 214 V/cm separation with 24 V/cm
pullback, B) LIF-ME with 500 V/cm injection for 20 s with 214 V/cm separation and
C) LIF-CE with 194 V/cm injection for 7 s with 214 V/cm separation. All runs were
performed in 0.1% PHEA coated chip or capillary with 1% PHEA separation matrix.
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analysis time, the separation voltage was increased to 380 V/cm (Figure 2). This led to a
separation ~5 times faster compared to LIF-CE.
A previous study by Mohamadi et al. utilized LIF-ME to separate five synthetic
Fluoroprobe-488 labeled Aβ peptides (Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42) dissolved in
borate buffer (pH 10.5) [6]. The migration time obtained for Aβ1-42 was ~1.5 min, which is
similar to the migration time obtained in our studies for FAM-Aβ1-42 (Figure 2). The separation
channel length used in our studies was about twice as long as what was utilized in the Mohamadi
et al. study (7.9 cm versus 3.5 cm). This suggests that a faster FAM-Aβ1-42 migration time could
be obtained in our studies if a shorter separation channel distance is used. Furthermore, the
Mohamadi et al. study observed extraneous peaks before and after the peak for Aβ1-42, which
they suggest are due to unbound dye and peptide containing variations in the label number,
respectively. Our study demonstrates the ability of the LIF-ME system built in our laboratory to
detect FAM-Aβ1-42 with a similar peak pattern to LIF-CE, but with a greatly reduced analysis
time.
3.2. Detection of β-sheet formation by Aβ1-40 using LIF-ME and comparison to ThT binding
Insoluble Aβ fibrils containing a β-sheet structure are important for the clinical
determination of Alzheimer’s Disease [22,23]. Various fluorescent dyes exist which are capable
of binding to the β-sheet structure present in Aβ aggregates such as ThT and BTA-1. BTA-1 is
an uncharged benzothiazole ThT analogue which has been shown to bind Aβ aggregates with a
higher affinity than ThT (11.5 nM [13] versus 240 – 890 nM [15,16] for ThT) and is 3000 times
more fluorescent than ThT [14]. The structures of ThT and BTA-1 are shown in Table 1.
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Figure 33 Effect of increased LIF-ME separation voltage on the detection of FAM-labeled
Aβ1-42.
Figure 2 Effect of increased LIF-ME separation voltage on the detection of FAMlabeled Aβ1-42. FAM-labeled Aβ1-42 was prepared at 0.15 mg/mL in 40 mM Tris-HCl
(pH 8.0) and analyzed via LIF-ME with 500 V/cm injection for 20 s and 214 V/cm or
380 V/cm separation with 24 V/cm pullback. All runs were performed in 0.1%
PHEA coated chip with 1% PHEA separation matrix.
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Table 1 Structure and spectral properties of ThT and BTA-1.
Table 6 Structure and spectral properties of ThT and BTA-1.
Fluorophore

Structure

Excitation/Emission
Wavelength

Unbound
385/445 [11]
Thioflavin T
Bound
450/482 [11]

BTA-1

360/460 [14]
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The purpose of our studies is twofold; 1) investigate the ability of LIF-ME to detect the binding
of BTA-1 to Aβ1-40 aggregates and 2) validate β-sheet formation using a fluorometer to detect
ThT binding. In Chapter 3, we have previously demonstrated the detection of Aβ1-40 oligomers
> 300 kDa via UV-CE after ~28 hours of agitation at 800 rpm. To explore the utility of ME for
the detection of β-sheet containing Aβ1-40 aggregates, the same sample preparation utilized in
Chapter 3 was used to promote amyloid assembly. The reaction was analyzed using ME at early
and late time points to assess the appearance of β-sheet containing Aβ1-40 aggregates. At 0 hours,
no peaks with S/N > 3 were observed using ME (Figure 3). After 8 and 24 hours of aggregation,
two small peaks were detected with migration times of ~3 and 6 min. A similar peak pattern was
obtained after 28 hours with the appearance of two sharper, more intense peaks at ~4.5 min with
S/N > 3. Furthermore, the S/N ratio for the peak at ~3 min was > 3.
A study by Levine et al. explored the binding of BTA-1 to Aβ1-40 fibrils using
fluorometry [14]. Since there is no change in BTA-1 fluorescence upon binding to Aβ1-40 fibrils
[14], centrifugation was necessary in order to determine the amount of bound BTA-1 in the
resuspended fibril pellet. This pre-separation step is unnecessary for ME analyses due to the
ability of ME to separate and detect aggregates in one step.
In order to validate the results obtained via ME to a more traditional method of detecting
amyloid aggregates containing a β-sheet structure, ThT with analysis via fluorometry was used to
follow Aβ aggregation. Aβ1-40 aggregate detection using ThT with fluorometry was conducted
simultaneously on the same sample as the studies utilizing BTA-1 with ME. Aβ1-40 was
aggregated at pH 8.0 (40 mM Tris) and 25 °C with agitation (800 rpm) in the presence of 5 mM
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NaCl. The general trend for the growth of aggregates analyzed via ThT fluorescence (Figure 4)
was similar to that observed using ME, thus validating the formation of β-sheet aggregates.

Figure 34 Detection of BTA-1 binding to Aβ1-40 using LIF-ME.
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Figure 3 Detection of BTA-1 binding to Aβ1-40 using LIF-ME. Aβ1-40 was aggregated
under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM
NaCl and at 25 °C. At 0 – 28 hours, Aβ1-40 was diluted into BTA-1 for final Aβ1-40
and BTA-1 concentrations of 0.021 mg/mL (4.8 µM) and 0.0058 mg/mL (24.2 µM),
respectively. Fluorescence was monitored via ME with LIF detection with a 200-600
V/cm injection for 10-20 s with a 380 V/cm separation with 12-24 V/cm pullback.
All runs were performed in 0.1% PHEA coated chip with 1.5% PHEA separation
matrix.

Figure 35 Detection of ThT binding to Aβ1-40 using fluorometry.
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Figure 4 Detection of ThT binding to Aβ1-40 using fluorometry. Aβ1-40 was
aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0)
containing 5 mM NaCl and at 25 °C. At 0 – 36 hours, Aβ1-40 was diluted into ThT for
final Aβ1-40 and ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL
(24.2 µM), respectively. Fluorescence was monitored via fluorometry (excitation =
460 nm, emission = 480–500 nm).
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4. Conclusions
In these studies, we have demonstrated the capability of ME to detect both monomeric
FAM-Aβ1-42 and Aβ1-40 aggregates. The detection of FAM-Aβ1-42 was achieved in ~1.5 minutes,
which is ~5 times faster than analyses via LIF-CE. Furthermore, ME was utilized to detect βsheet formation using the conformationally specific dye BTA-1. A fluorometer was also
employed in order to validate β-sheet formation using ThT binding. We found that similar trends
were observed for BTA-1 binding detection via ME compared to ThT binding detection via
fluorometry. Although BTA-1 is an attractive alternative to ThT for the detection of Aβ1-40
aggregates, Aβ1-40 aggregates must be separated in order for the use of BTA-1 to be effective and
this separation is typically achieved via centrifugation for ~15 min. We have demonstrated the
utility of ME to both separate and detect Aβ1-40 aggregates using BTA-1 in < 7 min, which is 2 –
3 times faster than traditional measures of BTA-1 fluorescence (ie. centrifugation with
fluorometry). Further studies must be conducted which optimize the BTA-1 and Aβ1-40
concentrations for analysis via ME. In particular, a saturation binding curve must be generated
for BTA-1 by varying the BTA-1 concentration with a constant concentration of Aβ1-40 and
analyzing the peak pattern obtained via ME. This will give the maximum BTA-1 fluorescence
which can be obtained at a given Aβ1-40 concentration. In order to explore the utility of ME to
detect physiologically relevant concentrations of β-sheet aggregates formed by Aβ1-40, the
saturation binding curve will be repeated for different Aβ1-40 concentrations down to
physiologically relevant concentrations (ie. varying the BTA-1 concentration with 5 µM Aβ1-40,
varying the BTA-1 concentration with 0.5 µM Aβ1-40, etc). This will give the optimal BTA-1
concentration necessary for a range of Aβ1-40 concentrations and further indicate whether ME is
capable of detecting physiologically relevant concentrations. In addition, the ME injection
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voltage and time as well as the separation polymer concentration and chip separation length must
be optimized in order to achieve the best detection of Aβ1-40.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS
1. Impact of the presented work
The detection of oligomers and aggregates formed by two amyloid proteins, insulin and
Aβ, is of particular importance due to the role which these species play in Diabetes and
Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques
or alternative techniques must be explored in order to identify and quantify the size of these
oligomeric and aggregate species without disrupting their structure and develop treatments that
target these pivotal aggregation events.
In Chapters 1 and 2, the advantages and disadvantages of traditional methods for the
detection of insulin and Aβ oligomers and aggregates were outlined. We also introduced the
potential of microchannel electrophoresis (CE and ME) as a complimentary technique for the
existing analyses. This thesis focuses on addressing previously unexplored areas for the
development of CE and ME as early amyloid aggregation detection techniques.
In Chapter 3, we reported the first studies on the use of UV-CE with a polymer
separation matrix to detect native insulin aggregates ranging in size from 30 – 100 kDa. In
particular, we looked at the ability of UV-CE to detect insulin aggregates formed using a
relatively low sample concentration (0.2 mg/mL), near neutral pH (8.0), and physiological salt
concentration (150 mM). Thioflavin T binding was utilized to compare the lag times observed
with UV-CE and and it was found that UV-CE displayed a lag time ~3 times faster than ThT
binding. This suggests that UV-CE is detecting oligomers which are present prior to β-sheet
aggregates. In addition, the effect of salt on the formation of insulin aggregates was determined
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and it was found that the time to insulin oligomer appearance was unaffected by salt
concentrations ranging from 100 – 250 mM. In order to draw conclusions on the ability of CE to
detect physiologically relevant insulin and Aβ concentrations, the detection limit for UV-CE was
compared to LIF-CE and it is shown that LIF-CE can detect physiologically relevant FITCinsulin concentrations. Furthermore, the detection sensitivity of LIF-CE was ~35,000 fold higher
than UV-CE for the detection of FITC-insulin. In addition, we explored the potential for LIF-CE
to monitor the formation of oligomers and aggregates of FITC-labeled insulin. It is shown that
FITC-labeled insulin is unable to incorporate into unlabeled insulin oligomers. This demonstrates
that LIF-CE is a promising technique for the detection of low concentrations of monomeric
FITC-insulin but caution must be taken when choosing a fluorescent dye for the detection of
FITC-insulin oligomers and aggregates.
In Chapter 4, we demonstrated ability of UV-CE with a polymer separation matrix to
detect native small oligomeric Aβ1-40 species (10 – 30 kDa) and larger oligomeric species (100–
300 kDa and > 300 kDa). Specifically, we looked at the ability of UV-CE to detect Aβ1-40
aggregates formed using a relatively low sample concentration (0.2 mg/mL), near neutral pH
(8.0), and low salt concentration (5 mM). In addition, the effect of sample preparation on the
formation of Aβ aggregates was determined. Dot blots were utilized to verify the presence of Aβ
oligomeric and fibril species detected via UV-CE and compare lag times. It was found that the
lag times for oligomers and aggregates obtained using UV-CE were nearly identical to those
obtained via dot blotting. Furthermore, we found that the lag time to oligomer formation for
SEC-isolated Aβ1-40 samples was ~23 hours shorter compared to non-purified Aβ1-40 samples.
This indicates that the initial sample sizes present have a drastic effect on the lag time to
oligomer formation. In order to draw conclusions on the ability of CE to detect physiologically
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relevant Aβ concentrations, the detection limit for UV-CE was compared to LIF-CE and it was
shown that LIF-CE can detect physiologically relevant FAM-Aβ1-40 and FAM-Aβ1-42
concentrations. Furthermore, the detection sensitivity of LIF-CE was 250,000 – 5,000,000 fold
higher than UV-CE for the detection of FAM-Aβ. This demonstrates that LIF-CE is a promising
technique for the detection of low concentrations of monomeric FAM-Aβ. We also explored the
potential for LIF-CE to monitor the formation of oligomers and aggregates of FAM-Aβ1-42 and
found that FAM-labeled Aβ1-42 is capable of incorporating into unlabeled Aβ1-42 oligomers but
not aggregates. Furthermore, the ability to detect FAM- Aβ1-42 is highly dependent on the protein
lot utilized. These results demonstrate that while LIF-CE is a promising technique for the
detection of physiologically relevant FAM-Aβ concentrations, caution must be taken when
choosing a dye for detection of oligomeric and aggregate species. In particular, dye properties
including size, effect of dye on the net protein charge, or dye attachment site may interfere with
the native aggregation of insulin and Aβ and thereby misrepresent the species detected via LIFCE.
Since the studies in Chapters 3 and 4 demonstrated that covalently bound dyes can
interfere with the formation of insulin and Aβ aggregates and thereby misrepresent the “true”
native aggregation of the protein [1], we investigated the use of dyes which bind to the β-sheet
structure and offer a way to monitor the native aggregation of Aβ in Chapter 5. Due to the fact
that the UV- and LIF-CE instruments in our lab are not capable of detecting the excitation and
emission wavelengths associated with β-sheet binding amyloid dyes (ie. BTA-1), we explored
the utility of ME to detect β-sheet formation. In particular, we determined that ME could detect
monomeric FAM-labeled Aβ1-42 in ~1.5 min and the binding of BTA-1 to β-sheet containing
Aβ1-40 aggregates in < 7 min. Furthermore, the ME results obtained with BTA-1 were compared
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to results obtained using a fluorometer to detect ThT fluorescence. We found that BTA-1 was
capable of detecting low levels of Aβ1-40 aggregates ~7 hours earlier compared to ThT binding.
Further studies must be conducted which optimize the BTA-1 and Aβ1-40 concentrations for
analysis via ME.
In this work, we have demonstrated that UV-CE is capable of detecting insulin and Aβ
oligomers in a native state. The drawbacks of current techniques include the requirement of
conditions that induce non-native behavior (SDS-PAGE) or destabilize oligomers (SEC), limited
resolution of individual sizes of oligomers and aggregates (Native-PAGE, DLS, FCS, and TEM),
limited ability to detect a wide range of populations (oligomers - fibrils) within a sample
(MALS), inability to provide size information about oligomers or fibrils (dot blotting, ELISA),
and reliance on assumptions in the model to predict size (centrifugation, FCS). The main
advantages of UV-CE over alternative techniques are the ability to detect the native formation of
oligomers and aggregates and the ability to detect a wide range of sizes (oligomers - fibrils)
within a sample. The advantages of LIF-CE and ME compared to UV-CE are the capability to
detect physiologically relevant concentrations and enhanced resolution. Further improvements
must be made in order to model and determine limitations on the ability of CE and ME to resolve
different species. A major disadvantage of LIF-CE is the interference of fluorescent dyes
necessary for detection with native protein aggregation. Compared to fluorometry, ME is capable
of monitoring the binding of conformationally dependent dyes which do not exhibit a shift in
fluorescence upon binding without the use of another separation method. Further improvements
to LIF-CE and ME must be made in order to overcome the disadvantages associated with these
techniques. These include the exploration of alternative dyes which do not interfere with
aggregation (LIF-CE) and the optimization of dye and protein concentrations (ME) to determine
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whether physiologically relevant concentrations of β-sheet aggregates can be detected via ME.
The specifics for these improvements are given in the next section.
2. Future directions
2.1. Testing of alternative dyes with LIF-CE
The use of a fluorescent dye which is covalently bound to amyloid proteins is necessary
in order to achieve detection via LIF-CE of smaller oligomeric species formed prior to species
containing a β-sheet structure. In Chapter 3, we demonstrated the ability to detect physiologically
relevant concentrations of monomeric FITC-insulin and FAM-Aβ using LIF-CE. In order to
determine whether physiologically relevant concentrations of oligomeric insulin and Aβ could be
detected via LIF-CE, we explored the ability of FITC-insulin and FAM-Aβ to incorporate into
oligomers formed by unlabeled insulin and Aβ in Chapter 4. We found that FITC-labeled insulin
was unable to incorporate into oligomers formed by the unlabeled protein while FAM-labeled
Aβ1-42 was capable of incorporating into oligomers formed by unlabeled Aβ1-42 but not aggregate
species. However, the ability of FAM-labeled Aβ1-42 to incorporate into oligomers formed by
unlabeled Aβ1-42 was highly dependent on the lot employed. These findings necessitate the
exploration of alternative covalently bound fluorescent dyes. Since some small compounds have
been previously reported as inhibitors of β-sheet formation, it is possible that the FITC and FAM
labels are acting as inhibitors to aggregation. Another possibility is that the FITC and FAM
attachment sites are critical for proper β-sheet folding. A similar extension of the lag time to
aggregation has been observed following the methylation of amino groups within the Aβ protein
[2] and the introduction of a mutant that mimics phosphorlyation of serine residues within the
Huntington protein [3]. In addition, the quantity of amyloid aggregates formed is reduced
following the citraconylation of lysine residues within lysozyme [4] or stilbine modification of ε-
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amino groups within transthyretin [5]. Therefore, dyes with alternative properties or attachment
sites may need to be explored. In particular, dyes with a wider linker region, such as BODIPY,
dyes which do not alter the net protein charge, or attachment of dyes exclusively at the N- or Cterminus would be less likely to impact aggregate formation. Table 1 gives the structures for
FITC and FAM as well as three alternative dyes which we are interested in exploring. Since
FITC and FAM are bulky dyes, alter the net protein charge upon attachment, and are attached to
the N-terminus and Lysine residues, we have chosen the alternative dyes BODIPY, CE503, and
AMCA-Hydrazide in order to explore the three properties given above, respectively.
Preliminary studies in our lab have indicated the potential for BODIPY to be used to
monitor the formation of oligomers and larger aggregates formed by unlabeled Aβ1-40. Since we
already had data for the behavior of 100% unlabeled Aβ1-40 (Chapter 3), we used this data as a
control to determine the effect of the wider linker region of BODIPY on the aggregation of
unlabeled Aβ1-40. Therefore, we used identical Aβ1-40 sample and aggregation conditions to
determine whether BODIPY-Aβ1-40 interfered with the formation of oligomers and aggregates.
Aβ1-40 was labeled with BODIPY according to the manufacturers’ protocol. Separate stock
solutions of unlabeled Aβ1-40 and BODIPY-labeled Aβ1-40 were prepared in 5 mM NaOH and
diluted into 40 mM Tris (pH 8.0) containing 5 mM NaCl. These solutions were combined to
yield a sample consisting of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40 with a total Aβ1-40
concentration of 0.22 mg/mL (50 µM) and incubated at 25°C under continuous agitation (800
rpm). Both prior to the onset of aggregation and at times between 5 and 72 hours following the
onset of aggregation, a 20 µL sample was removed and analyzed by LIF-CE to determine the
elution time and intensity of all peaks. Figure 1 shows the peak pattern obtained at all time
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Table 1 Structure and spectral properties of FITC, FAM, BODIPY, CE503, and
AMCA-Hydrazide
Table 7 Structure and spectral properties of FITC, FAM, BODIPY, CE503, Adrazide

Fluorophore

Structure

Fluorescein,
isothiocyanate
(FITC)

Excitation/Emission
Wavelength

494/518 [6]

Fluorescein,
succinimidyl ester
(FAM)

492/518 [7]

BODIPY,
sulfosuccinimidyl ester

504/513 [8]

CE503

Unconjugated
612/665 [9]
Conjugated
503/600 [9]

AMCA-Hydrazide

350/450 [10]
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points where Panel A shows all peaks and Panel B is zoomed in on the early peaks with
migration times < 40 min. At 0 hours, a sharp peak at ~20 min (Peak 3, Figure 1A and B) was
observed in addition to several smaller intensity peaks with migration times ranging from10 – 40
min (Peaks 1, 2, and 4 – 8, Figure 1A and B). A possible explanation for the observance of
several smaller intensity peaks is that these peaks are due to variations in the BODIPY label
number since BODIPY labels the N-terminus and Lysine residues, thus creating 7 different
possible variations of label number per Aβ1-40 peptide. A similar peak pattern was observed after
5 and 10 hours with an initial increase in the intensity of peaks 1 – 8 followed by a decrease after
10 hours. After 24 hours, two new peaks with an S/N > 3 were observed; a sharp peak with a
faster migration time at ~8 min (Peak 9, Figure 1A and B) and a small peak with a longer
migration time at ~53 min (Peak 10, Figure 1A). Furthermore, the intensity of peaks 1 - 8 was
drastically reduced. The same peak pattern as was obtained after 24 hours was obtained after 28
– 72 hours with an increase in intensity of peak 9 at ~8 min and peak 10 at ~53 min. In addition,
dot blots showed a positive A11 (oligomer) stain at 28 hours (data not shown).
In order to better understand the growth process, the area for peaks 1 – 8 with migration
times ranging from 10 – 40 min was compared to the area for peak 9 with a migration time of ~8
min which appeared after 24 hours of aggregation. As shown in Figure 2, the area for peaks 1 –
8 initially increases and then starts to decrease after 10 hours (blue diamonds). This initial
increase in peak area is similar to the results obtained in Chapter 3 using UV-CE to detect
oligomers formed by 0.22 mg/mL unlabeled Aβ1-40. After 24 hours, the area for peaks 1 - 8
decreases further (blue diamonds) while peak 9 with a faster migration time of ~8 min appears
(red squares). The sharp peak observed at 24 hours using LIF-CE is similar to the sharp peak
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Figure 36 Coaggregation of BODIPY-labeled Aβ1-40 and unlabeled Aβ1-40 with analysis via
LIF-CE.
Figure 1 Coaggregation of BODIPY-labeled Aβ1-40 and unlabeled Aβ1-40 with
analysis via LIF-CE. Aβ1-40 solutions consisting of 20% BODIPY-labeled Aβ1-40 and
80% unlabeled Aβ1-40 were prepared at a concentration of 0.22 mg/mL in 40 mM Tris
(pH 8.0) containing 5 mM NaCl and aggregated under agitation (800 rpm, 25°C). At
0 – 72 hours, CE was performed in conjunction with LIF detection (n = 1 - 2) with a
7 kV injection for 7 s with separation at 7 kV using 1.5% PHEA separation matrix in
a PHEA coated capillary. Panel A shows all peaks while panel B is zoomed in on the
early peaks.
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Figure 37 Effect of aggregation time on the area for peaks 1 - 8 (, n = 1 - 2) and peak 9
(, n = 1 - 2) obtained for BODIPY-Aβ1-40.
Figure 2 Effect of aggregation time on the area for peaks 1 - 8 (, n = 1 - 2) and
peak 9 (, n = 1 - 2) obtained for BODIPY-Aβ1-40. Aβ1-40 was aggregated under
agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl
and at 25 °C. At 0 – 72 hours, CE was performed in conjunction with LIF detection
with a 7 kV injection for 7 s with separation at 7 kV using 1.5% PHEA separation
matrix in a PHEA coated capillary.
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observed after 28 hours using UV-CE to detect oligomers formed by 0.22 mg/mL unlabeled Aβ140

in Chapter 3. Furthermore, the overall trend for the changes in peak areas are similar for

aggregates formed by 100% unlabeled Aβ1-40 with analysis via UV-CE (Figure 3A) and
aggregates formed by a mixture of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40 with analysis
via LIF-CE (Figure 3B) Since a similar peak pattern is obtained for UV-CE and LIF-CE after 28
hours, this suggests that BODIPY-Aβ1-40 has the potential to be used to detect oligomers formed
by unlabeled Aβ1-40. In addition, since 20% of BODIPY-Aβ1-40 is mixed with unlabeled Aβ1-40,
only 20% of oligomers formed will be labeled with BODIPY-Aβ1-40 and detected via LIF-CE.
Figure 4 shows the UV-CE data obtained for 100% unlabeled Aβ1-40 multiplied by 20% and the
LIF-CE data obtained for a mixture of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40. Overall,
the peak areas obtained after 0, 5, 10, 24, 36, and 48 hours are similar while the peak areas
obtained after 28 hours are somewhat different. This further demonstrates that BODIPY-Aβ1-40
has the potential to be used to detect oligomers formed by unlabeled Aβ1-40.
The appearance of a peak with a faster migration time was obtained using both BODIPY
and FAM (Chapter 4) for the analysis of Aβ1-40 and Aβ1-42, respectively. In contrast, BODIPY
was able to detect the appearance of peaks with migration times > 40 min. This indicates that dye
size may play a role in the ability of LIF-CE to detect Aβ1-40 oligomers and aggregates. In
addition, we have successfully labeled Aβ1-40 with CE503 and AMCA-Hydrazide in our lab.
CE503 is a dye which does not alter the net protein charge upon attachment while AMCAHydrazide is attached exclusively to the C-terminus. Future studies will be conducted to explore
the effects of net protein charge (CE503) and attachment site (AMCA-Hydrazide) on the ability
of LIF-CE to
Figure
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38 Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa (, n = 3) and > 300 kDa (, n = 3) Aβ1-40
species analyzed via UV-CE and B) peak 1 - 8 (, n =d peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species analed

via LIF-CE.
Figure 3 Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa
(, n = 3) and > 300 kDa (, n = 3) Aβ1-40 species analyzed via UV-CE and B) peak
1 - 8 (, n = 1 - 2) and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species analyzed via
LIF-CE. Samples containing 100% Aβ1-40 and samples containing 20% BODIPYlabeled Aβ1-40 and 80% unlabeled Aβ1-40 were aggregated under agitation (800 rpm)
at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 –
48 hours, CE was performed in conjunction with A) UV detection with a 0.5 psi
pressure injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix
in a PEO coated capillary or B) LIF detection with a 7 kV injection for 7 s with
separation at 7 kV using 1.5% PHEA separation matrix in PHEA coated capillary.
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Figure 39 Effect of aggregation time on the peak areas obtained for > 300 kDa (, n = 3) Aβ1-40 species
detected via UV-CE and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species detected via LIF-CE.

Figure 4 Effect of aggregation time on the peak areas obtained for > 300 kDa (, n
= 3) Aβ1-40 species detected via UV-CE and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40
species detected via LIF-CE. The peak areas for the UV-CE data were multiplied by
20% in order to facilitate comparisons between UV-CE and LIF-CE. Samples
containing 100% Aβ1-40 and samples containing 20% BODIPY-labeled Aβ1-40 and
80% unlabeled Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in
40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary
or LIF detection with a 7 kV injection for 7 s with separation at 7 kV using 1.5%
PHEA separation matrix in PHEA coated capillary.
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detect oligomers and aggregates formed by unlabeled Aβ1-40. Future work will need to be done to
determine if these dyes can be used to label the aggregation process in a way that does not affect
the natural aggregation. Once the optimal dye is identified, the potential for LIF-CE to detect
physiologically relevant concentrations of Aβ1-40 oligomers and aggregates can be determined.
3. Conclusions
The detection of oligomers and aggregates formed by two amyloid proteins, insulin and
Aβ, is of particular importance due to the role which these species play in Diabetes and
Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present
at low concentrations, and difficult to isolate. The present work has demonstrated the potential
for CE and ME to detect the native aggregation of insulin and Aβ proteins, in particular the
formation of oligomers and aggregates. Specifically, we have demonstrated that UV-CE is
capable of monitoring native aggregation and provides a size range for the oligomeric and
aggregate species produced. LIF-CE is capable of detecting physiologically relevant
concentrations of FITC-insulin and FAM-Aβ but the fluorescent dye necessary for these analyses
interferes with native aggregation and thus could give inexact information about the amount of
oligomers and aggregates formed. ME is capable of detecting physiological concentrations of
FAM-Aβ but detection of the binding of BTA-1 to physiological concentrations of unlabeled Aβ
was not demonstrated. Therefore, significant work lies ahead to investigate alternative
fluorescent dyes and optimization of dye concentration in order to achieve the detection of
physiologically relevant concentrations of insulin and Aβ. This work has laid the foundation for
future studies by establishing UV-CE, LIF-CE, and LIF-ME protocols for the detection of
amyloid aggregates. We feel that this work has demonstrated the potential for LIF-CE and LIF-
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ME to detect physiological concentrations although a significant amount of work is needed in the
future in order for these techniques to be applied in a clinical setting.
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Appendix
Doctoral committee comments addressed
Shear and temperature sensitivity of the various constructs
The effect of shear stress on Aβ1-40 fibrils has been previously investigated [11,12]. The
Young’s Moduli for Aβ1-40 fibrils ranges from 12 – 30 GPa where longer fibrils are generally
more stable [11,12]. For Aβ1-40 fibrils < 50 nm in length, Xu et al. found that shear effects
dominate lateral deformation.[12] However, the amount of total stress necessary to break apart
hydrogen bonds in Aβ1-40 fibrils is ~0.14 GPa (20,300 psi) [11]. Since our studies are conducted
at atmospheric pressure (14.7 psi), it is unlikely that shear effects would produce a significant
change in the structure of the Aβ constructs produced in our experiments. Furthermore, the
radius of the pores within the polymer network of the capillary is in the µm range which results
in a relatively open network for the Aβ constructs to travel through.
It is widely accepted that an increase in temperature leads to an increase in the rate of
fibrillation for amyloid proteins [13]. Thus, larger aggregate sizes will be obtained at elevated
temperatures. During CE experiments, an increase in capillary temperature may occur as a result
of Joule heating. In order to determine what run voltages will produce a significant amount of
Joule heating, an Ohm’s law plot was generated for the Aβ1-40 conditions utilized in these
studies. It was found that above a separation voltage of 9 kV, Joule heating began to occur.
Therefore, all Aβ1-40 experiments were carried out at a separation voltage of 7 kV in order to
minimize the production of heat. Furthermore, the capillary is surrounded by coolant which pulls
heat away and maintains a constant capillary temperature during the experiments. A study by
Sabella et al. found that increasing the CE separation voltage from 1 – 16 kV had no effect on
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the peak pattern obtained for Aβ1-40 [14]. It is unlikely that the change in temperature occurring
during these CE experiments has an affect on the stability of the amyloid constructs.
Mass balances in electropherograms
In order to determine whether a mass balance could be performed using the CE
electropherograms, the peak areas obtained for experiments in Chapter 3 were summed. The
values obtained were not constant over time. When the 10 – 30 kDa and > 300 kDa peak areas
were summed, the total peak area decreased over an aggregation time of 48 hours for both HFIPtreated and SEC-isolated Aβ1-40 samples (Figure A). Since we did not account for the peaks with
longer migration times in these calculations, this decrease in area could be due to the
incorporation of the 10 – 30 kDa peak into larger aggregate sizes which would elute at longer
migration times. When all peaks with S/N > 3 were summed, the total peak area increased over
an aggregation time of 48 hours for both HFIP-treated and SEC-isolated Aβ1-40 samples (Figure
B). Since the β-sheet structure absorbs light at around 214 nm, this increase in area over time
could be due to the presence of this structure. Alternatively, Aβ could be retained on the capillary
wall between runs which would lead to an increase in area over time. These observations
highlight the difficulty of performing a mass balance analysis of this data.
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Figure: Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa + >
300 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species and B)
All Peaks (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species. Aβ1-40
was aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0)
containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was performed in
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
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Results of reinjection of capillary effluent
The volume injected into the capillary using a pressure injection can be calculated
according to the following equation:
𝑉𝑜𝑙𝑢𝑚𝑒 = 𝜋𝑟 2 ×

∆𝑃𝑟 2 𝑡𝑖𝑛𝑗
× 0.00069
8𝜂𝐿𝑡

Where volume = volume introduced (nL), ΔP = pressure difference (psi), r = inner radius of
capillary (µm), tint = introduction time (s), η = viscosity of sample (mPa*s), Lt = total length of
capillary (cm). For the experimental conditions used in Chapter 3, the volume introduced is ~14
nL. The recovery of such a small volume of sample makes the reinjection of the capillary
effluent quite difficult, since the sample would be highly diluted in buffer solution at the outlet.
Number of theoretical plates calculations
The number of theoretical plates (N) was calculated for the 10 – 30 kDa and > 300 kDa
peaks obtained in Chapter 3 experiments. The equations used to calculate N are as follows[15]:
𝑁=

𝐿𝑡
𝐻𝐸𝑇𝑃

Where N = number of theoretical plates, Lt = total capillary length (cm), and HETP = height
equivalent of a theoretical plate (cm). HETP is calculated as follows[16]:
𝐻𝐸𝑇𝑃 =

𝑊1/2 2
𝐿𝑑
×�
�
5.54
𝑡𝑚

Where Ld = effective capillary length to detector (cm), W1/2 = peak width at half maximum
(min), and tm = migration time (min). The number of theoretical plates obtained for the 10 – 30
kDa peak at various points throughout aggregation is shown in Figure A. For both HFIP-treated
Aβ1-40 and SEC-isolated Aβ1-40, N for the 10 – 30 kDa peak decreases over an aggregation time
of 48 hours. The number of theoretical plates obtained for the > 300 kDa peak at various points
throughout aggregation is shown in Figure B. The values of N obtained for this peak are
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significantly larger (~70 times greater) compared to the values obtained for the 10 – 30 kDa
peak. Similar values as those obtained for the number of theoretical plates for the > 300 kDa
peak have been obtained in the literature for cytochrome C [17]. The HETP for capillary
electrophoresis can be thought of as the fraction of the capillary occupied by the analyte. Since
higher values of N are obtained for the > 300 kDa peak versus the 10 – 30 kDa peak, this
indicates that the > 300 kDa is occupying less space in the capillary.
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Figure: Effect of aggregation time on the theoretical plate number obtained for A) 10
– 30 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species and B) >
300 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species. Aβ1-40
was aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0)
containing 5 mM NaCl and at 25 °C. At 0 – 48 hours, CE was performed in
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary.
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Experimental Protocols
Long Chain Poly-N-Hydroxyethyl Acrylamide Polymerization Protocol (Coating Polymer)
NOTE: Wear gloves and a lab coat at all times as HEA monomer is very toxic.
4% Initial Monomer Solution:
Add 16.5 mL of N-hydroxyethyl acrylamide to 383.5 mL of dH2O
Note:

The N-hydroxyethylacrylamide solution is 97% w/w aqueous solution so calculate

amounts by
M1V1 = M2V2
(97)*(x) = (4)*(400)
x = 16.5 mL N-hydroxyethyl acrylamide (PHEA) so 400-16.5 = 383.5 mL of dH2O
-Run 400 mL PHEA solution through MEHQ inhibitor remover column at speed 6 (~1.8
mL/min). The solution will take ~ 4 hours to run through the column.
Solution de-oxygenation:
-Deoxygenate solution in 47°C water bath by bubbling nitrogen through the mixture for 2 hours.
0.02% V-50 Solution:
0.04 mL (40 μL) of V-50 for every 200 mL of polymer solution.
-Add 40 µL of V-50 to 200 mL PHEA solution and then blow nitrogen over the solution for 4-5
hours.
-Transfer final solution to dialysis tubing bags (MWCO = 100,000 Da).
-Place dialysis tubes with polymer in them in the fish bowls (4 tubes per fish bowl) and fill fish
bowls with 18 MΩ de-ionized water so the water covers tubing.
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Water changes:
-Change the de-ionized water in the fish bowls 10 times total. Each water change should be at
least 4 hours apart.
Freezing and lyophilizing polymer:
-After 10 water changes have been completed, transfer the polymer to 45 mL falcon tubes (~35
mL polymer solution in each tube).
-Place falcon tubes in freezer box and store in -80°C freezer for 2 days.
-After polymer has been stored in -80°C freezer for 2 days, lyophilize polymer for 2 days,
making sure polymer does not melt during lyophilization.
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Short Chain Poly-N-Hydroxyethyl Acrylamide Polymerization Protocol (Separation Polymer)
NOTE: Wear gloves and a lab coat at all times as HEA monomer is very toxic.
4% Initial Monomer Solution:
Add 16.5 mL of N-hydroxyethyl acrylamide to 383.5 mL of dH2O
Note:

The N-hydroxyethylacrylamide solution is 97% w/w aqueous solution so calculate

amounts by
M1V1 = M2V2
(97)*(x) = (4)*(400)
x = 16.5 mL N-hydroxyethyl acrylamide (PHEA) so 400-16.5 = 383.5 mL of dH2O
-Run 400 mL PHEA solution through MEHQ inhibitor remover column at speed 6 (~1.8
mL/min). The solution will take ~ 4 hours to run through the column.
Isopropanol (chain transfer agent):
-For ~770 kDa polymer, 2 mL isopropanol (IPA) added to 100 mL of 5% initial monomer
solution (Hert et al.) Therefore, add 3.2 mL IPA to 200 mL of 4% initial monomer solution.
Swirl IPA into solution.
2 mL IPA/100 mL of 5% initial monomer = x mL/200 mL of 4% initial monomer
2 mL IPA/5 mL initial monomer = x mL/8 mL initial monomer
x = 3.2 mL IPA
-Deoxygenate solution in 47°C water bath by bubbling nitrogen through the mixture for 2 hours.
0.02% V-50 Solution:
0.04 mL (40 μL) of V-50 for every 200 mL of polymer solution.
-Add 40 µL of V-50 to 200 mL PHEA solution and then blow nitrogen over the solution for 4-5
hours.
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-Transfer final solution to dialysis tubing bags (MWCO = 100,000 Da).
-Place dialysis tubes with polymer in them in the fish bowls (4 tubes per fish bowl) and fill fish
bowls with 18 MΩ de-ionized water so the water covers tubing.
Water changes:
-Change the de-ionized water in the fish bowls 10 times total. Each water change should be at
least 4 hours apart.
Freezing and lyophilizing polymer:
-After 10 water changes have been completed, transfer the polymer to 45 mL falcon tubes (~35
mL polymer solution in each tube).
-Place falcon tubes in freezer box and store in -80°C freezer for 2 days.
-After polymer has been stored in -80°C freezer for 2 days, lyophilize polymer for 2 days,
making sure polymer does not melt during lyophilization.
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Polymer Molecular Weight determination using Multi-Angle Light Scattering (MALS)
NOTE: Wear gloves and safety glasses when handling polymer solutions!
Sample preparation:
-Prepare 6 mL of a 5 mg/mL stock solution of your polymer in de-ionized water. For example,
if analyzing PDMA polymer, dissolve 30 mg of dry PDMA in 6 mL of de-ionized water. If
sample limited, adjust calculations accordingly.
-Prepare 10 mL of the following concentrations by diluting 5 mg/mL stock PDMA solution:
1 mg/mL
0.75 mg/mL
0.5 mg/mL
0.25 mg/mL
0.1 mg/mL
For example, to prepare 1 mg/mL dilution:
M1V1 = M2V2
(5 mg/mL)*(V1) = (1 mg/mL)*(10 mL)
V1 = 2 mL of 5 mg/mL stock PDMA solution
So add 2 mL of 5 mg/mL stock PDMA solution to 8 mL of de-ionized water
Fill five 10 mL plastic syringes (without rubber tips) with PDMA dilutions.
Fill one 10 mL plastic syringe with de-ionized water.
Use 0.02 µm syringe filters for water/solvent solutions and 0.2 µm syringe filters for PDMA
samples.

222

Computer:
Double click the Astra 5.3.4.14 icon.
Click the green circle to start experiment.
Once experiment has started, use the syringe pump to flush water through system until ~5
minutes of a stable baseline is obtained.
Using syringe pump, flush 1 mg/mL polymer solution through system until ~3 minutes of a
stable line is obtained.
Using syringe pump, flush 0.75 mg/mL polymer solution through system until ~3 minutes of a
stable line is obtained.
Using syringe pump, flush 0.5 mg/mL polymer solution through system until ~3 minutes of a
stable line is obtained.
Using syringe pump, flush 0.25 mg/mL polymer solution through system until ~3 minutes of a
stable line is obtained.
Using syringe pump, flush 0.1 mg/mL polymer solution through system until ~3 minutes of a
stable line is obtained.
Using syringe pump, flush water through system until ~5 minutes of a stable baseline is
obtained.
NOTE: Water must be flushed through the system before and after sample data collection in
order to obtain a proper baseline for data analysis.
Once water and all 5 sample dilutions have been flushed through system, press the red stop
button at the top of the page.
The software will ask you to draw your baseline and define peaks. You must do this before the
software will generate a Zimm Plot!
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Under the Procedures tab, click “Peaks” and enter in the concentrations for each peak you have
defined and a dn/dc value of 0.175 for each peak. You must enter in these values to generate the
Zimm Plot!
View the Zimm Plot by clicking “A2, Mass & Radius from LS”. The mass and rms radius are
given under the Zimm Plot.
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Cleaning MALS Flowcell with 0.1 M Nitric Acid
NOTE: Nitric Acid (HNO3) is extremely toxic. Work with in hood and do not inhale fumes.
0.1 M HNO3 is in fume hood in BEC 2238.
1) Flow ~6 mL of 0.1 M HNO3 through the MALS instrument.
2) Let solution sit in MALS instrument for 3 hours.
3) After 3 hours, rinse with filtered de-ionized water for 15 min (or flow ~5 mL through)
4) Rinse with 100% ethanol for 15 min (or flow ~5 mL through)
5) Rinse with 100% toluene for 15 min (or flow ~5 mL through)
6) Rinse with 100% ethanol for 15 min (or flow ~5 mL through)
7) Rinse with filter de-ionized water for 15 min (or flow ~5 mL through)
Compare the light scattering voltages for the toluene to the voltages given in the certificate of
performance. If similar, the flow cell should be clean.
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Polymer Solution Preparation for use on CE
NOTE: All solution percents are calculated as weight/volume (w/v).
Preparation of coating polymer:
Coating polymers should have a higher molecular weight (ie. > 1,500,000 g/mol)
To prepare a 1% PHEA solution, use the following calculation:
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑛𝑒𝑒𝑑𝑒𝑑 (𝑚𝐿)

=

1%
(𝑚𝑔))
100 × 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
1%
�100�

(𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔)) − (

Always add water to coating polymer solutions!
Preparation of separation matrix polymer:

Separation matrix polymers should have a lower molecular weight (ie. < 1,500,000 g/mol)
Same protocol as above except dissolve separation polymer solutions in CE separation buffer (ie.
40 mM Tris-HCl, pH 8.0 for LIF-CE and ME or 100 mM Tris-HCl, pH 8.0 for UV-CE)
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0.1% Polyhydroxyethyl acrylamide (PHEA) Capillary Coating Protocol
-Capillary should be 31 cm total length, 10 cm effective length, and 50 μm ID.
-All steps done using reverse rinses (outlet to inlet)
15 minute de-ionized water rinse at 20 psi
15 minute 1 M HCl rinse at 20 psi
20 minute 0.1% w/v PHEA polymer solution rinse at 20 psi
15 minute de-ionized water rinse at 20 psi
-Ensure 4 outlet vials contain liquid at end of procedure to ensure proper coating.
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0.5% Polyethylene oxide (PEO) Capillary Coating Protocol
-Capillary should be 31 cm total length, 10 cm effective length, and 50 μm ID.
-Protocol adapted from Fung et al. 1995-“High-Speed DNA Sequencing by Using Mixed
Poly(ethylene oxide) Solutions in Uncoated Capillary Columns”
-All steps done using reverse rinses (outlet to inlet)
10 min rinse with water at 20 psi
15 min rinse with 0.1 M HCl at 20 psi
30 min rinse with 0.5% PEO at 50 psi
(PEO from Sigma Cat # 372803, Mv ~2,000,000 prepared in de-ionized water)
15 min rinse with water at 20 psi
-Ensure 4 outlet vials contain liquid at end of procedure to ensure proper coating.
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Microchip Coating Procedure
15 min de-ionized water
15 min 1 M HCl
20 min 0.1% PHEA (dissolved in de-ionized water)
15 min de-ionized water
-Pull solution through channels with the vacuum pump.
-Let each solution sit in chip for given amount of time. Watch for evaporation. If evaporation
occurs, pull more solution through channel.
-After given amount of time, pull solution out of channels.
-Repeat procedure for each solution.
-Store chip dry with no buffer.
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40 mM Tris-HCl Protocol
Buffer recipe, generated by Buffer Calculator (c) Rob Beynon 1996-2006
http://www.liv.ac.uk/buffers
BUFFER:
To make 1000 ml of 0.04 M Tris (pKa = 8.06) Buffer, pH = 8,
Ionic strength = 0.022 M,
(Ionic strength due to the buffer = 0.022M )
Thermodynamic pKa = 8.06, Apparent pKa' = 8.12
Temperature coefficient = -0.028 per oC
Prepared at 25oC, used at 25 oC
RECIPE:
Weigh out 3.594 g Tris-HCl crystals (0.0228 mol of acid component)
Weigh out 2.071 g Tris base crystals (0.0171 mol of basic component)
(No added neutral salts, I due to buffer alone.)
Make up to 1000 ml with pure water
Check to make sure pH = 8.0. If pH does not equal 8, add 0.04 g more Tris-HCl crystals and 0.04
g more Tris base crystals.
NOTE: Can also make 100 mM Tris-HCl (pH 8.0) with this calculator.
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Monomerization by HFIP and storage of Aβ1-40 peptide
Objective: Aβ1-40 storage
Stock Solutions:
A. Assay Buffer:
HFIP (1,1,1,3,3,3-hexafluoro-2-propanol)
B. Aβ1-40: 1mg/vial

Anaspec

Procedure:
1. Solid Aβ1-40 is stored as a solid at -80C. Remove and place on ice when ready to prepare stock
peptide films.
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is
highly corrosive and very volatile. Add enough HFIP to Aβ1-40 such that the final peptide
concentration is 1mM (e.g. 231 ul cold HFIP to 1 mg Aβ1–40). Rinse vial thoroughly.
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and
colorless. Any traces of yellow color or cloudy suspension indicate poor peptide quality and
should not be used.
4. Place peptide—HFIP solution back on ice for 5–10 min.
5. Separate the HFIP into vials with 0.0625 mg/vial. That means each vial has 14.4 µL stock.
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes.
7. Allow HFIP to evaporate overnight in the hood at room temperature.
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the
bottom of the tubes. The peptide should not be white or chunky.
9. Store dried peptide films over desiccant at -80C. These stocks should be stable for several
months.
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Monomerization by HFIP and storage of FAM-Aβ1-40 peptide
Objective: FAM-Aβ1-40 storage
Stock Solutions:
A. Assay Buffer:
HFIP (1,1,1,3,3,3-hexafluoro-2-propanol)
B. FAM-Aβ1-40: 0.1mg/vial

Anaspec

Procedure:
1. Solid FAM-Aβ1-40 is stored as a solid at -80C. Remove and place on ice when ready to prepare
stock peptide films.
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is
highly corrosive and very volatile. Add enough HFIP to FAM-Aβ1-40 such that the final peptide
concentration is 0.1 mM (e.g. 213.3 ul cold HFIP to 0.1 mg FAM-Aβ1–40). Rinse vial thoroughly.
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and
colorless. A cloudy suspension indicates poor peptide quality and should not be used.
4. Place peptide—HFIP solution back on ice for 5–10 min.
5. Separate the HFIP into vials with 0.01563 mg/vial. That means each vial has 33.3 µL stock.
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes.
7. Allow HFIP to evaporate overnight in the hood at room temperature. Cover with foil!
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the
bottom of the tubes. The peptide should not be white or chunky.
9. Store dried peptide films over desiccant at -80C. These stocks should be stable for several
months.
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Monomerization by HFIP and storage of Aβ1-42 peptide
Objective: Aβ1-42 storage
Stock Solutions:
A. Assay Buffer:
HFIP (1,1,1,3,3,3-hexafluoro-2-propanol)
B. Aβ1-42: 1mg/vial

Anaspec

Procedure:
1. Solid Aβ1-42 is stored as a solid at -80C. Remove and place on ice when ready to prepare stock
peptide films.
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is
highly corrosive and very volatile. Add enough HFIP to Aβ1-42 such that the final peptide
concentration is 1mM (e.g. 222 ul cold HFIP to 1 mg Aβ1–42). Rinse vial thoroughly.
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and
colorless. Any traces of yellow color or cloudy suspension indicate poor peptide quality and
should not be used.
4. Place peptide—HFIP solution back on ice for 5–10 min.
5. Separate the HFIP into vials with 0.0271 mg/vial. That means each vial has 6.02 µL stock.
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes.
7. Allow HFIP to evaporate overnight in the hood at room temperature.
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the
bottom of the tubes. The peptide should not be white or chunky.
9. Store dried peptide films over desiccant at -80C. These stocks should be stable for several
months.
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Monomerization by HFIP and storage of FAM-Aβ1-42 peptide
Objective: FAM-Aβ1-42 storage
Stock Solutions:
A. Assay Buffer:
HFIP (1,1,1,3,3,3-hexafluoro-2-propanol)
B. FAM-Aβ1-42: 0.1mg/vial

Anaspec

Procedure:
1. Solid FAM-Aβ1-42 is stored as a solid at -80C. Remove and place on ice when ready to prepare
stock peptide films.
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is
highly corrosive and very volatile. Add enough HFIP to FAM-Aβ1-42 such that the final peptide
concentration is 0.1mM (e.g. 205.2 ul cold HFIP to 0.1 mg FAM-Aβ1–42). Rinse vial thoroughly.
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and
colorless. A cloudy suspension indicates poor peptide quality and should not be used.
4. Place peptide—HFIP solution back on ice for 5–10 min.
5. Separate the HFIP into vials with 0.006775 mg/vial. That means each vial has 13.9 µL stock.
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes.
7. Allow HFIP to evaporate overnight in the hood at room temperature. Cover tubes with foil!
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the
bottom of the tubes. The peptide should not be white or chunky.
9. Store dried peptide films over desiccant at -80C. These stocks should be stable for several
months.
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Insulin Oligomer Time Course Protocol for Analysis Via UV-CE
1 mg/mL insulin stock sample preparation:
1) Weigh out ~1 mg insulin and add 5 mM NaOH such that the ratio of NaOH:40 mM Tris-HCl
is 500:10000, assuming a 1 mg/mL final concentration. For example, if 1 mg insulin weighed
out, amount of NaOH added is as follows:
500

(10000 × 1000 µ𝐿) = 50 µ𝐿 5 𝑚𝑀 𝑁𝑎𝑂𝐻

2) Let insulin solution sit in 5 mM NaOH for 30 min.

3) Bring up to 1 mg/mL with 40 mM Tris-HCl (pH = 8.0)
4) Dilute the 1 mg/mL solution to 0.2 mg/mL in 40 mM Tris-HCl supplemented with 0 - 250
mM NaCl by adding the appropriate amount of 4.4 M NaCl to the tube. The final total volume
should be 800 µL. For example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a
sample supplemented with 150 mM NaCl is as follows:
𝑀1 𝑉1 = 𝑀2 𝑉2

(4,400 𝑚𝑀 𝑁𝑎𝐶𝑙) × (𝑥) = (150 𝑚𝑀 𝑁𝑎𝐶𝑙) × (800 µ𝐿)
�1

𝑥 = 27.3 µ𝐿 4,400 𝑚𝑀 𝑁𝑎𝐶𝑙

𝑚𝑔
𝑚𝑔
𝑖𝑛𝑠𝑢𝑙𝑖𝑛� × (𝑥) = �0.2
𝑖𝑛𝑠𝑢𝑙𝑖𝑛� × (800 µ𝐿)
𝑚𝐿
𝑚𝐿
𝑥 = 160 µ𝐿 1

𝑚𝑔
𝑖𝑛𝑠𝑢𝑙𝑖𝑛
𝑚𝐿

𝑆𝑜, 𝑓𝑜𝑟 𝑎 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 800 µ𝐿, 𝑎𝑑𝑑 160 µ𝐿 1

𝑚𝑔
𝑖𝑛𝑠𝑢𝑙𝑖𝑛 + 27.3 µ𝐿 4,400 𝑚𝑀 𝑁𝑎𝐶𝑙
𝑚𝐿

+ (800 µ𝐿 − 27.3 µ𝐿 − 160 µ𝐿) = 612.7 µ𝐿 40 𝑚𝑀 𝑇𝑟𝑖𝑠 − 𝐻𝐶𝑙 (𝑝𝐻 8.0)

5) Agitate sample at 25°C and 185 rpm. At various time points, take 50 µL sample and analyze
via UV-CE.

235

CE conditions:
NOTE: For studies in this thesis, 0.1% poly-N-hydroxyethyl acrylamide (PHEA) was used to
coat the capillary and 0.5% PHEA was used for separation. However, PHEA interferes with the
detection of insulin at 214 nm so 0.5% poly-ethylene oxide (PEO) coated capillaries should be
utilized with 0.5% PEO separation matrix. A new capillary should be coated before each time
course.
Capillary dimensions: Lt = 31 cm, Ld = 10 cm
Before each time point run, perform the following steps on the Beckman P/ACE instrument:
Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi
Reverse rinse with 0.5% PEO for 10 min at 50 psi
0.5 psi injection for 8 s
7 kV normal polarity separation using 100 mM Tris-HCl for 60 - 240 min.
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Aβ1-40 Oligomer Time Course Protocol for Analysis Via UV-CE
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie.
add 14.2 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL. For
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with
5 mM NaCl is as follows:
𝑀1 𝑉1 = 𝑀2 𝑉2

(4,400 𝑚𝑀 𝑁𝑎𝐶𝑙) × (𝑥) = (5 𝑚𝑀 𝑁𝑎𝐶𝑙) × (284 µ𝐿)
𝑥 = 0.33 µ𝐿 4,400 𝑚𝑀 𝑁𝑎𝐶𝑙

𝑆𝑜, 𝑓𝑜𝑟 𝑎 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 284 µ𝐿, 𝑎𝑑𝑑 (284 µ𝐿 − 0.33 µ𝐿 − 14.2 µ𝐿)
= 269.5 µ𝐿 40 𝑚𝑀 𝑇𝑟𝑖𝑠 − 𝐻𝐶𝑙 (𝑝𝐻 8.0)

5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze
via UV-CE.
CE conditions:
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO
separation matrix. A new capillary should be coated before each time course.
Capillary dimensions: Lt = 31 cm, Ld = 10 cm
Before each time point run, perform the following steps on the Beckman P/ACE instrument:
Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi
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Reverse rinse with 0.5% PEO for 10 min at 50 psi
0.5 psi injection for 8 s
7 kV normal polarity separation using 100 mM Tris-HCl for 60 - 240 min.
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Size Estimation Analysis Via Centrifugal Filter Units
1) Perform protocols for either “Insulin Oligomer Time Course” or “Aβ1-40 Oligomer Time
Course”.
2) When taking time points throughout aggregation, take a 50 µL sample and centrifuge at
14,000 x g for 20 minutes.
3) Analyze filtrate and retained solutions via UV-CE.
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Protocol for Aggregation of Aβ1-40 in Presence of Congo Red
Congo Red stock solution:
1) Prepare a 16.7 µM (0.23 mg/mL) stock solution of congo red in DMSO by adding ~18.9 mg
congo red + 1.6 mL 100% DMSO.
NOTE: Amounts may be adjusted according to how much congo red is weighed out.
Aβ1-40 Aggregation Assay with Congo Red:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.221 mg/mL (51.02 µM) final
concentration (ie. add 14.15 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.221 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 282.93 µL. For
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with
5 mM NaCl is 268.5 µL 40 mM Tris-HCl (pH 8.0) and 0.32 µL 4.4 M NaCl.
4) Add 5.77 µL of 16.7 µM congo red stock solution to sample in Step 3. The final percent
DMSO in solution should be 2% and the final Aβ1-40 concentration should be 50 µM.
5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze
via UV-CE.
CE conditions:
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO
separation matrix. A new capillary should be coated before each time course.
Capillary dimensions: Lt = 31 cm, Ld = 10 cm
Before each time point run, perform the following steps on the Beckman P/ACE instrument:
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Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi
Reverse rinse with 0.5% PEO for 10 min at 50 psi
0.5 psi injection for 8 s
7 kV normal polarity separation using 100 mM Tris-HCl for 60 - 240 min.
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Protocol for Aggregation of Aβ1-40 in Presence of Orange G
Orange G stock solution:
1) Prepare a 16.7 µM (0.23 mg/mL) stock solution of orange G in DMSO by adding ~12.1 mg
congo red + 1.6 mL 100% DMSO.
NOTE: Amounts may be adjusted according to how much orange G is weighed out.
Aβ1-40 Aggregation Assay with Orange G:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.221 mg/mL (51.02 µM) final
concentration (ie. add 14.15 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.221 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 282.93 µL. For
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with
5 mM NaCl is 268.5 µL 40 mM Tris-HCl (pH 8.0) and 0.32 µL 4.4 M NaCl.
4) Add 5.77 µL of 16.7 µM orange G stock solution to sample in Step 3. The final percent
DMSO in solution should be 2% and the final Aβ1-40 concentration should be 50 µM.
5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze
via UV-CE.
CE conditions:
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO
separation matrix. A new capillary should be coated before each time course.
Capillary dimensions: Lt = 31 cm, Ld = 10 cm
Before each time point run, perform the following steps on the Beckman P/ACE instrument:
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Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi
Reverse rinse with 0.5% PEO for 10 min at 50 psi
0.5 psi injection for 8 s
7 kV normal polarity separation using 100 mM Tris-HCl for 60 - 240 min.
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Aβ1-40 Dot Blot Protocol
NOTE: Wear gloves and safety glasses when dealing with antibodies.
Chemicals Needed:
5% milk/TBS-T
Dissolve 2 g dry milk in 40 mL 1X TBST
A11 primary antibody (anti-Aβ oligomer, 1 mg/mL)
Anti-rabbit secondary antibody (use with A11 and OC primary, 2 mg/mL)
6E10 primary antibody (anti-Aβ monomer, 1 mg/mL)
Anti-mouse secondary antibody (use with 6E10 primary, 0.6 mg/mL)
OC primary antibody (anti-Aβ fibril)
Procedure:
1) Cut single nitrocellulose membrane into 0.5” wide pieces. At each aggregation time point,
spot 3 µL of sample onto each membrane.
2) After all spots have been applied to membrane, allow last applied spot to dry for 1 hour.
3) Block membranes in 5% milk/TBS-T solution at 4°C for 1 hour with gentle shaking.
4) Wash membranes 3 times in 1X TBS-T.
5) Cover each membrane with the following amounts of primary antibody:
Membrane 1: 5 mL 5% milk/TBS-T + 2.5 µL A11 primary antibody (1:2000 dilution)
Membrane 2: 5 mL 5% milk/TBS-T + 2.5 µL 6E10 primary antibody (1:2000 dilution)
Membrane 3: 5 mL 5% milk/TBS-T + 1.25 µL OC primary antibody (1:4000 dilution)
6) Incubate with gentle shaking at 4°C for 1 hour.
7) Wash membranes 3 times in 1X TBS-T.
8) Cover each membrane with the following amounts of secondary antibody:
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Membrane 1: 5 mL 5% milk/TBS-T + 0.83 µL anti-rabbit secondary antibody (1:3000
dilution)
Membrane 2: 5 mL 5% milk/TBS-T + 4.17 µL anti-mouse secondary antibody (1:2000
dilution)
Membrane 3: 5 mL 5% milk/TBS-T + 0.83 µL anti-rabbit secondary antibody (1:3000
dilution)
9) Incubate with gentle shaking at 4°C for 1 hour.
7) Wash membranes 3 times in TBS-T/MgCl2. NOTE the use of TBS-T/MgCl2 for this step.
8) Develop membranes by adding the following amounts of developing solution to each
membrane:
Membrane 1: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50
mg/mL)
Membrane 2: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50
mg/mL)
Membrane 3: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50
mg/mL)
NOTE: Stock BCIP (50 mg/mL) prepared in 100% DMF and stock NBT (50 mg/mL) prepared
in 70% DMSO.
9) Allow membranes to develop and when begin to see spots, rinse membrane with 10% acetic
acid to stop reaction. It typically takes 5-10 minutes for membranes to develop.
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25% FITC-labeled Insulin/75% Unlabeled Insulin Oligomer Time Course Protocol for Analysis
Via LIF-CE
-Prepare unlabeled insulin and FITC-labeled insulin separately:
Unlabeled Insulin (0.3 mg/mL) supplemented with 150 mM NaCl:
0.3 mg unlabeled insulin + 966 µL of 40 mM Tris-HCl + 34.1 µL of 4.4 M NaCl
Note: If exact amounts are not weighed out, adjust volumes using excel spreadsheet but do not
weigh out more than 0.3 mg unlabeled insulin!
FITC-labeled Insulin (0.2 mg/mL) supplemented with 150 mM NaCl:
0.1 mg FITC-labeled insulin + 483 µL of 40 mM Tris-HCl + 17 µL of 4.4 M NaCl
Note: If exact amounts are not weighed out, adjust volumes using excel spreadsheet but do not
weight out more than 0.1 mg FITC-labeled insulin!
-Combine unlabeled insulin with FITC-labeled insulin so that final unlabeled insulin
concentration is 0.2 mg/mL and final FITC-labeled insulin concentration is 0.067 mg/mL and
place on shaking incubator at 185 rpm.
-After 0, 4, 8, 10, 24, and 36 hours, take 20 µL of sample and dilute to 0.013 mg/mL in 40 mM
Tris-HCl (pH 8.0). Run sample on LIF-CE.
CE conditions:
Rinse capillary with de-ionized water in between each run using syringe pump.
12 kV injection for 12 s
15 kV separation
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Aβ1-42/FAM-Aβ1-42 Oligomer Formation Assay with DMSO and Tween for Analysis Via LIF-CE
1) When ready to start experiment, take vial containing 0.0271 mg Aβ1-42 and 0.006775 mg
FAM-Aβ1-42 out of the -80°C freezer. Make a 5 mM Aβ1-42 stock and a 1.16 mM FAM-Aβ1-42
stock in 100% DMSO. Pipette thoroughly, washing down the sides of the tube to ensure
complete re-suspension of peptide film.
2) Dilute Aβ1-42 and FAM-Aβ1-42 peptide stocks to 30 µM (0.14 mg/mL) with 40 mM Tris-HCl
(pH 8.0) supplemented with 10 mM NaCl.
3) Combine Aβ1-42 and FAM-Aβ1-42 samples to yield a total final concentration of 30 µM (0.14
mg/mL) containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled Aβ1-42.
NOTE: Look at excel spreadsheet for exact volume amounts.
4) Allow oligomer prep to sit in microcentrifuge tube at room temperature (25°C) with cap on.
5) At 0, 3, 6, 9, and 24 hours, add tween to obtain a final volume containing 0.1% tween. (ie.
Prepare 1% tween stock solution by adding 10 µL pure tween to 990 µL de-ionized water. Take
27 µL aliquot and add 3 µL of 1% tween.
6) Analyze sample via LIF-CE.
CE conditions:
Rinse capillary with de-ionized water in between each run using syringe pump.
7 kV injection for 7 s
7 kV separation
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Aβ1-40 Oligomer Formation Assay With BTA-1 for Analysis Via LIF-ME
BTA-1 stock solution:
1) Prepare a 1 mg/mL stock solution of BTA-1 by adding ~1 mg BTA-1 to ~1 mL 100% DMSO.
2) Dilute stock solution to 0.0064 mg/mL (4160 µM) in 40 mM Tris-HCl (pH 8.0).
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie.
add 14.2 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL (ie. add
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl).
4) Agitate sample at 25°C and 800 rpm. At various time points, take aliquot and combine with
BTA-1 for final Aβ1-40 and BTA-1 concentrations of 0.021 mg/mL (4.8 µM) and 0.0058 mg/mL
(24.2 µM), respectively. The final BTA-1 concentration in solution (24.2 µM) should be 5 times
the final Aβ1-40 concentration (4.84 µM). Analyze sample via LIF-ME.
ME conditions:
1% PHEA dissolved in 40 mM Tris-HCl used for separation matrix
40 mM Tris-HCl used for buffer
200-600 V/cm injection for 10-20 s
380 V/cm separation with 12-24 V/cm pullback
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Aβ1-40 Oligomer Formation Assay With Thioflavin T for Analysis Via Fluorometer
Thioflavin T (ThT) stock solution:
1) Prepare a 2.32 mM ThT stock in de-ionized water.
2) Solution is stable in 20°C freezer for 2-6 months.
3) On day of experiment, dilute ThT stock to 26.8 µM in 40 mM Tris-HCl (pH 8.0).
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie.
add 14.2 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL (ie. add
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl).
4) Agitate sample at 25°C and 800 rpm. At various time points, take aliquot and combine with
ThT for final Aβ1-40 and ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL (24.2
µM), respectively (ie. add 19.4 µL Aβ1-40 to 180.6 µL 26.8 µM ThT). Use 1.5 mL quartz cuvette
for analyses.
5) Monitor fluorescence at the onset of aggregation and at times between 5 and 28 hours
following the onset of aggregation using a Shimadzu RF-Mini-150 fluorometer (Columbia, MD)
(excitation = 460 nm, emission = 480–500 nm). Blank with 26.8 µM ThT solution.
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Protocol for Labeling Aβ1-40 with BODIPY
Step 1: Prepare 100 µl of 0.5 mg/ml Aβ pre-treated with HFIP in 0.1 M sodium bicarbonate, pH
8.3 on ice.
Step 2: Add 7.5 µl dye –BODIPY-FL (Invitrogen D6140 MW = 491.20 g/mol)
BODIPY was dissolved in sequencing grade DMF at 10 mg/mL from dried aliquots in 20oC freezer
Step 3: Incubate on ice for 1.5 hours
Step 4: Stop the reaction by adding 10 µL of freshly prepared 1.5 M hydroxylamine, pH 8.5,
(To prepare hydroxylamine soln. carefully, add only ½ volume of sodium bicarbonate
soln. then pH)
Step 5: Incubate on ice an additional 30 minutes
Step 6: Rinse Centricon 3kDa with 40 mM Tris, pH 8.0, Add Reaction soln. dilute to 500 µl
Spin at 14 krpm in microcentrifuge in refrigerator for 20 min; repeat 5 more times to
change buffer to Tris and separate unreacted dye - should be approx. 100µl volume at end
Step 7: Store at -80oC until need
To figure concentration of dye BODIPY-FL:
Use Beer’s Law

A = є × path length × concentration

A = Absorbance maxima 502 nm shifts to 504 nm after conjugation
ε = 75,000 cm-1 M-1
Path length is typically 1 cm (on nanodrop path length can change so use protein:dye program)
Solve for dye concentration in M (moles/L)

c = ε x path length/ A

To figure concentration of protein (This requires additional steps)
Use Beer’s Law

A = є × path length × concentration
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ε = 1490 cm-1 M-1 at 280 nm
Some of the absorbance at 280 nm will be due to the BODIPY dye
Therefore A280nm x 0.0573 = Adye
To Solve for concentration of Aβ in M (moles/L)

c = ε x path length/ (A280nm - Adye)

(Caution on attributing 280nm to Aβ concentration the extinction coefficient will change
depending on the oligomeric/monomer state- therefore this method has been somewhat
inconsistent)
We do know that approx. 30% of total protein we started with is lost during our labeling
procedures.
Double-check your numbers for Aβ
Determination of degree of labeling
Concentration of dye (M) / Concentration of protein (M) will give you a ratio of dye:protein per
mole
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Aβ1-40/BODIPY-Aβ1-40 Oligomer Time Course Protocol for Analysis Via LIF-CE
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration:
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie.
add 14.2 µL 5 mM NaOH).
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min.
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be ~284 µL (ie. add
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl).
4) Add BODIPY-Aβ1-40 to unlabeled Aβ1-40 such that final total concentration is ~50 µM Aβ.
NOTE: See excel spreadsheet for exact volumes.
5) Agitate sample at 25°C and 800 rpm. At various time points, take 7 µL sample and analyze
via LIF-CE.
CE conditions:
Rinse capillary with de-ionized water in between each run using syringe pump.
1.5% PHEA separation matrix in 0.1% PHEA coated capillary
7 kV injection for 7 s
7 kV separation
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Chip System 488 nm Laser Alignment and Operation
NOTE: Always wear safety glasses which are resistant to laser wavelength (orange lenses in
container on the wall). Always close the curtain around the chip system when conducting
experiments. Light put out by the laser can damage skin and eyes! Never shine the laser towards
yourself or your eyes!
488 nm Laser Operation:
-Align laser so it is shining into the back of the microscope.
-Ensure the 488 nm filter cube is in the correct position.
-Ensure both filter wheels are in the “O” position.
-Ensure the microscope is on the “Eye” port.
-Ensure the key switch for the laser is in the “off” position (vertical up and down).
-The “interlock” light should be green.
-Plug in the laser fan.
-Turn the key switch to the “on” position (horizontal side to side).
-The laser will warm up and you will hear a click when it turns on.
-Use the remote interface to turn the discharge switch to “On” and the run switch to “On”.
-Turn off the laser by switching the remote interface discharge switch to “off”, run switch to
“idle”, and the key switch on the power supply box to the “off” position.
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488 nm Laser Alignment:
NOTE: Before turning the laser on, ensure that the microscope objective is near well “D” of the
microchip. Also, ensure the microscope is on the “Eye” port.

-Turn on the 488 nm laser.
-You should see a dot for the laser in the microchip well. You will need a source of light
(flashlight) in order to see the laser dot on the microchip. Adjust the stage of the microscope so
that the dot for the laser is in the middle of the microchip well and as close to well “D” as
possible.

-Record the position of the gauges on each side of the microscope stage.
-Record the position of the actual laser on the table.
-These readings will be used each time the laser is utilized.
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Chip System High Voltage Power Supply Operation
NOTE: Always be cautious when operating the high voltage power supply. NEVER touch the
stage or microchip when the high voltage power supply is enabled. This will result in
electrocution!
High Voltage Power Supply (HVPS) Operation:
-See directions from George on using the metal chip holder and plastic cover. Never try to pull
your chip out of the metal holder. This will break the chip! Instead, remove entire metal holder
from stage to remove chip from stage.
-Place the electrodes for each HVPS wire into the microchip wells as follows:

-Ensure the electrodes are submerged in buffer within each well. In proper placement will result
in loss of current.
-Turn on the HVPS by pushing the button on the front of the HVPS box.
-Click the “Sequence” icon on the desktop.
-You can create your own program by going to “tools, simple sequence wizard”.
-Press the
-The

icon to toggle between offline and online status.

icon should be highlighted. This means the high voltage is not enabled.

-Press the

icon to enable high voltage. Do NOT touch any part of the stage or microchip!

-Run your sequence by clicking the “Sequencer” tab and pressing the “A” button.
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-You can monitor the output of voltage and current for each well. The voltage values should
equal what you set the program for and the current values should remain relatively steady.
-When the run is finished, press the

and turn off the HVPS.
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Chip System Microscope Parts
Microscope ports:
There are 3 ports located on the microscope base:
1) Eye-Put on this when want to look through eyepiece at microchip
2) R-Right side port-Put on this when want to operate CCD camera (Hamamatsu)
3) L-Left side port-Put on this when want to operate CCD camera (Andor)
4) Aux-We will not use this port
Microscope should be set on “Eye” by default.
NOTE: Never turn the knob to R or L with the CCD camera ON and the overhead lights ON.
This will burnout the CCD camera!
Filter cube wheel positions:
There are 2 positions on the filter cube wheel:
C) Closed
O) Open
Filter wheels should be set to “C” by default.
There are 6 filter cube positions within the filter wheel.
The 488 nm laser filter cube is in position 6 on the lower filter wheel.
NOTE: Excitation filter = 470 nm and emission filter = 500 nm long pass
The 355 nm laser filter cube is in position 5 on the lower filter wheel.
NOTE: Excitation filter = 355 nm and emission filter is interchangeable with either 430
or 525 nm
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Chip System UV Laser Alignment and Operation
NOTE: Always wear safety glasses which are UV resistant (orange lenses in container on the
wall). Always close the curtain around the chip system when conducting experiments with the
UV laser. Light put out by the UV laser can damage skin and eyes! Never shine the laser towards
yourself or your eyes!
UV Laser Operation:
-Align laser so it is shining into the back of the microscope.
-Ensure the 355 nm filter cube is in the correct position.
-Ensure both filter wheels are in the “O” position.
-Ensure the microscope is on the “Eye” port.
-Ensure the key switch is in the “off” position (vertical up and down).
-Turn on the power button on the back of the power supply box (Coherent) for the UV laser.
-Click the “OPSL” icon on the desktop. This is the user interface to operate the UV laser from
the computer.
-Wait until the “system fault” light is not red and the “interlock OK” light is yellow. The laser is
now warmed up.
-Turn the key switch to the “on” position (horizontal side to side).
-The “laser on” light should be green indicating that the laser is on.
-You can adjust the laser power using the “control” tab. Click “local” and set the power in the
white box in the top part of the user interface.
-Turn off the laser by switching the key switch to the “off” position and turning the power button
off.
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UV Laser Alignment:
NOTE: Before turning the UV laser on, ensure that the microscope objective is near well “D” of
the microchip. Also, ensure the microscope is on the “Eye” port.

-Turn on the UV laser and adjust power to ~10?
-You should see a dot for the laser in the microchip well. You will need a source of light
(flashlight) in order to see the laser dot on the microchip. Adjust the stage of the microscope so
that the dot for the laser is in the middle of the microchip well and as close to well “D” as
possible.

-Record the position of the gauges on each side of the microscope stage.
-Record the position of the actual UV laser on the table.
-These readings will be used each time the UV laser is utilized.
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CONCLUSION
Existing techniques are limited in the ability to detect insulin and Aβ oligomers due to the
fact that these early aggregates are transient, present at low concentrations, and difficult to
isolate. A literature review was conducted by the author in the Fall of 2009 and later published in
the International Journal of Molecular Sciences. This publication gave a broad overview of the
techniques suitable for the determination of Aβ oligomer size and was thus reproduced in the
literature review porition (Chapter 1) of this dissertation. The author contributed to more than
50% of the work necessary to write this published review paper.
The present work has demonstrated the potential for CE and ME to detect the native
aggregation of insulin and Aβ proteins, in particular the formation of oligomers and aggregates.
Specifically, we have demonstrated that UV-CE is capable of monitoring native aggregation and
provides a size range for the oligomeric and aggregate species produced. LIF-CE is capable of
detecting physiologically relevant concentrations of FITC-insulin and FAM-Aβ but the
fluorescent dye necessary for these analyses interferes with native aggregation and thus could
give inexact information about the amount of oligomers and aggregates formed. Chapter 3
outlines studies conducted using CE to detect insulin oligomers and aggregates. This information
was published in Fall 2011 in the International Journal of Molecular Sciences. Again, since this
author contributed to writing over 50% of this publication, this publication was reproduced in
Chapter 3 as a part of this dissertation.
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